Compounds and compositions for ocular treatment

By induced crosslinking in the cornea with specific chemical entity compounds and electromagnetic radiation, the problem of unstable structural changes in the treatment of abnormal corneal shape is solved, the correction effect and durability are improved, and it is suitable for postoperative dilation of LASIK and other conditions.

CN114072149BActive Publication Date: 2024-11-12AFDRO GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980091188.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-12-04
Filing Date
2019-12-04
Publication Date
2024-11-12
Estimated Expiration
2039-12-04

AI Technical Summary

Technical Problem

The prior art When treating diseases caused by abnormal corneal shape, the structural changes of the crosslinking agent are unstable, resulting in weakening or reversal of the correction effect, especially in the expansion of LASIK after LASIK, making it difficult to maintain the correction effect for a long time.

Method used

Using specific chemical entity compounds and compositions thereof, cross-linking is induced by applying electromagnetic radiation to the cornea, enhancing the mechanical stiffness and stability of the corneal structure, and is used to treat diseases such as keratoconus, myopia, hyperopia, astigmatism, etc.

Benefits of technology

It effectively improves the stability and correction effect of corneal structure, extends the durability of treatment results, and reduces the occurrence of postoperative complications such as LASIK postoperative dilation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FDA0004998985920000011
    Figure FDA0004998985920000011
  • Figure FDA0004998985920000012
    Figure FDA0004998985920000012
  • Figure FDA0004998985920000021
    Figure FDA0004998985920000021
Patent Text Reader

Abstract

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or prodrugs of compounds) that produce crosslinks in the cornea in response to exposure to electromagnetic radiation. The present disclosure also features compositions comprising the chemical entities and other methods of using and preparing the same. The chemical entities can be used, for example, to treat a subject (e.g., a human) suffering from a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulging)) causes the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic diseases; (ii) vision conditions; (iii) diseases, disorders, or conditions that are sequelae of or coexist with any of the above or any of the diseases, disorders, or conditions described herein. More specific non-limiting examples of such diseases, disorders or conditions include keratoconus, corneal sphericity, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, such as post-LASIK ectasia), Terrien marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism and presbyopia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 775,305, filed December 4, 2018, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or prodrugs of compounds) that produce crosslinks in the cornea in response to exposure to electromagnetic radiation. The present disclosure also features compositions comprising the chemical entities and other methods of using and preparing the same. The chemical entities can be used, for example, to treat a subject (e.g., a human) suffering from a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulging)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; (iii) diseases, disorders, or conditions that are sequelae of or coexist with any of the above or any of the disclosed herein. More specific non-limiting examples of such diseases, disorders or conditions include keratoconus, keratosphere, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, such as post-LASIK ectasia), Terrien marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism and presbyopia. Background Art

[0004] Various eye conditions, such as myopia, keratoconus, and hyperopia, involve an abnormal shape of the cornea. For example, laser-assisted in situ keratomileusis (LASIK) is one of several corrective treatments that reshape the cornea so that light passing through it is properly focused onto the retina at the back of the eye. The success of a specific treatment to address the abnormal shape of the cornea depends on the stability of the structural changes after the treatment is applied.

[0005] Although treatment can initially achieve desired corneal remodeling, if the collagen fibrils in the cornea continue to change after achieving desired remodeling, the desired effect of remodeling the cornea may be at least partially weakened or reversed. For example, due to LASIK surgery causing corneal thinning and weakening, a complication known as post-LASIK ectasia may occur. During post-LASIK ectasia, the cornea gradually becomes steeper (protuberance). In order to strengthen and stabilize the structure of the cornea after remodeling, some treatments can also induce crosslinking in corneal tissue. For example, a photosensitizer (such as riboflavin) is applied to the cornea as a crosslinking agent. Once the crosslinking agent is applied to the cornea, the crosslinking agent is activated by a light source (such as ultraviolet (UV) light), causing the crosslinking agent to absorb enough energy, thereby releasing free oxygen radicals (such as singlet oxygen) and / or other free radicals in the cornea. Once released, the free radicals form covalent bonds between the corneal collagen fibrils, thereby crosslinking the corneal collagen fibrils and strengthening and stabilizing the corneal structure.

[0006] Because of the beneficial structural changes induced by crosslinkers, they can be used as a primary component of certain therapeutic approaches. For example, crosslinkers can be used to treat keratoconus. Crosslinking therapy can also be used to induce refractive changes in the cornea to correct conditions such as myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.

[0007] U.S. Patent Application Publication No. 2011 / 0237999, filed March 18, 2011; U.S. Patent Application Publication No. 2012 / 0215155, filed April 3, 2012; U.S. Patent Application No. 2014 / 0343480, filed May 19, 2014; U.S. Patent Application No. 2013 / 0060187, filed October 31, 2012; International Patent Application Publication No. 2011 / 130356, filed April 13, 2011 International Patent Application No. 2015 / 130944, filed February 26, 2015, and International Patent Application No. 2016 / 090016, filed December 2, 2015, describe systems and compositions (e.g., riboflavin or riboflavin phosphate eye drops) that can produce cross-linking activity in the cornea with or without removal of corneal epithelial cells in the treatment of ocular diseases, such as keratoconus (e.g., progressive keratoconus) or corneal ectasia after refractive surgery. VISCOUS (riboflavin 5'-phosphate 20% dextran eye drops) 0.146% and (Riboflavin 5'-phosphate eye drops) 0.146% is suitable for KXL TM A photoenhancer for a system for corneal collagen cross-linking to treat progressive keratoconus. Summary of the Invention

[0008] The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or prodrugs of compounds) that produce crosslinks in the cornea in response to exposure to electromagnetic radiation. The present disclosure also features compositions comprising the chemical entities and other methods of using and preparing the same. The chemical entities can be used, for example, to treat a subject (e.g., a human) suffering from a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulge)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic diseases; (ii) vision conditions; (iii) diseases, disorders, or conditions that are sequelae to or coexist with any of the above or any of the disclosed herein. More specific non-limiting examples of such diseases, disorders or conditions include keratoconus, keratosphere, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, such as post-LASIK ectasia), Terrien marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism and presbyopia.

[0009] In one aspect, the characteristic chemical entity comprises a compound of Formula I or a pharmaceutically acceptable salt thereof:

[0010]

[0011] where R 1 , R 2 , R 3 , X, Y, Z and Z X May be as defined anywhere herein.

[0012] In one aspect, a pharmaceutical composition is characterized by including a chemical entity described herein (eg, a compound as generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same) and one or more pharmaceutically acceptable excipients.

[0013] In one aspect, a method for producing crosslinks in the cornea is characterized by contacting the cornea with a chemical entity as described herein (e.g., a compound as generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same); and applying electromagnetic radiation to the cornea. The method can include, for example, administering the chemical entity to the cornea of ​​a subject (e.g., a human) suffering from a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulge)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., keratoconus, corneal sphericity, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia); and applying electromagnetic radiation to the cornea. Methods may include, but are not limited to, providing refractive correction to the cornea (eg, by imparting mechanical rigidity) and strengthening and stabilizing the structure of the cornea.

[0014] In another aspect, the method of treating a disease, disorder, or condition is characterized in that an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulge)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. The method comprises administering a chemical entity described herein (e.g., a compound generally or specifically described herein, a pharmaceutically acceptable salt thereof, or a composition comprising the same) in an amount effective to treat the disease, disorder, or condition.

[0015] In another aspect, a method for treating a disease, disorder, or condition is characterized in that an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulge)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. The method comprises administering to the cornea of ​​a subject in need of such treatment an effective amount of a chemical entity as described herein (e.g., a compound generally or specifically described herein, a pharmaceutically acceptable salt thereof, or a composition comprising the same); and applying electromagnetic radiation to the cornea.

[0016] A non-limiting example of such diseases, disorders, and conditions is a corneal ectatic disease. In certain embodiments, the corneal ectatic disease is keratoconus. In certain embodiments, the corneal ectatic disease is keratoglobus. In certain embodiments, the corneal ectatic disease is pellucid marginal degeneration. In certain embodiments, the corneal ectatic disease is corneal ectasia (e.g., postoperative ectasia, such as post-LASIK ectasia). In certain embodiments, the corneal ectatic disease is Terrien marginal degeneration.

[0017] Another non-limiting example of such diseases, disorders, and conditions is a vision condition. In certain embodiments, the vision condition is myopia. In certain embodiments, the vision condition is hyperopia. In certain embodiments, the vision condition is myopia. In certain embodiments, the vision condition is hyperopia. In certain embodiments, the vision condition is astigmatism. In certain embodiments, the vision condition is irregular astigmatism. In certain embodiments, the vision condition is presbyopia.

[0018] Implementations can include one or more of the following advantageous features.

[0019] In some embodiments, the chemical entities and compositions described herein can be applied to the cornea without prior removal of corneal epithelial cells, thereby increasing patient comfort.

[0020] In some embodiments, the chemical entities and compositions described herein can be cross-linked in the cornea using relatively short durations of electromagnetic radiation.

[0021] Other implementations include those described in the detailed description and / or claims.

[0022] Other definitions

[0023] In order to promote the understanding of the disclosure set forth herein, a plurality of other terms are defined below. Generally, the nomenclature used herein and the laboratory procedures of organic chemistry, medicinal chemistry and pharmacology described herein are well-known and commonly used in the art. Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art. Each patent, application, disclosed application and other publications mentioned throughout the specification, as well as the appendix attached, are incorporated herein by reference in their entirety.

[0024] As used herein, the term "acceptable" with respect to a formulation, composition or ingredient means having no persistent detrimental effect on the general health of the subject being treated.

[0025] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a chemical entity (e.g., a compound described generally or specifically herein, a pharmaceutically acceptable salt thereof, or a composition comprising the same) administered to alleviate to some extent one or more symptoms of the disease or condition being treated. Results include reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant alleviation of the symptoms of the disease. In any individual case, an appropriate "effective" amount may be determined using any appropriate technique (e.g., a dose escalation study).

[0026] The term "excipient" or "pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In one embodiment, each component is "pharmaceutically acceptable" in the sense that it is compatible with the other ingredients of the pharmaceutical formulation and is suitable for use in contact with human and animal tissues or organs without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, and is commensurate with a reasonable benefit / risk ratio. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed., Ash and Ash, eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed., Gibson, ed., CRC Press LLC: Boca Raton, FL, 2009.

[0027] The term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some cases, pharmaceutically acceptable salts are obtained by reacting the compounds described herein with acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. In some cases, pharmaceutically acceptable salts are obtained by reacting the compounds described herein having an acidic group with a base to form a salt such as an ammonium salt, an alkali metal salt (such as a sodium salt or potassium salt), an alkaline earth metal salt (such as a calcium salt or magnesium salt), a salt of an organic base (such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine), and a salt formed with an amino acid (such as arginine, lysine, etc.), or by other methods previously determined. There is no particular limitation on the pharmacologically acceptable salt, as long as it can be used in medicine. Examples of salts of the compounds described herein with bases include: salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; salts with organic bases such as methylamine, ethylamine, and ethanolamine; salts with basic amino acids such as lysine and ornithine; and ammonium salts. The salts may be acid addition salts, specifically exemplified by acid addition salts with the following acids: inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid.

[0028] The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components (collectively referred to herein as "excipients"), such as carriers, stabilizers, diluents, dispersants, suspending agents, and / or thickening agents. Pharmaceutical compositions facilitate administration of a compound to an organism. Various techniques exist in the art for administering a compound, including, but not limited to, rectal, oral, intravenous, aerosol, parenteral, ocular, pulmonary, and topical administration.

[0029] The term "subject" can refer to an animal, including but not limited to a primate (e.g., a human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" are used interchangeably herein, e.g., to refer to a mammalian subject, e.g., a human.

[0030] In the context of treating a disease, disorder or condition, the term "treat," ...

[0031] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).

[0032] The term "alkyl" refers to a hydrocarbon chain which may be straight or branched, containing the indicated number of carbon atoms. For example, C 1-10 Indicates that the group may have 1 to 10 (inclusive) carbon atoms. Non-limiting examples include methyl, ethyl, isopropyl, tert-butyl, n-hexyl.

[0033] The term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by independently selected halogens.

[0034] The term "alkoxy" refers to an -O-alkyl group (eg, -OCH3).

[0035] The term "haloalkoxy" refers to an -O-haloalkyl group (eg, -OCF3).

[0036] The term "alkylene" refers to a branched or unbranched divalent alkyl group (eg, -CH2-).

[0037] The term "arylene" and the like refer to the divalent form of the ring system, here a divalent aryl group.

[0038] The term "alkenyl" refers to a hydrocarbon chain that may be straight or branched and has one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C 2-6 It means that the group may have 2 to 6 (inclusive) carbon atoms.

[0039] The term "alkynyl" refers to a hydrocarbon chain that may be straight or branched and has one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C 2-6 It means that the group may have 2 to 6 (inclusive) carbon atoms.

[0040] The term "aryl" refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system, wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted with substituents, and the ring containing the monocyclic group is aromatic, and at least one of the fused rings containing the bicyclic or tricyclic group is aromatic, for example, tetrahydronaphthyl. Examples of aryl groups also include phenyl, naphthyl, and the like.

[0041] The term "cycloalkyl" as used herein includes saturated cyclic hydrocarbon groups having 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, wherein the cycloalkyl group may be optionally substituted. Preferred cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0042] The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, the heteroatoms being selected from O, N or S (e.g., carbon atoms and 1-3, 1-6 or 1-9 heteroatoms of N, O or S for the monocyclic, bicyclic or tricyclic rings, respectively), wherein 0, 1, 2, 3 or 4 atoms of each ring may be substituted with substituents, and the ring in which the monocyclic group is contained is aromatic, and at least one of the fused rings in which the bicyclic or tricyclic group is contained is aromatic, but need not necessarily be a ring containing heteroatoms, such as tetrahydroisoquinolinyl. Exemplary heteroaryl systems are derived from, but are not limited to, the following ring systems: pyrrole, furan, thiophene, imidazole, pyrazole, oxazole (= [1,3] oxazole), isoxazole (= [1,2] oxazole), thiazole (= [1,3] thiazole), isothiazole (= [1,2] thiazole), [1,2,3] triazole, [1,2,4] triazole, [1,2,4] oxadiazole, [1,3,4] oxadiazole, [1,2,4] thiadiazole, [1,3,4] thiadiazole, tetrazole, pyridine, pyridazine , pyrimidine, pyrazine, [1,2,3]triazine, [1,2,4]triazine, [1,3,5]triazine, indole, isoindole, benzofuran, benzothio[1,3]benzoxazole, [1,3]benzothiazole, benzimidazole, indazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, various naphthyridines such as [1,8]naphthyridine, various thienopyridines such as thieno[2,3-b]pyridine, and purines.

[0043] The term "heterocyclyl" refers to a non-aromatic 5-8 membered monocyclic, 8-12 membered bicyclic or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, wherein the heteroatoms are selected from O, N or S (e.g., carbon atoms and 1-3, 1-6 or 1-9 heteroatoms of N, O or S for the monocyclic, bicyclic or tricyclic rings, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted with substituents. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl and the like.

[0044] As used herein, the term "heterocyclenyl" refers to a partially unsaturated ring system having 3-16 ring atoms (e.g., a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system), with 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic or polycyclic), the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S for the monocyclic, bicyclic, or tricyclic ring, respectively), wherein 0, 1, 2, or 3 atoms of each ring may be substituted with a substituent. Examples of heterocyclenyl groups include, but are not limited to, imidazolinyl, tetrahydropyridinyl, dihydropyrazinyl, dihydropyridinyl, and dihydropyrrolyl.

[0045] As used herein, when a ring is described as "partially unsaturated," it is meant that the ring has one or more additional degrees of unsaturation (in addition to the unsaturation attributable to the ring itself; for example, one or more double or triple bonds between atoms comprising the ring), provided that the ring is not aromatic. Examples of such rings include: cyclopentene, cyclohexene, cycloheptene, dihydropyridine, tetrahydropyridine, dihydropyrrole, dihydrofuran, dihydrothiophene, and the like.

[0046] In addition, the atoms comprising the compounds of the present invention are intended to include all isotopic forms of said atoms. As used herein, isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include 13 C and 14 C.

[0047] The details of one or more embodiments of the invention are set forth in the following description and in the appended appendix, which is expressly considered a part of this disclosure. Other features and advantages will also be apparent from the claims. Detailed Description of the Invention

[0049] Compounds of formula (I)

[0050] In one aspect, the disclosure features compounds of formula (I):

[0051]

[0052] or a pharmaceutically acceptable salt thereof;

[0053] in:

[0054] X is selected from H, NR 4X R 5X and optionally 1-3 R a Substituted C1-C6 alkyl;

[0055] Y is selected from the following group:

[0056] (i)CO2R 6Y ;

[0057] (ii)C(O)NR 4Y R 5Y ;

[0058] (iii) a heteroaryl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c Replacement; and

[0059] (iv) a heterocycloalkenyl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heterocyclenyl ring carbon atoms are optionally replaced by 1-2 independently selected R b replace;

[0060] Z is selected from the following group:

[0061] (i)H,

[0062] (ii)C 1-6 alkyl,

[0063] (iii)NR 4Z R 5Z ,

[0064] (iv)OR 6Z ,

[0065] (v)OC(O)R 7Z ,

[0066] (vi)OP(O)OR 8Z OR 9Z ,and

[0067] (vii); a heterocyclic group containing 4-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R h replace;

[0068] Each Z x It is H; or each Z x Together with their respective attached carbons, they form C=O;

[0069] R 1 、R 2 and R3 Each independently selected from R 6A 、C(O)R 7A and P(O)OR 8A OR 9A ;

[0070] R 4X and R 5X Each independently selected from: H, C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;

[0071] R 4Y and R 5Y Each independently selected from the following group:

[0072] (i)H;

[0073] (ii)C 1-12 Alkyl, which is optionally replaced by 1-6 R a replace;

[0074] (iii) a heteroaryl group containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h replace;

[0075] (iv)–(W 1 –W 2 ) n -W 3 ,in:

[0076] Every time it appears, W 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0077] Every time it appears, W 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0078] W 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 Ra Replacement; and

[0079] n is 2-4;

[0080] or

[0081] (v)R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R 4Y and R 5Y N(H), N(R) d ), O and S;

[0082] R 4Z and R 5Z Each independently selected from the following group:

[0083] (i)H;

[0084] (ii)C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a replace;

[0085] (iii)C 3-6 Cycloalkyl;

[0086] (iv)-C(O)(C 1-4 alkyl);

[0087] (v)-C(O)O(C 1-4 alkyl);

[0088] (vi)-CON(R')(R");

[0089] (vii)-S(O) 1-2 (NR’R”);

[0090] (viii)-S(O) 1-2 (C 1-4 alkyl);

[0091] (ix)–OH;

[0092] (x)C 1-4 alkoxy; and

[0093] (xi)–(Q 1 –Q 2 ) q -Q 3 ,in:

[0094] · Every time it appears, Q 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0095] · Every time it appears, Q 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0096] Q 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a Replacement; and

[0097] q is 2-4;

[0098] Each time it appears, R 6A Independently selected from the group consisting of:

[0099] (i) H; and

[0100] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0101] R 6Z Independently selected from the following group:

[0102] (i)H;

[0103] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0104] (iii)–(C 0-2 alkylene)-(C 6-10 aryl), wherein C 6-10 Aryl is optionally substituted with 1-2 independently selected R h replace;

[0105] (iv)–(C 0-2 alkylene)-(heteroaryl), wherein the heteroaryl group contains 5-10 ring atoms, 1-4 of which are heteroatoms, each independently selected from N, N(H), N(C 1-3 alkyl), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h replace;

[0106] (v)–(C 1-2 Alkylene)-C(=O)NH-(C 1-3 Alkylene)-R 6Z’ ,and

[0107] (vi)–(T 1 –T 2 ) t -T 3 ,in:

[0108] Each time it appears, T 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0109] Each time it appears, T 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0110] ·T 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a Replacement; and

[0111] t is 2-4;

[0112] R 6Z’ Select from the following groups:

[0113] C(=O)OH,N(C 1-4 alkyl)2, NH2, NH(C 1-4 alkyl), and heterocyclyl containing 3-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected C 1-3 Alkyl substitution;

[0114] Each time it appears, R 6Y Independently selected from the group consisting of:

[0115] (i)H;

[0116] (ii)-(Y 1 ) m -Y 2 ,in:

[0117] m is 0 or 1;

[0118] ·Y 1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a Replacement; and

[0119] ·Y 2 yes:

[0120] (a)C 3-10Cycloalkyl, which is optionally substituted by 1-4 R b replace,

[0121] (b)C 6-10 Aryl, which is optionally substituted by 1-4 R c replace;

[0122] (c) a heteroaryl group containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or

[0123] (d) a heterocyclic group containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace;

[0124] (iii)C 1-12 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0125] (iv)–(Z 1 –Z 2 ) p -Z 3 ,in:

[0126] · Every time it appears, Z 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0127] · Every time it appears, Z 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0128] ·Z 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a Replacement; and

[0129] p is 2-4;

[0130] Each time it appears, R 7Z and R 7A Each independently selected from the following group:

[0131] (i)H;

[0132] (ii)C 1-10Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0133] (iii)C 6-10 Aryl, which is optionally substituted by 1-4 R c Replacement; and

[0134] (iv)C 3-6 Cycloalkyl, which is optionally substituted by 1-4 R b replace;

[0135] Each time it appears, R 8A 、R 8Z 、R 9A and R 9Z Each independently

[0136] (i) H; or

[0137] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0138] Each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 0-2 (C 1-4 alkyl); C(=NH)N(R')(R"); cyano; and C 3-6 Cycloalkyl, which is optionally substituted by 1-4 independently selected C 1-4 Alkyl substitution;

[0139] Each occurrence of R b Independently selected from the group consisting of: C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2(NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and C 3-6 Cycloalkyl, which is optionally substituted by 1-4 independently selected C 1-4 Alkyl substitution;

[0140] Each occurrence of R c Independently selected from the group consisting of:

[0141] (i) halogen;

[0142] (ii) cyano;

[0143] (iii)C 1-10 alkyl;

[0144] (iv) 1-6 independently selected R a Substituted C 1-10 alkyl;

[0145] (v) optionally 1-3 independently selected R b Substituted C 3-6 Cycloalkyl;

[0146] (vi)C 2-6 alkenyl;

[0147] (vii)C 2-6 Alkynyl;

[0148] (viii)C 1-4 alkoxy;

[0149] (ix)C 1-4 haloalkoxy;

[0150] (x) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;

[0151] (xi)-S(O) 1-2 (C 1-4 alkyl);

[0152] (xii)-NR e R f ;

[0153] (xiii)–OH;

[0154] (xiv)-S(O) 1-2 (NR’R”);

[0155] (xv)-C 1-4 Thioalkoxy;

[0156] (xvi)-NO2;

[0157] (xvii)-C(=O)(C 1-4 alkyl);

[0158] (xviii)-C(=O)O(C 1-4 alkyl);

[0159] (xix)-C(=O)OH; and

[0160] (xx)-C(=O)N(R′)(R”);

[0161] R d Selected from the group consisting of: optionally 1-3 independently selected R g Substituted C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;

[0162] Each occurrence of R e and R f Independently selected from the group consisting of: H; C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;

[0163] Or, R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R e and R f N(H), N(R) d ), O and S;

[0164] Each occurrence of R g Independently selected from the group consisting of: -OH, -F, NR'R", C 1-3 Alkoxy, -CON(R')(R"), -CONHS(O)2(C 1-4 alkyl) and –C(O)OH;

[0165] Each occurrence of R h Independently selected from the group consisting of: C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 haloalkoxy and halogen;

[0166] as well as

[0167] Each occurrence of R' and R" is independently selected from the group consisting of H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each ring carbon atom is replaced by 1-2 independently selected from H and C 1-3 and (b) 0-3 ring heteroatoms (excluding the nitrogen atoms connected to R' and R ") each independently selected from N (H), N (R d ), O and S.

[0168] In some embodiments, the compound is not one or more of the following:

[0169]

[0170] or a pharmaceutically acceptable salt thereof.

[0171] In some embodiments, the compound is not one or more of the following:

[0172] or a pharmaceutically acceptable salt thereof.

[0173] In another aspect, provided herein are compounds of formula (I):

[0174]

[0175] or a pharmaceutically acceptable salt thereof;

[0176] in:

[0177] X is selected from H, NR 4X R 5X and optionally 1-3 R a Substituted C1-C6 alkyl;

[0178] Y is selected from the following group:

[0179] (i)CO2R 6Y ;

[0180] (ii)C(O)NR 4Y R 5Y ;and

[0181] (iii) a heteroaryl group containing 5 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace;

[0182] Z is selected from H, C 1-6 Alkyl, NR 4Z R 5Z , OR 6Z 、OC(O)R 7Z and OP(O)OR 8Z OR 9Z ;

[0183] Each Z x It is H; or each Z x Together with their respective attached carbons, they form C=O;

[0184] R 1 、R 2 and R 3 Each independently selected from R 6A 、C(O)R 7A and P(O)OR 8A OR 9A ;

[0185] R 4X and R 5X Each independently selected from the group consisting of: H, C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;

[0186] R 4Y and R 5Y Each independently selected from the following group:

[0187] (i)H;

[0188] (ii)C 1-12 Alkyl, which is optionally replaced by 1-6 R a replace;

[0189] (iii)–(W 1 –W 2 ) n -W 3 ,in:

[0190] Every time W appears 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0191] Every time W appears 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0192] W 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a Replacement; and

[0193] n is 2-4;

[0194] or

[0195] (iv)R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R 4Y and R 5Y N(H), N(R) d ), O and S;

[0196] R 4Z and R 5Z Each independently selected from the following group:

[0197] (i)H;

[0198] (ii)C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a replace;

[0199] (iii)C 3-6 Cycloalkyl;

[0200] (iv)-C(O)(C1-4 alkyl);

[0201] (v)-C(O)O(C 1-4 alkyl);

[0202] (vi)-CON(R')(R");

[0203] (vii)-S(O) 1-2 (NR’R”);

[0204] (viii)-S(O) 1-2 (C 1-4 alkyl);

[0205] (ix)–OH;

[0206] (x)C 1-4 alkoxy; and

[0207] (xi)–(Q 1 –Q 2 ) q -Q 3 ,in:

[0208] · Every time Q appears 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a Replace; · Every time Q appears 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0209] Q 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a substituted; and q is 2-4;

[0210] Every time R appears 6A Independently selected from the group consisting of:

[0211] (i) H; and

[0212] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0213] R 6Z Independently selected from the following group:

[0214] (i)H;

[0215] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a Replacement; and

[0216] (iii)–(T 1 –T 2 ) t -T 3 ,in:

[0217] · Every time T appears 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a Replace; Every time T appears 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0218] ·T 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a substituted; and t is 2-4;

[0219] Every time R appears 6Y Independently selected from the group consisting of:

[0220] (i)H;

[0221] (ii)-(Y 1 ) m -Y 2 ,in:

[0222] m is 0 or 1;

[0223] ·Y 1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a Replacement; and

[0224] ·Y 2 yes:

[0225] (a)C 3-10 Cycloalkyl, which is optionally substituted by 1-4 R b replace,

[0226] (b)C 6-10 Aryl, which is optionally substituted by 1-4 R c replace;

[0227] (c) a heteroaryl group containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or

[0228] (d) a heterocyclic group containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace;

[0229] (iii)C 1-12 Alkyl, optionally substituted with 1-6 independently selected R a Replacement; and

[0230] (iv)–(Z 1 –Z 2 ) p -Z 3 ,in:

[0231] · Every time Z appears 1 Independently C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0232] · Every time Z appears 2 are independently -N(H)-, -N(R d )-, -O-, or –S-;

[0233] ·Z 3 Is H or C 1-7 Alkyl, which is optionally replaced by 1-4 R a Replacement; and

[0234] p is 2-4;

[0235] Each time it appears, R 7Z and R 7A Each independently selected from the following group:

[0236] (i)H;

[0237] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0238] (iii)C 6-10 Aryl, which is optionally substituted by 1-4 R c Replacement; and

[0239] (iv)C 3-6 Cycloalkyl, which is optionally substituted by 1-4 R b replace;

[0240] Each time it appears, R 8A 、R 8Z 、R 9A and R9Z Each independently

[0241] (i) H; or

[0242] (ii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace;

[0243] Each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 0-2 (C 1-4 alkyl); cyano; and C 3-6 Cycloalkyl, which is optionally substituted by 1-4 independently selected C 1-4 Alkyl substitution;

[0244] Each occurrence of R b Independently selected from the group consisting of: C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and C 3-6 Cycloalkyl, which is optionally substituted by 1-4 independently selected C 1-4 Alkyl substitution;

[0245] Each occurrence of R c Independently selected from the group consisting of:

[0246] (i) halogen;

[0247] (ii) cyano;

[0248] (iii)C 1-10 alkyl;

[0249] (iv) 1-6 independently selected R a Substituted C 1-10 alkyl;

[0250] (v) optionally 1-3 independently selected R b Substituted C 3-6 Cycloalkyl;

[0251] (vi)C 2-6 alkenyl;

[0252] (vii)C 2-6 Alkynyl;

[0253] (viii)C 1-4 alkoxy;

[0254] (ix)C 1-4 haloalkoxy;

[0255] (x) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;

[0256] (xi)-S(O) 1-2 (C 1-4 alkyl);

[0257] (xii)-NR e R f ;

[0258] (xiii)–OH;

[0259] (xiv)-S(O) 1-2 (NR’R”);

[0260] (xv)-C 1-4 Thioalkoxy;

[0261] (xvi)-NO2;

[0262] (xvii)-C(=O)(C 1-4 alkyl);

[0263] (xviii)-C(=O)O(C 1-4 alkyl);

[0264] (xix)-C(=O)OH; and

[0265] (xx)-C(=O)N(R′)(R”);

[0266] R d Select from the following group: C1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;

[0267] Each occurrence of R e and R f Independently selected from the group consisting of: H; C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy; and

[0268] Each occurrence of R' and R" is independently selected from the group consisting of H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each ring carbon atom is replaced by 1-2 independently selected from H and C 1-3 and (b) 0-3 ring heteroatoms (excluding the nitrogen atoms connected to R' and R ") each independently selected from N (H), N (R d ), O and S.

[0269] In some embodiments, the compound is not one or more of the following:

[0270] or a pharmaceutically acceptable salt thereof.

[0271] In some embodiments, the compound is not one or more of the following:

[0272] or a pharmaceutically acceptable salt thereof.

[0273] In some embodiments, when X is optionally replaced by 1-3 R aWhen X is substituted C1-C6 alkyl (e.g., unsubstituted C1-C6 (e.g., C1-C3) alkyl, e.g., X is CH3), Y is not CO2H, CO2Me, CO2Et or CO2NH2; or Y is not CO2H or CO2NH2.

[0274] In some embodiments, when X is optionally replaced by 1-3 R a When Z is OH, Y is not CO2H, CO2Me, CO2Et or CO2NH2.

[0275] In some embodiments, when X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl (eg, X is unsubstituted C1-C6 (eg, C1-C3) alkyl, eg, X is CH3), R 1 、R 2 and R 3 When each is H and Z is OH, Y is not CO2H, CO2Me, CO2Et or CO2NH2.

[0276] In some embodiments, when X is optionally replaced by 1-3 R a When Z is substituted C1-C6 alkyl (eg, X is unsubstituted C1-C6 (eg, C1-C3) alkyl, eg, X is CH3) and Z is OAc, Y is not CO2H or CO2NH2.

[0277] In some embodiments, when X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl (eg, X is unsubstituted C1-C6 (eg, C1-C3) alkyl, eg, X is CH3), R 1 、R 2 and R 3 When each is C(O)Me and Z is OAc, Y is not CO2H or CO2NH2.

[0278] In some embodiments, when X is NR 4X R 5X (For example, R 4X and R 5X Each is independent of C 1-6 Alkyl; for example, R 4X and R 5X When each is CH3) and Z is OH, Y is not CO2H.

[0279] In some embodiments, when X is NR 4X R 5X (For example, R 4Xand R 5X Each is independent of C 1-6 Alkyl; for example, R 4X and R 5X Each is CH3), R 1 、R 2 and R 3 When each is H and Z is OH, Y is not CO2H.

[0280] In some embodiments, when X is NR 4X R 5X (For example, R 4X and R 5X Each is independent of C 1-6 Alkyl; for example, R 4X and R 5X When each is CH3) and Z is OAc, Y is not CO2H.

[0281] In some embodiments, when X is NR 4X R 5X (For example, R 4X and R 5X Each is independent of C 1-6 Alkyl; for example, R 4X and R 5X Each is CH3), R 1 、R 2 and R 3 When each is C(O)Me and Z is OAc, Y is not CO2H.

[0282] In some embodiments, when R 1 、R 2 and R 3 When each is H, and when Z is OH, Y is not CO2H, CO2Me, CO2Et or CO2NH2.

[0283] In some embodiments, when R 1 、R 2 and R 3 When each is C(O)Me, and when Z is OAc (ie, OC(O)Me), Y is not CO2H or CONH2.

[0284] VARIABLE X

[0285] In some embodiments, X is H.

[0286] In some embodiments, X is C1-C6 alkyl, which is optionally substituted with 1-3 R a replace.

[0287] In some embodiments, X is an unsubstituted C1-C6 alkyl group (e.g., an unsubstituted C 1- C3 alkyl). In some embodiments, X is CH3.

[0288] In some embodiments, X is a C1-C6 alkyl group, which is surrounded by 1-3 R a replace.

[0289] In some embodiments, X is replaced by 1-3 R a Substituted methyl (eg, X is trifluoromethyl or difluoromethyl).

[0290] In some embodiments, X is C2-C6 alkyl, which is optionally substituted with 1-3 R a replace.

[0291] In some embodiments, X is a C2-C6 alkyl group, which is surrounded by 1-3 R a replace.

[0292] In certain of the foregoing embodiments, wherein X is optionally replaced by 1-3 R a Substituted C 1- C6 alkyl, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.

[0293] In certain of the foregoing embodiments, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 haloalkoxy; cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.

[0294] In some embodiments, X is NR 4X R5X .

[0295] In certain embodiments, R 4X and R 5X None of them are H (e.g., R 4X and R 5X are each independently selected C1-C6 alkyl).

[0296] In certain embodiments, R 4X and R 5X One of them is H; and R 4X and R 5X The other one is not H (for example, R 4X and R 5X One of them is H; and R 4X and R 5X The other of which is an independently selected C1-C6 alkyl).

[0297] In certain embodiments, R 4X and R 5X Both are H.

[0298] In certain embodiments, R 4X and R 5X Each independently selected from the group consisting of: H; C 1-6 Alkyl; C 3-6 Cycloalkyl; and C 1-4 Alkoxy.

[0299] In certain embodiments, R 4X and R 5X One of which is independently selected from the group consisting of H, C 1-6 Alkyl; C 3-6 Cycloalkyl; and C 1-4 Alkoxy; R 4X and R 5X The other of 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH.

[0300] In certain embodiments, when X is NR 4X R 5X When R 4X and R 5X Each is independently H or C 1-6 alkyl.

[0301] In certain embodiments, R4X and R 5X Each is an independent C 1-6 Alkyl (e.g., independent C 1-3 In certain embodiments, R 4X and R 5X All the same C 1-6 Alkyl. For example, R 4X and R 5X In other embodiments, R 4X and R 5X Each is a different C 1-6 alkyl.

[0302] variable Y

[0303] In some embodiments, Y is CO2R 6Y .

[0304] variable R 6Y

[0305] In some embodiments, R 6Y It’s H.

[0306] In some embodiments, R 6Y Yes-(Y 1 ) m -Y 2 .

[0307] In some embodiments, m is 0.

[0308] In other embodiments, m is 1. In certain of the foregoing embodiments, Y 1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a As a non-limiting example, Y 1 It may be an ethylene group or a methylene group (eg, an unsubstituted ethylene group or a methylene group).

[0309] In some embodiments, Y 2 It is C 3-10 Cycloalkyl, which is optionally substituted by 1-4 R b replace.

[0310] In certain embodiments, Y 2 It is C 3-8 Cycloalkyl, which is optionally substituted by 1-4 R b replace.

[0311] In certain embodiments, Y 2 is a C3 cycloalkyl group, which is optionally substituted by 1-2 R b replace.

[0312] In certain embodiments, Y 2 It is C 5-6 Cycloalkyl, which is optionally substituted by 1-4 R b replace.

[0313] In certain embodiments, Y 2 is a C5 cycloalkyl group, which is optionally substituted by 1-4 R b replace.

[0314] In certain embodiments, Y 2 is a C6 cycloalkyl group, which is optionally substituted by 1-4 R b replace.

[0315] In some embodiments, Y 2 It is C 6-10 Aryl, which is optionally substituted by 1-4 R c replace.

[0316] In certain embodiments, Y 2 is a C6 aryl group, which is optionally substituted by 1-4 R c replace.

[0317] In certain embodiments, Y 2 It is C 10 Aryl, which is optionally substituted by 1-4 R c replace.

[0318] In some embodiments, Y 2 is a heteroaryl group containing 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c replace.

[0319] In certain embodiments, Y 2 is a heteroaryl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c replace.

[0320] In some embodiments, Y 2 is a heterocyclic group containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace.

[0321] In certain embodiments, Y 2 is a heterocyclic group containing 4-6 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-2 independently selected R b replace.

[0322] In some embodiments, R 6Y It is C 1-12 (For example, C 1-6 , C 2-6 , C 2-3 ) alkyl, which is optionally substituted by 1-6 (eg, unsubstituted; or by 1-2, eg, 1) independently selected R a replace.

[0323] In some embodiments, R 6Y It is C 1-12 Alkyl, optionally substituted by 1-6 (e.g., 1-2) independently selected R a replace.

[0324] In some embodiments, R 6Y It is C 1-6 Alkyl, optionally substituted by 1-6 (e.g., 1-2) independently selected R a replace.

[0325] In some embodiments, R 6Y It is C 2-6 Alkyl, optionally substituted by 1-6 (e.g., 1-2) independently selected R a replace.

[0326] In some embodiments, R 6Y It is C 1-3 Alkyl, optionally substituted by 1-6 (e.g., 1-2) independently selected R a replace.

[0327] In certain embodiments, R 6Y It is C 2-3 Alkyl, optionally substituted by 1-6 (e.g., 1-2) independently selected R a substituted (e.g., optionally with 1 R a substituted C2 alkyl).

[0328] In certain embodiments, R 6Y It is C 1-3 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a substituted C2 alkyl).

[0329] In certain embodiments, R 6Y yes where R a As defined elsewhere herein (in certain embodiments, R a Selected from the group consisting of: –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 haloalkoxy).

[0330] In certain embodiments, R 6Y yes And R a It is NR e R f In certain of these embodiments, R e and R f Each is H or C 1-6 Alkyl. For example, R e and R f Each can be C 1-3 alkyl.

[0331] In certain embodiments, R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 (e.g., 5-6) ring atoms, wherein the ring contains: (a) 1-7 (e.g., 1-5) ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R e and R f N(H), N(R) d ), O and S;

[0332] As a non-limiting example, R 6Y Can be

[0333] In certain of the foregoing embodiments, when R 6Y It is C 1-12 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 0-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.

[0334] In certain embodiments, when R 6Y It is C 1-12 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0335] In some embodiments, R 6Y is unsubstituted C 1-12 alkyl.

[0336] In some embodiments, R 6Y is unsubstituted C 1-6 alkyl.

[0337] In some embodiments, R 6Y is unsubstituted C 1-4 Alkyl (eg, methyl or ethyl).

[0338] In some embodiments, R 6Y is unsubstituted C 2-12 alkyl.

[0339] In some embodiments, R 6Y is unsubstituted C 2-6 alkyl.

[0340] In some embodiments, R 6Y is unsubstituted C 2-4 alkyl.

[0341] In some embodiments, R 6Y is unsubstituted C 2-3 alkyl.

[0342] In some embodiments, R 6Y is unsubstituted C 2-12 alkyl.

[0343] In some embodiments, R 6Y is unsubstituted C 3-6 alkyl.

[0344] In some embodiments, R 6Y is unsubstituted C 3-4 alkyl.

[0345] In some embodiments, R 6Y Yes – (Z 1 –Z 2 ) p -Z 3 .

[0346] In certain embodiments, p is 2-4 (e.g., 2-3). In certain of the foregoing embodiments, each occurrence of Z 1 Independently selected from C 1-3 Alkylene (eg, C2 alkylene), optionally substituted by 1-4 (eg, 1-2) R a As a non-limiting example, each Z 1 It may be an unsubstituted C2 alkylene group.

[0347] In some embodiments, each occurrence of Z 2 are independently selected from -N(H)-, -N(R d )-, -O-, and –S-.

[0348] In certain embodiments, each occurrence of Z 2 are independently selected from -N(H)-, -N(Me)-, and -O-.

[0349] In some embodiments, Z 3 Is H or C 1-3 Alkyl, which is optionally replaced by 1-4 R a replace.

[0350] In certain embodiments, Z 3 is H or unsubstituted C 1-3 alkyl.

[0351] In certain embodiments, when R 6Y Yes – (Z 1 –Z 2 ) p -Z 3 , p is 2-3; each occurrence of Z 1 is an unsubstituted C2 alkylene group; each occurrence of Z 2 are independently selected from -N(H)-, -N(Me)-, and -O-; and Z 3 is H or unsubstituted C 1-3 alkyl.

[0352] In some embodiments, when Y is CO2R 6Y When Y is selected from CO2H and CO2Me.

[0353] In some embodiments, when Y is CO2R 6Y When Y is In certain of the foregoing embodiments, R on Y a Selected from –OH; -F; –NR e R f (e.g. NMe2); C 1-4 Alkoxy; and C 1-4 Haloalkoxy (for example, Y can be ).

[0354] In some embodiments, when Y is CO2R 6Y When Y is not CO2H, CO2Me or CO2Et.

[0355] In some embodiments, Y is C(O)NR 4Y R 5Y .

[0356] variable R 4Y / R 5Y

[0357] In certain of the foregoing embodiments, when Y is C(O)NR 4Y R 5Y When R 4Y and R 5Y Each independently selected from the following group:

[0358] (i)H;

[0359] (ii)C 1-12 Alkyl, which is optionally replaced by 1-4 R a replace;

[0360] (iii)–(W 1 –W 2 ) n -W 3 ,in:

[0361] W 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;

[0362] W 2 It is -N(H)-, -N(R d )-, -O-, or –S-;

[0363] W 3 Is H or C 2-7 Alkyl, which is optionally replaced by 1-4 R a Replacement; and

[0364] n is 2-4;

[0365] or

[0366] (iv)R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R 4Y and R 5Y N(H), N(R) d ), O and S;

[0367] In some embodiments, R 4Y It’s H.

[0368] In some embodiments, R 4Y It is C 1-12 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0369] In certain embodiments, R 4Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R a substituted C2 alkyl).

[0370] In certain embodiments, R 4Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a substituted C2 alkyl).

[0371] In certain embodiments, R 4Y yes where R a As defined elsewhere herein. In certain of the foregoing embodiments, R a It is –OH, –NR e R f 、C 1-4 Alkoxy or C 1-4 As a non-limiting example, R 4Y Can be

[0372] In certain of the foregoing embodiments, when R 4Y It is C 1-12 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NRe R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and C 3-6 Cycloalkyl, which is optionally substituted by 1-4 independently selected C 1-4 Alkyl substitution.

[0373] In certain embodiments, when R 4Y It is C 1-12 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0374] In some embodiments, R 4Y is unsubstituted C 1-12 alkyl.

[0375] In certain embodiments, R 4Y is unsubstituted C 1-6 alkyl.

[0376] In certain embodiments, R 4Y is unsubstituted C 1-4 Alkyl (eg, methyl, ethyl, n-propyl, or isopropyl).

[0377] In certain embodiments, R 4Y is a heteroaryl group containing 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h In certain of these embodiments, R 4Y is a heteroaryl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h Replace. For example, R 4Y It may be a tetrazolyl group, wherein the ring nitrogen atom is optionally replaced by Rd Replace. For example, R 4Y Can be (For example ). In certain of the foregoing embodiments, R 5Y It’s H.

[0378] In some embodiments, R 5Y It’s H.

[0379] In some embodiments, R 5Y It is C 1-12 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0380] In certain embodiments, R 5Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R a substituted C2 alkyl).

[0381] In certain embodiments, R 5Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a substituted C2 alkyl).

[0382] In certain embodiments, R 5Y yes where R a As defined elsewhere herein. In certain of the foregoing embodiments, R a It is –OH, –NR e R f 、C 1-4 Alkoxy or C 1-4 As a non-limiting example, R 5Y Can be

[0383] In certain of the foregoing embodiments, when R 5Y It is C 1-12 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2(NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and C 3-6 Cycloalkyl, which is optionally substituted by 1-4 independently selected C 1-4 Alkyl substitution.

[0384] In certain embodiments, when R 5Y It is C 1-12 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0385] In some embodiments, R 5Y is unsubstituted C 1-12 alkyl.

[0386] In certain embodiments, R 5Y is unsubstituted C 1-6 alkyl.

[0387] In certain embodiments, R 5Y is unsubstituted C 1-4 Alkyl (eg, methyl, ethyl, n-propyl, or isopropyl).

[0388] In certain embodiments, R 5Y is a heteroaryl group containing 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h In certain of these embodiments, R 5Y is a heteroaryl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h Replace. For example, R 5Y It may be a tetrazolyl group, wherein the ring nitrogen atom is optionally replaced by R d Replace. For example, R 5Y Can be (For example ). In certain of the foregoing embodiments, R 4Y It’s H.

[0389] In some embodiments, R 4Y Yes – (W1 –W 2 ) n -W 3 .

[0390] In other embodiments, n is 2-4 (e.g., 2-3). In certain of the foregoing embodiments, each occurrence of W 1 Independently selected from C 1-3 Alkylene (e.g., C2 alkylene), optionally substituted by 1-4 R a replace.

[0391] In certain embodiments, each occurrence of W 1 Independently C 2-3 Alkylene (e.g., C2 alkylene).

[0392] In certain embodiments, each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O- (e.g., one W 2 It is –O-; another W 2 (When present) is –N(Me)-).

[0393] In certain embodiments, W 3 Selected from H and C 1-3 alkyl.

[0394] As a non-limiting example, R 4Y Can be selected from:

[0395] In some embodiments, R 5Y Yes – (W 1 –W 2 ) n -W 3 .

[0396] In other embodiments, n is 2-4 (e.g., 2-3). In certain of the foregoing embodiments, each occurrence of W 1 Independently selected from C 1-3 Alkylene (e.g., C2 alkylene), optionally substituted by 1-4 R a replace.

[0397] In certain embodiments, each occurrence of W 1 Independently C 2-3 Alkylene (e.g., C2 alkylene).

[0398] In certain embodiments, each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O- (e.g., one W 2 It is –O-; another W2 (When present) is –N(Me)-).

[0399] In certain embodiments, W 3 Selected from H and C 1-3 alkyl.

[0400] As a non-limiting example, R 5Y Can be selected from:

[0401] In some embodiments, R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 In certain of the foregoing embodiments, R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl.

[0402] In certain embodiments, n is 2-4 (eg, n is 2; or n is 3).

[0403] In certain embodiments, n is 2 or 3.

[0404] In certain embodiments, each occurrence of W 1 Independently C 2-3 Alkylene (e.g., C2 alkylene).

[0405] In certain embodiments, each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O- (e.g., one W 2 It is –O-; another W 2 (When present) is –N(Me)-).

[0406] In certain embodiments, W 3 Selected from H and C 1-3 alkyl.

[0407] As a non-limiting example of the foregoing embodiment, R 4Y and R 5Y One of them can be selected from: R 4Y and R 5Y The other of can be selected from H and C 1-3 alkyl.

[0408] In certain embodiments, R 4Y and R 5Y None of them are H (e.g., R 4Y and R 5YEach is an independently selected C1-C6 alkyl group, which is optionally replaced by 1-3 R a replace).

[0409] In certain embodiments, R 4Y and R 5Y One of them is H; and R 4Y and R 5Y The other one is not H (for example, R 4Y and R 5Y One of them is H; and R 4Y and R 5Y The other is an independently selected C1-C6 alkyl group, which is optionally substituted by 1-3 R a As a non-limiting example, R 4Y and R 5Y One of them can be H; R 4Y and R 5Y The other of the can be an independently selected C2-C4 alkyl group (e.g., C2 alkyl group), which is optionally substituted by 1-3 R a replace.

[0410] In certain embodiments, R 4Y and R 5Y Both are H.

[0411] In some embodiments, R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5Y N(H), N(R) d ), O and S.

[0412] In certain embodiments, R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 5 ring atoms, wherein the ring contains: (a) 1-4 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5Y N(H), N(R) d ), O and S.

[0413] In certain embodiments, R4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 6 ring atoms, wherein the ring contains: (a) 1-5 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5Y N(H), N(R) d ), O and S.

[0414] As a non-limiting example of the foregoing, Y may be:

[0415] In some embodiments, when Y is C(O)NR 4Y R 5Y When Y is CONH2.

[0416] In some embodiments, when Y is C(O)NR 4Y R 5Y When Y is selected In certain of the foregoing embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Haloalkoxy (for example, Y can be ).

[0417] In some embodiments, when Y is C(O)NR 4Y R 5Y When Y is selected from:

[0418] In some embodiments, when Y is CONR 4Y R 5Y When Y is selected from:

[0419] In some embodiments, Y is C(O)NHR 5Y In some of these embodiments, R 5Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a In certain embodiments, R 5Y yes In certain of these embodiments, R a It is NR e R fIn certain of these embodiments, R e and R f Each is H or C 1-6 Alkyl. For example, R e and R f Each can be C 1-3 alkyl.

[0420] In certain embodiments, R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 (e.g., 5-6) ring atoms, wherein the ring contains: (a) 1-7 (e.g., 1-5) ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R e and R f N(H), N(R) d ), O and S;

[0421] As a non-limiting example, R 5Y Can be

[0422] In certain embodiments, Y is C(O)NHR 5Y ; and R 5Y is a heteroaryl group containing 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h In certain of these embodiments, R 5Y is a heteroaryl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h Replace. For example, R 5Y It may be a tetrazolyl group, wherein the ring nitrogen atom is optionally replaced by R d Replace. For example, R 5Y Can be (For example, ).

[0423] In some embodiments, Y is a heteroaryl group containing 5 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0424] In some embodiments, Y is a heteroaryl group containing 5 ring atoms, wherein 2-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0425] In some embodiments, Y is a heteroaryl group containing 5 ring atoms, wherein 3-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0426] In certain of the foregoing embodiments, when Y is a heteroaryl group containing 5 ring atoms, each occurrence of R c Independently selected from the group consisting of:

[0427] (i) halogen;

[0428] (ii) cyano;

[0429] (iii)C 1-10 alkyl;

[0430] (iv) 1-6 independently selected R a Substituted C 1-10 alkyl;

[0431] (v) optionally 1-3 independently selected R b Substituted C 3-6 Cycloalkyl;

[0432] (vi)C 2-6 alkenyl;

[0433] (vii)C 2-6 Alkynyl;

[0434] (viii)C 1-4 alkoxy;

[0435] (ix)C 1-4 haloalkoxy;

[0436] (x) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;

[0437] (xi)-S(O) 1-2 (C 1-4 alkyl);

[0438] (xii)-NR e R f ;

[0439] (xiii)–OH;

[0440] In certain of the foregoing embodiments, when Y is a heteroaryl group containing 5 ring atoms, each occurrence of R d Select from the following group: C 1-6 Alkyl; 1-6 independently selected R a Substituted C 1-10 alkyl; optionally substituted by 1-3 independently selected R b Substituted C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R"); and -S(O) 1-2 (C 1-4 alkyl).

[0441] In certain embodiments, when Y is a heteroaryl group containing 5 ring atoms, Y is selected from tetrazolyl, triazolyl, oxadiazolyl, imidazolyl, and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0442] In certain embodiments, when Y is a heteroaryl group containing 5 ring atoms, Y is selected from tetrazolyl, triazolyl, oxadiazolyl, and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0443] In certain of the foregoing embodiments, each R c When present, independently selected from:

[0444] (i) halogen;

[0445] (iii)C 1-10 alkyl;

[0446] (iv) 1-6 (e.g., 1) independently selected R a Substituted C 1-10 alkyl; and

[0447] (v) optionally 1-3 independently selected R b Substituted C 3-6 Cycloalkyl (e.g., each R c can independently be (iii) C 1-10 alkyl or (iv) 1-6 independently selected R a Substituted C 1-10 alkyl).

[0448] In some of the foregoing embodiments, R d It is C 1-6 Alkyl, which is optionally substituted by 1-3 independently selected R g In certain of these embodiments, R d is unsubstituted C 1-3 alkyl.

[0449] In certain other embodiments, R d It is C 1-3 Alkyl, which is optionally substituted by 1-3 independently selected R g In certain of these embodiments, R g Selected from the group consisting of: -OH, -F, N(C 1-3 Alkyl)2, C 1-3 Alkoxy, -CONH2, -CONHS(O)2(C 1-4 alkyl) and –C(O)OH.

[0450] R d Non-limiting examples may include the following:

[0451]

[0452] In certain of the foregoing embodiments, Y is selected from the group consisting of: (For example, R a can be selected from -OH, -OMe and -NMe2). For example, Y can be

[0453] In certain embodiments, Y is selected from the group consisting of: For example, Y can be In certain embodiments, R d is unsubstituted C 1-3 Alkyl groups, such as methyl.

[0454] In certain additional of the foregoing embodiments, R d It is C 1-3 Alkyl, which is optionally substituted by 1-3 independently selected R g In certain of these embodiments, R gSelected from the group consisting of: -OH, -F, N(C 1-3 Alkyl)2, C 1-3 Alkoxy, -CONH2, -CONHS(O)2(C 1-4 Alkyl) and –C(O)OH. R d Non-limiting examples may include the following:

[0455]

[0456] In certain embodiments, Y is In certain of these embodiments, R c is NH2, C(=O)N(R')(R"), C(=O)OH, or optionally replaced by R a Substituted C 1-3 Alkyl (e.g., R c Can be ).

[0457] In some embodiments, Y is a heteroaryl group containing 6 ring atoms, wherein 1-3 ring atoms are ring nitrogen atoms, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c As non-limiting examples, Y can be pyridyl or pyrimidinyl, each of which is optionally substituted with 1-2 independently selected R c As a non-limiting example, Y may be

[0458] In some embodiments, Y is a heterocycloalkenyl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heterocyclenyl ring carbon atoms are optionally replaced by 1-2 independently selected R b In certain of these embodiments, Y is imidazolinyl, wherein the ring nitrogen is optionally replaced by R d Replace (for example, ).

[0459] Variable Z

[0460] In some embodiments, Z is selected from H, NR 4Z R 5Z , OR 6Z and OC(O)R 7Z .

[0461] In some embodiments, Z is NR 4Z R 5Z .

[0462] variable R 4Z / R 5Z

[0463] In some embodiments, R 4Z It’s H.

[0464] In some embodiments, R 4Z It is C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a In some of the aforementioned embodiments, R 4Z It is C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a replace.

[0465] In certain embodiments, R 4Z It is C 1-3 Alkyl, optionally substituted by 1 R a As a non-limiting example, R 4Z Can be (In certain embodiments, R a Selected from –OH, –NR e R f 、C 1-4 Alkoxy and C 1-4 Haloalkoxy, for example, R 4Z Can be ).

[0466] In some embodiments, R 4Z is unsubstituted C 1-10 In some of the aforementioned embodiments, R 4Z is unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 Alkyl groups, such as unsubstituted C 1-3 alkyl, such as methyl).

[0467] In some embodiments, R 4Z Selected from the group consisting of: -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl).

[0468] In some embodiments, R 5Z It’s H.

[0469] In some embodiments, R 5Z It is C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a In some of the aforementioned embodiments, R5Z It is C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a replace.

[0470] In certain embodiments, R 5Z It is C 1-3 Alkyl, optionally substituted by 1 R a As a non-limiting example, R 5Z Can be (In certain embodiments, R a Selected from –OH, –NR e R f 、C 1-4 Alkoxy and C 1-4 Haloalkoxy, for example, R 5Z Can be ).

[0471] In some embodiments, R 5Z is unsubstituted C 1-10 In some of the aforementioned embodiments, R 5Z is unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 Alkyl groups, such as unsubstituted C 1-3 alkyl, such as methyl).

[0472] In some embodiments, R 5Z Selected from the group consisting of: -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl).

[0473] In certain embodiments, R 4Z and R 5Z None of them are H (e.g., R 4Z and R 5Z Each is an independently selected C1-C6 alkyl group, which is optionally replaced by 1-3 R a Substitution, such as R 4Z and R 5Z are each independently selected unsubstituted C1-C6 alkyl).

[0474] In certain embodiments, R 4Z and R 5Z One of them is H; and R 4Z and R 5Z The other one is not H (for example, R 4Z and R5Z One of them is H; and R 4Z and R 5Z The other is an independently selected C1-C6 alkyl group, which is optionally substituted by 1-3 R a Substitution, such as R 5Z is an independently selected unsubstituted C1-C6 alkyl).

[0475] In certain embodiments, R 4Z and R 5Z Both are H.

[0476] In certain embodiments, when Z is NR 4Z R 5Z When R 4Z and R 5Z are each independently selected from H and optionally 1-6 independently selected R a Substituted C 1-10 alkyl.

[0477] In certain embodiments, when Z is NR 4Z R 5Z When R 4Z and R 5Z Each independently selected from H and optionally 1-2 independently selected R a Substituted C 1-6 alkyl.

[0478] In certain embodiments, when Z is NR 4Z R 5Z When R 4Z and R 5Z are each independently selected from H and optionally substituted by 1 R a Substituted C 1-3 alkyl.

[0479] In certain embodiments, when Z is NR 4Z R 5Z When R 4Z and R 5Z are each independently selected from H and unsubstituted C 1-10 alkyl.

[0480] In certain of the foregoing embodiments, R 4Z and R 5Z Each is independently H or methyl.

[0481] In certain embodiments, when Z is NR 4Z R 5Z When R 4Z and R 5Z Each independently selected from H and As a non-limiting example, R 4Zand R 5Z R on a Can be selected from –OH, –NR e R f 、C 1-4 Alkoxy and C 1-4 For example, R 4Z and R 5Z Each can be independently selected from H and

[0482] In certain embodiments, R 4Z and R 5Z 1-2 of them are H.

[0483] In certain embodiments, R 4Z and R 5Z are each independently H or unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 Alkyl groups, such as unsubstituted C 1-3 alkyl, such as methyl).

[0484] In some embodiments, Z is OR 6Z .

[0485] In certain embodiments, R 6Z selected from H and optionally 1-6 independently selected R a Substituted C 1-10 alkyl.

[0486] In some embodiments, R 6Z It’s H.

[0487] In some embodiments, R 6Z It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0488] In certain embodiments, R 6Z It is C 1-6 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0489] In certain embodiments, R 6Z It is C 1-3 Alkyl, optionally substituted by 1-2 (eg, 1) independently selected R a Substitution (in certain embodiments, R 6Z R on a Selected from –OH, –NR e R f 、C 1-4 Alkoxy and C 1-4 haloalkoxy).

[0490] As a non-limiting example of the foregoing, R 6Z Can be (For example ).

[0491] In certain embodiments, when Z is OR 6Z When R 6Z selected from H and optionally 1-6 independently selected R a Substituted C 1-10 alkyl.

[0492] In certain embodiments, Z is OH.

[0493] In certain embodiments, Z is -O(C 1-3 alkyl), wherein C 1-3 The alkyl moiety is optionally replaced by 1-2 independently selected R a replace.

[0494] As a non-limiting example of the foregoing embodiment, Z may be:

[0495]

[0496] In some embodiments, when Z is OR 6Z When R 6Z Yes – (T 1 –T 2 ) t -T 3 .

[0497] In certain of the foregoing embodiments, t is 2-3 (eg, t is 2).

[0498] In certain embodiments, each occurrence of T 1 Independently C 2-3 Alkylene (e.g., C2 alkylene).

[0499] In certain embodiments, each occurrence of T 2 is independently -N(H)-, -N(Me)-, or -O-.

[0500] In certain embodiments, T 3 Is H or C 1-3 Alkyl (eg, H or methyl).

[0501] As a non-limiting example of the foregoing embodiment, Z may be:

[0502]

[0503] In some embodiments, Z is OC(O)R 7Z .

[0504] In some embodiments, R 7Z It’s H.

[0505] In some embodiments, R 7Z It is C 1-10 Alkyl (e.g., C 1-6 alkyl), optionally substituted by 1-6 (eg, 1-4, eg, 1-3, eg, 1) independently selected R a In certain of the foregoing embodiments, R 7Z It is C 1-6 Alkyl, optionally substituted by 1-3 (eg, 1 or 2) independently selected R a replace.

[0506] In certain of the foregoing embodiments, when R 7Z is optionally 1-6 independently selected R a Substituted C 1-10 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C(=O)OH; C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0507] In certain of the foregoing embodiments, when R 7Z is optionally 1-6 independently selected R a Substituted C 1-10 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0508] In some embodiments, R 7Z is unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 Alkyl, for example, unsubstituted C 1-4 As a non-limiting example, R 7Z It may be methyl, ethyl or isopropyl.

[0509] In some embodiments, R 7Z It is C 6-10 Aryl, which is optionally substituted by 1-4 R c replace.

[0510] In certain embodiments, R 7Z is a C6 aryl group, which is optionally substituted by 1-4 R c replace.

[0511] In certain of the foregoing embodiments, when R 7Z is optionally replaced by 1-4 R c Substituted C 6-10 When the group is aromatic, each occurrence of R c Independently selected from the group consisting of:

[0512] (i) halogen;

[0513] (ii) cyano;

[0514] (iii)C 1-6 alkyl;

[0515] (iv)C 2-6 alkenyl;

[0516] (v)C 2-6 Alkynyl;

[0517] (vi)C 1-4 alkyl halide;

[0518] (vii)C 1-4 alkoxy;

[0519] (viii)C 1-4 haloalkoxy;

[0520] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;

[0521] (xi)-NR e R f ;and

[0522] (xii)–OH.

[0523] In some embodiments, R 7Z It is C 3-6 Cycloalkyl, which is optionally substituted by 1-4 R b replace.

[0524] In certain of the foregoing embodiments, when R 7Z is optionally replaced by 1-4 R b Substituted C 3-6 When the cycloalkyl group is present, each occurrence of R b Independently selected from the group consisting of: C 1-6 Alkyl; C 1-4Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 haloalkoxy; cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.

[0525] In some embodiments, Z is OP(O)OR 8Z OR 9Z For example, Z can be OP(O)OH(OH).

[0526] In some embodiments, R 8Z It’s H.

[0527] In some embodiments, R 8Z It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0528] In some embodiments, R 9Z It’s H.

[0529] In some embodiments, R 9Z It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0530] In some embodiments, Z is H.

[0531] In some embodiments, Z is a heterocyclyl group containing 4-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R h replace.

[0532] In certain of these embodiments, Z is a heterocyclyl group containing 5-6 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R h For example, Z can be piperidinyl, pyrrolidinyl, piperazinyl or morpholinyl, each of which is optionally substituted as described above. As a non-limiting example, Z can be morpholin-4-yl.

[0533] In some embodiments, Z is OR 6Z , where R 6Z yes:

[0534] (iii)–(C 0-2 alkylene)-(C 6-10 aryl), wherein C 6-10 Aryl is optionally substituted with 1-2 independently selected R h replace; or

[0535] (iv)–(C 0-2 alkylene)-(heteroaryl), wherein the heteroaryl group contains 5-10 ring atoms, 1-4 of which are heteroatoms, each independently selected from N, N(H), N(C 1-3 alkyl), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R h replace.

[0536] In certain of these embodiments, R 6Z Yes (iv)–(C 0-2 alkylene)-(heteroaryl), wherein the heteroaryl group contains 5-6 ring atoms, of which 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(C 1-3 alkyl), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 (e.g., 1, 2, 3 or 4) independently selected R h For example, Z can be

[0537] In some embodiments, Z is R 6Z , where R 6Z Yes: –(C 1-2 Alkylene)-C(=O)NH-(C 1-3 Alkylene)-R 6Z’ .

[0538] In certain of these embodiments, R 6Z’ Select from the following groups:

[0539] C(=O)OH,N(C 1-4 alkyl)2, NH2 and NH(C 1-4 alkyl).

[0540] As a non-limiting example, Z may be:

[0541]

[0542] In certain embodiments, R 6Z’ is a heterocyclic group containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected C 1-3 Alkyl substitution.

[0543] In certain of these embodiments, R 6Z’ is a heterocyclic group containing 5-6 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected C 1-3 Alkyl substitution.

[0544] As a non-limiting example, Z may be:

[0545]

[0546] variable R 1 , R 2 and R 3

[0547] In some embodiments, R 1 It is R 6A .

[0548] In certain embodiments, R 1 It is R 6A ; and R 2 and R 3 None of them are R 6A .

[0549] In certain embodiments, R 1 It is R 6A ; R 2 It is R 6A ; and R 3 Not R 6A .

[0550] In certain embodiments, R 1 It is R 6A ; R 3 It is R 6A ; and R 2 Not R 6A .

[0551] In certain embodiments, R 1 It is R 6A ; and R 2 and R 3 Each is independently selected R 6A .

[0552] In some embodiments, R 2 It is R 6A .

[0553] In certain embodiments, R 2It is R 6A ; and R 1 and R 3 None of them are R 6A .

[0554] In certain embodiments, R 2 It is R 6A ; R 3 It is R 6A ; and R 1 Not R 6A .

[0555] In some embodiments, R 3 It is R 6A .

[0556] In certain embodiments, R 3 It is R 6A ; and R 1 and R 3 None of them are R 6A .

[0557] In some embodiments, R 6A It’s H.

[0558] In some embodiments, R 6A It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0559] In some embodiments, R 1 It is C(O)R 7A .

[0560] In certain embodiments, R 1 It is C(O)R 7A ; and R 2 and R 3 Neither is C(O)R 7A .

[0561] In certain embodiments, R 1 It is C(O)R 7A ; R 2 It is C(O)R 7A ; and R 3 Not C(O)R 7A .

[0562] In certain embodiments, R 1 It is C(O)R 7A ; R 3 It is C(O)R 7A ; and R 2 Not C(O)R 7A .

[0563] In certain embodiments, R 1 It is C(O)R 7A ; and R 2 and R 3 All are C(O)R 7A .

[0564] In some embodiments, R 2 It is C(O)R 7A .

[0565] In certain embodiments, R 2 It is C(O)R 7A ; and R 1 and R 3 Neither is C(O)R 7A .

[0566] In certain embodiments, R 2 It is C(O)R 7A ; R 3 It is C(O)R 7A ; and R 1 Not C(O)R 7A .

[0567] In some embodiments, R 3 It is C(O)R 7A .

[0568] In certain embodiments, R 3 It is C(O)R 7A ; and R 1 and R 3 Neither is C(O)R 7A .

[0569] In some embodiments, R 7A It’s H.

[0570] In some embodiments, R 7A It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a substituted (e.g., optionally with 1-6 independently selected R a Substituted C 1-6 or C 1-3 Alkyl; for example, C 1-10 or C 1-6 or C 1-3 unsubstituted alkyl (e.g., CH3)). In certain of the foregoing embodiments, R 7A It is C 1-6 Alkyl, optionally substituted by 1-6 (e.g., 1-3) independently selected R a replace.

[0571] In certain of the foregoing embodiments, when R 7A is optionally 1-6 independently selected R a Substituted C 1-10 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0572] In some embodiments, R 7A It is C 6-10 Aryl, which is optionally substituted by 1-4 R c replace.

[0573] In certain embodiments, R 7A is a C6 aryl group, which is optionally substituted by 1-4 R c replace.

[0574] In certain of the foregoing embodiments, when R 7A is optionally replaced by 1-4 R c Substituted C 6-10 When the group is aromatic, each occurrence of R c Independently selected from the group consisting of:

[0575] (i) halogen;

[0576] (ii) cyano;

[0577] (iii)C 1-6 alkyl;

[0578] (iv)C 2-6 alkenyl;

[0579] (v)C 2-6 Alkynyl;

[0580] (vi)C 1-4 alkyl halide;

[0581] (vii)C 1-4 alkoxy;

[0582] (viii)C 1-4 haloalkoxy;

[0583] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;

[0584] (xi)-NRe R f ;and

[0585] (xii)–OH.

[0586] In some embodiments, R 7A It is C 3-6 Cycloalkyl, which is optionally substituted by 1-4 R b replace.

[0587] In certain of the foregoing embodiments, when R 7A is optionally replaced by 1-4 R b Substituted C 3-6 When the cycloalkyl group is present, each occurrence of R b Independently selected from the group consisting of: C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 haloalkoxy; cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.

[0588] In some embodiments, R 1 It is OP(O)OR 8A OR 9A .

[0589] In certain embodiments, R 1 It is OP(O)OR 8A OR 9A ; and R 2 and R 3 Neither OP(O)OR 8A OR 9A .

[0590] In certain embodiments, R 1 It is OP(O)OR 8A OR 9A ; R 2 It is OP(O)OR 8A OR 9A ; and R 3 Not OP(O)OR 8A OR 9A .

[0591] In certain embodiments, R 1 It is OP(O)OR 8A OR 9A ; R 3 It is OP(O)OR8A OR 9A ; and R 2 Not OP(O)OR 8A OR 9A .

[0592] In certain embodiments, R 1 It is OP(O)OR 8A OR 9A ; and R 2 and R 3 Both are OP(O)OR 8A OR 9A .

[0593] In some embodiments, R 2 It is OP(O)OR 8A OR 9A .

[0594] In certain embodiments, R 2 It is OP(O)OR 8A OR 9A ; and R 1 and R 3 Neither OP(O)OR 8A OR 9A .

[0595] In certain embodiments, R 2 It is OP(O)OR 8A OR 9A ; R 3 It is OP(O)OR 8A OR 9A ; and R 1 Not OP(O)OR 8A OR 9A .

[0596] In some embodiments, R 3 It is OP(O)OR 8A OR 9A .

[0597] In certain embodiments, R 3 It is OP(O)OR 8A OR 9A ; and R 1 and R 3 Neither OP(O)OR 8A OR 9A .

[0598] In some embodiments, R 8A It’s H.

[0599] In some embodiments, R8A It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0600] In some embodiments, R 9A It’s H.

[0601] In some embodiments, R 9A It is C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a replace.

[0602] In some embodiments, R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A .

[0603] In certain of the foregoing embodiments, each occurrence of R 7A Independently C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a substituted (e.g., optionally with 1-6 independently selected R a Substituted C 1-6 or C 1-3 Alkyl; for example, C 1-10 or C 1-6 or C 1-3 unsubstituted alkyl (e.g., CH3)).

[0604] In some embodiments, R 1 、R 2 and R 3 Each independently selected from H and C(O)Me (e.g., R 1 、R 2 and R 3 All are H; or R 1 、R 2 and R 3 are all C(O)Me).

[0605] In certain embodiments, R 1 、R 2 and R 3 One or more of is H. In certain of these embodiments, R 1 、R 2 and R 3 Each of them is H.

[0606] In certain other embodiments, R 1 、R 2 and R 3 Each of them is C(O)Me.

[0607] Variable Z x

[0608] In some embodiments, Z x Both are H.

[0609] In some embodiments, each Z x Together with the carbon to which they are attached they form C=O.

[0610] Non-restricted combinations

[0611] Unrestricted combination[1]

[0612] In some embodiments, the compound of formula (I) is a compound having formula (Ia):

[0613]

[0614] Where X, Y, Z, Z x 、R 1 、R 2 and R 3 As defined elsewhere herein.

[0615] Unrestricted combination[2]

[0616] In some embodiments:

[0617] X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl; and

[0618] Y is CO2R 6Y .

[0619] In certain embodiments of [2], R 6Y It is C 1-12 Alkyl, optionally substituted with 1-6 independently selected R a In certain embodiments, R 6Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 6Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 6Y yes where R a As defined elsewhere herein (in certain embodiments, Ra Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, R 6Y is methyl, 2-(dimethylamino)-eth-1-yl or 2-(hydroxy)-eth-1-yl. In certain embodiments of [2], R 6Y is unsubstituted C 1-12 alkyl.

[0620] In certain other embodiments of [2], R 6Y It’s H.

[0621] In certain embodiments of [2], R 6Y It’s H.

[0622] In certain embodiments of [2], R 6Y It is C 1-12 (For example, C 1-6 , C 2-6 , C 2-3 ) alkyl, which is optionally substituted by 1-6 independently selected R a Substituted (e.g., unsubstituted; or by 1-2, e.g., 1, independently selected R a replace).

[0623] In certain embodiments of [2], Y is selected from CO2H and CO2Me.

[0624] In certain embodiments of [2], Y is For example, Y can be

[0625] In certain embodiments of [2], Y is where R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Haloalkoxy (for example, Y can be As a non-limiting example, Y may be And R a Can be –OH or –NR e R f (e.g. NMe2).

[0626] In certain embodiments of [2], X is C 1-3 alkyl; and Y is In certain of these embodiments, X is methyl. In certain embodiments, R a Is –OH or –NR e R f (e.g., NMe2).

[0627] In certain embodiments of [2], Z is OR 6Z For example, Z may be OH.

[0628] In certain embodiments of [2], each Z x It’s H.

[0629] In certain embodiments of [2], each Z x Together with the carbon to which they are attached they form C=O.

[0630] In certain embodiments of [2], R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A For example, R 1 、R 2 and R 3 Each may be H. In another non-limiting example, R 1 、R 2 and R 3 Each can be an independently selected C(O)R 7A (e.g. C(O)Me).

[0631] Unrestricted combination[3]

[0632] In some embodiments:

[0633] X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl; and

[0634] Y is C(O)NR 4Y R 5Y .

[0635] In certain embodiments of [3], R 4Y is H. In certain other embodiments of [3], R 4Y It is C 1-12 (For example, C 1-6 , C 1-4 ) alkyl, optionally substituted by 1-6 independently selected R a In certain of the foregoing embodiments, R 4Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R aIn certain of the foregoing embodiments, R 4Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 4Y yes where R a As defined elsewhere herein (in certain embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, R 4Y is methyl, 2-(dimethylamino)-eth-1-yl or 2-(hydroxy)-eth-1-yl. In certain embodiments of [3], R 4Y is unsubstituted C 1-12 Alkyl (e.g., C 1-6 ,C 2-6 ,C 2-3 ).

[0636] In certain embodiments of [3], R 5Y is H. In certain other embodiments of [3], R 5Y It is C 1-12 (For example, C 1-6 , C 1-4 ) alkyl, optionally substituted by 1-6 independently selected R a In certain of the foregoing embodiments, R 5Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R a In certain of the foregoing embodiments, R 5Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 5Y yes where R a As defined elsewhere herein (in certain embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, R5Y is methyl, 2-(dimethylamino)-eth-1-yl or 2-(hydroxy)-eth-1-yl. In certain embodiments of [3], R 5Y is unsubstituted C 1-12 Alkyl (e.g., C 1-6 , C 2-6 , C 2-3 ).

[0637] In certain embodiments of [3], R 4Y and R 5Y None of them are H (e.g., R 4Y and R 5Y are each independently selected C1-C6 alkyl).

[0638] In certain embodiments of [3], R 4Y and R 5Y One of them is H; and R 4Y and R 5Y The other one is not H (for example, R 4Y and R 5Y One of them is H; and R 4Y and R 5Y The other of which is an independently selected C1-C6 alkyl).

[0639] In certain embodiments of [3], R 4Y and R 5Y Both are H.

[0640] In certain embodiments of [3], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 .

[0641] In certain of the aforementioned embodiments of [3], n is 2-3 (eg, n is 2; or n is 3).

[0642] In certain embodiments of [3], each occurrence of W 1 Independently C 2-3 Alkylene (e.g., C2 alkylene).

[0643] In certain embodiments of [3], each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O- (e.g., one W 2 It is –O-; another W 2 (When present) is –N(Me)-).

[0644] In certain embodiments of [3], W 3 Selected from H and C 1-3 alkyl.

[0645] As a non-limiting example of the foregoing embodiment, R 4Y and R 5Y One of them can be selected from:

[0646] In certain embodiments of [3], when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 When R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl.

[0647] In certain embodiments, R 4Y and R 5Y One of them is not H.

[0648] In certain embodiments of [3], R 4Y and R 5Y are each independently H or C 1-12 Alkyl (e.g., C 1-6 , C 1-4 ), which is optionally replaced by 1-6 (e.g., 1-3 or 1-2) independently selected R a replace.

[0649] In certain embodiments of [3], R 4Y and R 5Y Each independently is H or

[0650] In certain of these embodiments, R 4Y and R 5Y One of them is H; R 4Y and R 5Y The other one is

[0651] In certain of the foregoing embodiments of [3] (when R 4Y and R 5Y Each independently is H or ), R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0652] In certain of these embodiments (e.g., when R 4Y and R 5Y One of them is H; and R 4Y and R 5Y The other one is ), R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0653] In certain embodiments of [3], R 4Y and R 5Y Each is independently H,

[0654] In certain embodiments of [3], Y is CONH2.

[0655] In certain other embodiments of [3], Y is (For example, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 As a non-limiting example, Y may be

[0656] In certain embodiments of [3], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl.

[0657] In certain embodiments of [3], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 Alkyl; n is 2 or 3.

[0658] In certain embodiments of [3] (when R 4Y and R5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl), W 1 Each occurrence is independently C 2-3 Alkylene (e.g., C2 alkylene).

[0659] In certain embodiments of [3] (when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl), W 2 Each occurrence is independently -N(H)-, -N(Me)-, or -O-.

[0660] In certain embodiments of [3] (when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl), W 3 Selected from H and C 1-3 alkyl.

[0661] In certain embodiments of [3], R 4Y and R 5Y One of:

[0662] In certain embodiments of [3], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is H, wherein n is 2 or 3; W 1 Each occurrence is independently C 2-3 Alkylene (e.g., C2 alkylene); W 2Each occurrence is independently -N(H)-, -N(Me)-, or -O-; W 3 Selected from H and C 1-3 alkyl.

[0663] As a non-limiting example of the foregoing embodiment, when Y is C(O)NR 4Y R 5Y ; Y can be

[0664] In certain embodiments of [3], in some embodiments, R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5Y N(H), N(R) d ), O and S.

[0665] In certain of the foregoing embodiments, R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 6 ring atoms, wherein the ring contains: (a) 1-5 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5Y N(H), N(R) d ), O and S.

[0666] As a non-limiting example of the foregoing, Y may be:

[0667] In certain embodiments of [3], X is C1-C3 alkyl; Y is C(O)NHR 5Y In certain of these embodiments, X is methyl. In certain of the foregoing embodiments, R 5Y It is C 1-12 Alkyl (e.g., C 1-6 , C 1-4 ), optionally 1-6 (e.g., 1-3 or 1-2) independently selected R a As a non-limiting example, R 5Y Can be (For example, R a Can be –OH; -F; –NRe R f (e.g. NMe2); C 1-4 Alkoxy; or C 1-4 For example, R 5Y Can be

[0668] In certain embodiments of [3], X is C1-C3 alkyl; Y is C(O)NHR 5Y ; R 5Y Yes – (W 1 –W 2 ) n -W 3 ; where n is 2 or 3; each time W appears 1 Independently C 2-3 Alkylene (e.g., C2 alkylene); each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O-; and W 3 Selected from H and C 1-3 alkyl.

[0669] In certain embodiments of [3], Z is OR 6Z For example, Z may be OH.

[0670] In certain embodiments of [3], each Z x It’s H.

[0671] In certain embodiments of [3], each Z x Together with the carbon to which they are attached they form C=O.

[0672] In certain embodiments of [3], R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A For example, R 1 、R 2 and R 3 Each may be H. In another non-limiting example, R 1 、R 2 and R 3 Each can be an independently selected C(O)R 7A (e.g. C(O)Me).

[0673] Unrestricted combination[4]

[0674] In some embodiments:

[0675] X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl; and

[0676] Y is a heteroaryl group containing 5 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0677] In certain embodiments of [4], Y is a heteroaryl group containing 5 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0678] In certain embodiments of [4], Y is a heteroaryl group containing 5 ring atoms, wherein 1 ring atom is a heteroatom selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0679] In certain embodiments of [4], Y is a heteroaryl group containing 5 ring atoms, wherein 3-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0680] In certain embodiments of [4], Y is selected from tetrazolyl, triazolyl, oxadiazolyl and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0681] In certain of the foregoing embodiments, each R c When present, independently selected from:

[0682] (i) halogen;

[0683] (iii)C 1-10 alkyl;

[0684] (iv) 1-6 (e.g., 1) independently selected R a Substituted C 1-10 alkyl; and

[0685] (v) optionally 1-3 independently selected R b Substituted C 3-6Cycloalkyl (e.g., each R c can independently be (iii) C 1-10 alkyl or (iv) 1-6 independently selected R a Substituted C 1-10 alkyl).

[0686] In certain of the foregoing embodiments, Y is selected from the group consisting of: (For example, R a may be selected from -OH, -OMe and -NMe2).

[0687] In certain embodiments of [4], Y is selected from tetrazolyl, triazolyl, oxadiazolyl and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0688] In certain embodiments of [4], Y is selected from the group consisting of: (For example, R a may be selected from -OH, -OMe and -NMe2).

[0689] In certain embodiments of [4], X is C 1-3 Alkyl; Y is selected from tetrazolyl and triazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0690] In certain of these embodiments, X is methyl.

[0691] In certain of the foregoing embodiments, Y is As a non-limiting example, Y is (For example ).

[0692] In certain embodiments of [4], Z is OR 6Z For example, Z may be OH.

[0693] In certain embodiments of [4], each Z x It’s H.

[0694] In certain embodiments of [4], each Z x Together with the carbon to which they are attached they form C=O.

[0695] In certain embodiments of [4], R 1 、R 2and R 3 are each independently selected from H and C(O)R 7A For example, R 1 、R 2 and R 3 Each may be H. In another non-limiting example, R 1 、R 2 and R 3 Each can be an independently selected C(O)R 7A (e.g. C(O)Me).

[0696] Unrestricted combination[5]

[0697] In some embodiments:

[0698] X is NR 4X R 5X ;and

[0699] Y is CO2R 6Y .

[0700] In certain embodiments of [5], R 4X and R 5X None of them are H (e.g., R 4X and R 5X Each is an independently selected C1-C6 alkyl group, such as R 4X and R 5X are each methyl).

[0701] In certain embodiments of [5], R 4X and R 5X One of them is H; and R 4X and R 5X The other one is not H (for example, R 4X and R 5X One of them is H; and R 4X and R 5X The other of which is an independently selected C1-C6 alkyl).

[0702] In certain embodiments of [5], R 4X and R 5X Both are H.

[0703] In certain embodiments of [5], R 6Y is optionally 1-6 independently selected R a Substituted C 1-12 In certain embodiments, R 6Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R aIn certain embodiments, R 6Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 6Y yes where R a As defined elsewhere herein (in certain embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, R 6Y is methyl, 2-(dimethylamino)-eth-1-yl or 2-(hydroxy)-eth-1-yl. In certain embodiments of [5], R 6Y is unsubstituted C 1-12 alkyl.

[0704] In certain other embodiments of [5], R 6Y It’s H.

[0705] In certain embodiments of [5], R 6Y It’s H.

[0706] In certain embodiments of [5], R 6Y It is C 1-12 (For example, C 1-6 , C 2-6 , C 2-3 ) alkyl, which is optionally substituted by 1-6 independently selected R a Substituted (e.g., unsubstituted; or by 1-2, e.g., 1, independently selected R a replace).

[0707] In certain embodiments of [5], Y is selected from CO2H and CO2Me.

[0708] In certain embodiments of [5], Y is For example, Y can be

[0709] In certain embodiments of [5], Y is where R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Haloalkoxy (for example, Y can be As a non-limiting example, Y may be And R a Can be –OH or –NR e R f (e.g. NMe2).

[0710] In certain embodiments of [5], X is N(C 13 alkyl)2; Y is In certain of these embodiments, X is NMe2. In certain embodiments, Y is where R a Can be –OH or –NR e R f (e.g. NMe2).

[0711] In certain embodiments of [5], Z is OR 6Z For example, Z may be OH.

[0712] In certain embodiments of [5], each Z x It’s H.

[0713] In certain embodiments of [5], each Z x Together with the carbon to which they are attached they form C=O.

[0714] In certain embodiments of [5], R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A For example, R 1 、R 2 and R 3 Each may be H. In another non-limiting example, R 1 、R 2 and R 3 Each can be an independently selected C(O)R 7A (e.g. C(O)Me).

[0715] Unrestricted combination[6]

[0716] In some embodiments:

[0717] X is NR 4X R 5X ;and

[0718] Y is C(O)NR 4Y R 5Y .

[0719] In certain embodiments of [6], R 4Xand R 5X None of them are H (e.g., R 4X and R 5X are each independently selected C1-C6 alkyl).

[0720] In certain embodiments of [6], R 4X and R 5X One of them is H; and R 4X and R 5X The other one is not H (for example, R 4X and R 5X One of them is H; and R 4X and R 5X The other of which is an independently selected C1-C6 alkyl).

[0721] In certain embodiments of [6], R 4X and R 5X Both are H.

[0722] In certain embodiments of [6], R 4Y is H. In certain other embodiments of [6], R 4Y It is C 1-12 (For example, C 1-6 , C 1-4 ) alkyl, optionally substituted by 1-6 independently selected R a In certain of the foregoing embodiments, R 4Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R a In certain of the foregoing embodiments, R 4Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 4Y yes where R a As defined elsewhere herein (in certain embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, R 4Y is methyl, 2-(dimethylamino)-eth-1-yl or 2-(hydroxy)-eth-1-yl. In certain embodiments of [6], R 4Y is unsubstituted C 1-12 Alkyl (e.g., C1-6 , C 2-6 , C 2-3 ).

[0723] In certain embodiments of [6], R 5Y is H. In certain other embodiments of [6], R 5Y It is C 1-12 (For example, C 1-6 , C 1-4 ) alkyl, optionally substituted by 1-6 independently selected R a In certain of the foregoing embodiments, R 5Y It is C 1-6 Alkyl, optionally substituted with 1-3 independently selected R a substituted (e.g., optionally with 1 R a In certain of the foregoing embodiments, R 5Y It is C 1-4 Alkyl, optionally substituted with 1-2 independently selected R a substituted (e.g., optionally with 1 R a In certain embodiments, R 5Y yes where R a As defined elsewhere herein (in certain embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, R 5Y is methyl, 2-(dimethylamino)-eth-1-yl 2-(hydroxy)-eth-1-yl. In certain embodiments of [6], R 5Y is unsubstituted C 1-12 Alkyl (e.g., C 1-6 , C 2-6 , C 2-3 ).

[0724] In certain embodiments of [6], R 4Y and R 5Y None of them are H (e.g., R 4Y and R 5Y are each independently selected C1-C6 alkyl).

[0725] In certain embodiments of [6], R 4Y and R 5Y One of them is H; and R 4Y and R 5Y The other one is not H (for example, R 4Y and R5Y One of them is H; and R 4Y and R 5Y The other of which is an independently selected C1-C6 alkyl).

[0726] In certain embodiments of [6], R 4Y and R 5Y Both are H.

[0727] In certain embodiments of [6], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 .

[0728] In certain aforementioned embodiments of [6], n is 2-3 (eg, n is 2; or n is 3).

[0729] In certain embodiments of [6], each occurrence of W 1 Independently C 2-3 Alkylene (e.g., C2 alkylene).

[0730] In certain embodiments of [6], each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O- (e.g., one W 2 It is –O-; another W 2 (When present) is –N(Me)-).

[0731] In certain embodiments of [6], W 3 Selected from H and C 1-3 alkyl.

[0732] As a non-limiting example of the foregoing embodiment, R 4Y and R 5Y One of them can be selected from:

[0733] In certain embodiments of [6], when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 When R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl.

[0734] In certain embodiments, R 4Y and R 5Y One of them is not H.

[0735] In certain embodiments of [6], R 4Y and R 5Y are each independently H or C 1-12 Alkyl (e.g., C 1-6 , C 1-4 ), which is optionally replaced by 1-6 (e.g., 1-3 or 1-2) independently selected R a replace.

[0736] In certain embodiments of [6], R 4Y and R 5Y Each independently is H or

[0737] In certain of these embodiments, R 4Y and R 5Y One of them is H; R 4Y and R 5Y The other one is

[0738] In certain of the foregoing embodiments of [6] (when R 4Y and R 5Y Each independently is H or ), R 4Y or R 5Y R on a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0739] In certain of these embodiments (e.g., when R 4Y and R 5Y One of them is H; R 4Y and R 5Y The other one is ), R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0740] In certain embodiments of [6], R 4Y and R 5Y Each is independently H,

[0741] In certain embodiments of [6], Y is CONH2.

[0742] In certain other embodiments of [6], Y is (For example, R a Selected from –OH; -F; –NR e R f (e.g. NMe2); C 1-4 Alkoxy; and C 1-4 As a non-limiting example, Y may be

[0743] In certain embodiments of [6], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl.

[0744] In certain embodiments of [6], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 Alkyl; n is 2 or 3.

[0745] In certain embodiments of [6] (when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl), W 1 Each occurrence is independently C 2-3 Alkylene (e.g., C2 alkylene).

[0746] In certain embodiments of [6] (when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl), W2 Each occurrence is independently -N(H)-, -N(Me)-, or -O-.

[0747] In certain embodiments of [6] (when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl), W 3 Selected from H and C 1-3 alkyl.

[0748] In certain embodiments of [6], R 4Y and R 5Y One of:

[0749] In certain embodiments of [6], R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is H, wherein n is 2 or 3; W 1 Each occurrence is independently C 2-3 Alkylene (e.g., C2 alkylene); W 2 Each occurrence is independently -N(H)-, -N(Me)-, or -O-; W 3 Selected from H and C 1-3 alkyl.

[0750] As a non-limiting example of the foregoing embodiment, when Y is C(O)NR 4Y R 5Y When; Y can be

[0751] In certain embodiments of [6], in some embodiments, R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5YN(H), N(R) d ), O and S.

[0752] In certain of the foregoing embodiments, R 4Y and R 5Y Together with the nitrogen atom to which they are attached, they form a ring containing 6 ring atoms, wherein the ring contains: (a) 1-5 ring carbon atoms, each of which is replaced by 1-2 ring carbon atoms independently selected from H and C 1-3 Alkyl substituents substituted; and (b) 0-3 ring heteroatoms (excluding R 4Y and R 5Y N(H), N(R) d ), O and S.

[0753] As a non-limiting example of the foregoing, Y may be:

[0754] In certain embodiments of [5], X is N(C 1-3 alkyl)2; Y is C(O)NHR 5Y In certain of these embodiments, X is NMe2.

[0755] In certain of the foregoing embodiments, Y is (For example, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 As a non-limiting example, Y may be

[0756] In certain embodiments of [6], R 5Y Yes – (W 1 –W 2 ) n -W 3 ; where n is 2 or 3; each time W appears 1 Independently C 2-3 Alkylene (e.g., C2 alkylene); each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O-; and W 3 Selected from H and C 1-3 alkyl.

[0757] In certain embodiments of [6], Z is OR 6Z For example, Z may be OH.

[0758] In certain embodiments of [6], each Z x It’s H.

[0759] In certain embodiments of [6], each Z x Together with the carbon to which they are attached they form C=O.

[0760] In certain embodiments of [6], R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A For example, R 1 、R 2 and R 3 Each may be H. In another non-limiting example, R 1 、R 2 and R 3 Each can be an independently selected C(O)R 7A (e.g. C(O)Me).

[0761] Unrestricted combination[7]

[0762] In some embodiments:

[0763] X is NR 4X R 5X ;and

[0764] Y is a heteroaryl group containing 5 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0765] In certain embodiments of [7], R 4X and R 5X None of them are H (e.g., R 4X and R 5X are each independently selected C1-C6 alkyl). As a non-limiting example, R 4X and R 5X Each may be a methyl group.

[0766] In certain embodiments of [7], R 4X and R 5X One of them is H; and R 4X and R 5X The other one is not H (for example, R 4X and R 5X One of them is H; and R 4X and R 5XThe other of which is an independently selected C1-C6 alkyl).

[0767] In certain embodiments of [7], R 4X and R 5X Both are H.

[0768] In certain embodiments of [7], Y is a heteroaryl group containing 5 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0769] In certain embodiments of [7], Y is a heteroaryl group containing 5 ring atoms, wherein one ring atom is a heteroatom selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0770] In certain embodiments of [7], Y is a heteroaryl group containing 5 ring atoms, wherein 3-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.

[0771] In certain embodiments of [7], Y is selected from tetrazolyl, triazolyl, oxadiazolyl and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0772] In certain of the foregoing embodiments, each R c When present, independently selected from:

[0773] (i) halogen;

[0774] (iii)C 1-10 alkyl;

[0775] (iv) 1-6 (e.g., 1) independently selected R a Substituted C 1-10 alkyl; and

[0776] (v) optionally 1-3 independently selected R b Substituted C 3-6 Cycloalkyl (e.g., each R a can independently be (iii) C1-10 alkyl or (iv) 1-6 independently selected R a Substituted C 1-10 alkyl).

[0777] In certain of the foregoing embodiments, Y is selected from the group consisting of: (For example, R a may be selected from -OH, -OMe and -NMe2).

[0778] In certain embodiments of [7], Y is selected from tetrazolyl, triazolyl, oxadiazolyl and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0779] In certain embodiments of [4], Y is selected from the group consisting of: (For example, R a may be selected from -OH, -OMe and -NMe2).

[0780] In certain embodiments of [7], X is N(C 1-3 alkyl) 2; Y is selected from tetrazolyl and triazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0781] In certain of these embodiments, X is NMe2.

[0782] In certain of the foregoing embodiments, Y is As a non-limiting example, Y is (For example, ).

[0783] In certain embodiments of [7], Z is OR 6Z For example, Z may be OH.

[0784] In certain embodiments of [7], each Z x It’s H.

[0785] In certain embodiments of [7], each Z x Together with the carbon to which they are attached they form C=O.

[0786] In certain embodiments of [7], R 1 、R 2 and R 3 are each independently selected from H and C(O)R7A For example, R 1 、R 2 and R 3 Each may be H. In another non-limiting example, R 1 、R 2 and R 3 Each can be an independently selected C(O)R 7A (e.g. C(O)Me).

[0787] Z, R in the non-restricted combination [1]-[7] 1 、R 2 and R 3 Further exemplary embodiments of

[0788] In certain embodiments of [1]-[7], Z is selected from H, NR 4Z R 5Z , OR 6Z and OC(O)R 7Z .

[0789] In certain embodiments of [1]-[7], Z is NR 4Z R 5Z .

[0790] In certain of these embodiments, R 4Z and R 5Z are each independently selected from H and optionally 1-6 independently selected R a Substituted C 1-10 In certain of these embodiments, R 4Z and R 5Z Each independently selected from H and optionally 1-2 independently selected R a Substituted C 1-6 In certain of these embodiments, R 4Z and R 5Z are each independently selected from H and optionally substituted by 1 R a Substituted C 1-3 In certain of these embodiments, R 4Z and R 5Z Each independently selected from H and In certain of the foregoing embodiments, when R 4Z and R 5Z Each independently selected from H and When R a Selected from –OH, –NR e R f 、C 1-4 Alkoxy and C 1-4 In certain embodiments of [1]-[7], R 4Z and R 5Z Each independently selected from H and

[0791] In certain embodiments of [1]-[7], Z is NR 4Z R 5Z ; and R 4Z and R 5Z 1-2 of them are H.

[0792] In certain embodiments of [1]-[7], Z is NR 4Z R 5Z ; and R 4Z and R 5Z are each independently H or unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 Alkyl groups, such as unsubstituted C 1-3 alkyl, such as methyl).

[0793] In certain embodiments of [1]-[7], Z is OR 6Z In certain of these embodiments, R 6Z is H. In certain other embodiments, R 6Z It is C 1-6 Alkyl, optionally substituted with 1-6 independently selected R a Replace. For example, R 6Z is optionally 1-6 independently selected R a Substituted C 1-6 Alkyl, or R 6Z is optionally 1-2 (e.g. 1) independently selected R a Substituted C 1-3 As a non-limiting example, R 6Z Can be

[0794] In certain embodiments of [1]-[7], Z is OR 6Z ; R 6Z yes And R 6Z R on a Selected from –OH, –NR e R f , C 1-4 Alkoxy and C 1-4 For example, R 6Z Can be selected from

[0795] In certain embodiments of [1]-[7], Z is OC(O)R 7Z In certain of these embodiments, R 7Z is optionally 1-6 independently selected R a Substituted C 1-10Alkyl. For example, R 7Z is unsubstituted C 1-10 Alkyl groups (eg, methyl, ethyl, and isopropyl).

[0796] In certain of these embodiments, R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A .

[0797] In certain of these embodiments, each occurrence of R 7A is independently optionally 1-6 independently selected R a Substituted C 1-10 Alkyl (eg, optionally with 1-6 independently selected R a Substituted C 1-6 or C 1-3 Alkyl; for example, C 1-10 or C 1-6 or C 1-3 unsubstituted alkyl (e.g., CH3)).

[0798] In certain of the foregoing embodiments, R 1 、R 2 and R 3 Each independently selected from H and C(O)Me (e.g., R 1 、R 2 and R 3 Each is H; or R 1 、R 2 and R 3 each is C(O)Me).

[0799] In certain embodiments of [1]-[7], R 1 、R 2 and R 3 are each independently selected from H and C(O)Me. For example, R 1 、R 2 and R 3 Each can be H. For example, R 1 、R 2 and R 3 Each may be C(O)Me).

[0800] Unrestricted combination[8]

[0801] In some embodiments:

[0802] X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl; and

[0803] Z is OR6Z .

[0804] In certain embodiments, R 6Z It’s H.

[0805] In certain embodiments of [8], X is C 1-3 Alkyl, which is optionally replaced by 1-3 R a For example, X is methyl or trifluoromethyl. In certain of these embodiments, Z is OH.

[0806] Unrestricted combination[9]

[0807] In some embodiments:

[0808] X is optionally replaced by 1-3 R a Substituted C1-C6 alkyl; and

[0809] Z is OC(O)R 7Z .

[0810] In certain embodiments of [9], R 7Z It’s H.

[0811] In certain embodiments of [9], R 7Z is optionally 1-6 independently selected R a Substituted C 1-10 In certain of the foregoing embodiments, R 7Z It is C 1-6 Alkyl, optionally substituted by 1-6 (e.g., 1-3) independently selected R a replace.

[0812] In certain aforementioned embodiments of [9], when R 7Z is optionally 1-6 independently selected R a Substituted C 1-10 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0813] In certain embodiments of [9], when R 7Z is unsubstituted C 1-10 Alkyl (e.g., unsubstituted C 1-6 alkyl).

[0814] Non-restricted combinations

[10]

[0815] In some embodiments:

[0816] X is NR 4X R 5X ;and

[0817] Z is OR 6Z .

[0818] In certain embodiments, R 6Z It’s H.

[0819] In certain embodiments of

[10] , R 4X and R 5X None of them are H (e.g., R 4X and R 5X are each independently selected C1-C6 alkyl). As a non-limiting example, R 4X and R 5X Each may be a methyl group.

[0820] In certain embodiments of

[10] , R 4X and R 5X One of them is H; and R 4X and R 5X The other one is not H (for example, R 4X and R 5X One of them is H; and R 4X and R 5X The other of which is an independently selected C1-C6 alkyl).

[0821] In certain embodiments of

[10] , R 4X and R 5X Both are H.

[0822] Non-restricted combinations

[11]

[0823] In some embodiments:

[0824] X is NR 4X R 5X ;and

[0825] Z is OC(O)R 7Z .

[0826] In certain embodiments of

[11] , R 4X and R 5X None of them are H (e.g., R 4X and R 5X are each independently selected C1-C6 alkyl). As a non-limiting example, R 4X and R 5X Each may be a methyl group.

[0827] In certain embodiments of

[11] , R4X and R 5X One of them is H; and R 4X and R 5X The other one is not H (for example, R 4X and R 5X One of them is H; and R 4X and R 5X The other of which is an independently selected C1-C6 alkyl group). As a non-limiting example, R 4X and R 5X Each may be a methyl group.

[0828] In certain embodiments of

[11] , R 4X and R 5X Both are H.

[0829] In certain embodiments of

[11] , R 7Z It’s H.

[0830] In certain embodiments of

[11] , R 7Z is optionally 1-6 independently selected R a Substituted C 1-10 In certain of the foregoing embodiments, R 7Z It is C 1-6 Alkyl, optionally substituted by 1-6 (e.g., 1-3) independently selected R a replace.

[0831] In certain aforementioned embodiments of

[11] , when R 7Z is optionally 1-6 independently selected R a Substituted C 1-10 When the alkyl group is present, each occurrence of R a Independently selected from the group consisting of: -OH; -F; -NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0832] In certain embodiments of [8]-

[11] , Y is CO2R 6Y .

[0833] In certain embodiments of [8]-

[11] , R 6Y is H. In certain other embodiments, R 6Y It is C 1-12 (For example, C 1-6 , C 2-6 , C 2-3 ) alkyl, which is optionally substituted by 1-6 independently selected R aSubstituted (e.g., unsubstituted; or by 1-2, e.g., 1, independently selected R a replace).

[0834] In certain embodiments of [8]-

[11] , Y is selected from CO2H and CO2Me.

[0835] In certain embodiments of [8]-

[11] , Y is

[0836] In certain embodiments of [8]-

[11] , Y is And R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 For example, Y can be ).

[0837] In certain embodiments of [8]-

[11] , Y is CONR 4Y R 5Y In certain of these embodiments, R 4Y and R 5Y are each independently H or C 1-12 Alkyl (e.g., C 1-6 , C 1-4 ), which is optionally replaced by 1-6 (e.g., 1-3 or 1-2) independently selected R a In certain of the foregoing embodiments, R 4Y and R 5Y Each independently is H or In certain of these embodiments, R a Selected from –OH; -F; –NR e R f (e.g., NMe2); C 1-4 Alkoxy; and C 1-4 Halogenated alkoxy.

[0838] In certain embodiments of [8]-

[11] , Y is CONR 4Y R 5Y ; and R 4Y and R 5Y Each is independently H, For example, Y may be CONH2.

[0839] As another non-limiting example, Y is (For example, R a Selected from –OH; -F; –NR e R f(e.g. NMe2); C 1-4 Alkoxy; and C 1-4 haloalkoxy).

[0840] In certain embodiments of [8]-

[11] , Y is CONR 4Y R 5Y , where R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 alkyl.

[0841] In certain of these embodiments, n is 2 or 3.

[0842] In certain embodiments, when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 When W 1 Each occurrence is independently C 2-3 Alkylene (e.g., C2 alkylene).

[0843] In certain embodiments, when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 When W 2 Each occurrence is independently -N(H)-, -N(Me)-, or -O-.

[0844] In certain embodiments, when R 4Y and R 5Y One of them is –(W 1 –W 2 ) n -W 3 When W 3 Selected from H and C 1-3 alkyl.

[0845] In certain embodiments of [8]-

[11] , Y is CONR 4Y R 5Y ; R 4Y and R 5Y One of them is –(W 1 –W 2 )n -W 3 ; and R 4Y and R 5Y The other one is selected from H and C 1-3 Alkyl, wherein:

[0846] n is 2 or 3; each time W appears 1 Independently C 2-3 Alkylene (e.g., C2 alkylene); each occurrence of W 2 are independently -N(H)-, -N(Me)-, or -O-; and W 3 Selected from H and C 1-3 alkyl.

[0847] As a non-limiting example, R 4Y and R 5Y One of them can be selected from:

[0848] **

[0849] In certain of these embodiments, Y is selected from tetrazolyl, triazolyl, oxadiazolyl, and oxazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted; and wherein one of the heteroaryl ring nitrogen atoms is optionally replaced by R d replace.

[0850] In certain of the foregoing embodiments, Y is selected from the group consisting of: (For example, R a may be selected from -OH, -OMe and -NMe2).

[0851] As a non-limiting example, Y may be

[0852] In certain of these embodiments, R 1 、R 2 and R 3 are each independently selected from H and C(O)R 7A .

[0853] In certain of these embodiments, each occurrence of R 7A is independently optionally 1-6 independently selected R a Substituted C 1-10 Alkyl (eg, optionally with 1-6 independently selected R a Substituted C 1-6 or C 1-3 Alkyl; for example, C 1-10 or C 1-6 or C 1-3unsubstituted alkyl (e.g., CH3)).

[0854] In certain of the foregoing embodiments, R 1 、R 2 and R 3 Each independently selected from H and C(O)Me (e.g., R 1 、R 2 and R 3 Each is H; or R 1 、R 2 and R 3 each is C(O)Me).

[0855] In certain embodiments of [8]-

[11] , R 1 、R 2 and R 3 are each independently selected from H and C(O)Me. For example, R 1 、R 2 and R 3 Each can be H. For example, R 1 、R 2 and R 3 Each may be C(O)Me).

[0856] In certain embodiments of [1]-

[11] , each Z x It’s H.

[0857] In certain other embodiments of [1]-

[11] , each Z x Together with the carbon to which they are attached they form C=O.

[0858] In some embodiments, the compound is selected from the following Table A-1:

[0859] Table A-1.

[0860]

[0861]

[0862]

[0863]

[0864]

[0865]

[0866]

[0867]

[0868]

[0869]

[0870]

[0871]

[0872]

[0873]

[0874]

[0875]

[0876]

[0877]

[0878] or a pharmaceutically acceptable salt thereof.

[0879] In some embodiments, the compound is selected from the following Table A-2: Table A-2.

[0880]

[0881]

[0882]

[0883]

[0884]

[0885]

[0886]

[0887]

[0888]

[0889]

[0890]

[0891]

[0892]

[0893]

[0894]

[0895]

[0896]

[0897]

[0898] or a pharmaceutically acceptable salt thereof.

[0899] Pharmaceutical compositions and administration

[0900] Overview

[0901] In some embodiments, a chemical entity (e.g., a compound or a pharmaceutically acceptable salt and / or hydrate and / or prodrug of a compound) that produces cross-links in the cornea in response to exposure to photoactivating light is administered as a pharmaceutical composition comprising the chemical entity and one or more pharmaceutically acceptable excipients and, optionally, one or more additional therapeutic agents described herein.

[0902] In some embodiments, the pharmaceutical composition is as described in US2018 / 0236077, which is incorporated herein by reference in its entirety.

[0903] In some embodiments, the chemical entities described herein can be administered in combination with one or more delivery agents. Delivery agents include, but are not limited to, anesthetics, analgesics, tension agents, shear thinning agents, viscosity increasing agents, surfactants (e.g., ionic surfactants or nonionic surfactants), or chelating agents. Non-limiting examples of anesthetics can include pilocarpine, proparacaine, tetracaine, or oxybuprocaine. Non-limiting examples of analgesics include menthol, benzyl alcohol, or phenylethyl alcohol. Non-limiting examples of tension agents include glycerol, propylene glycol, polyethylene glycol (PEG) -8, ethanol, benzyl alcohol, phenylethyl alcohol, or triacetin. Non-limiting examples of shear thinning, viscosity increasing agents include carbomer, polycarbophil, gellan gum, xanthan gum, sodium carboxymethyl cellulose, or sodium hyaluronate. Non-limiting examples of ionic surfactants include benzalkonium chloride. Non-limiting examples of nonionic surfactants include poloxamer 407, tetronic 1107, tetronic 1304, polysorbate 80, polyethylene glycol (PEG) -40 hydrogenated castor oil, lecithin, polysorbate 60, polyethylene glycol (PEG) -35 castor oil, tocopherol (TPGS), nonoxynol -9 or tyloxapol. Non-limiting examples of chelating agents include ethylenediaminetetraacetic acid (EDTA) or citrate.

[0904] In some embodiments, the chemical entities described herein can be administered to the epithelium of the cornea in combination with one or more preparations. In certain embodiments, the preparation increases the permeability of the corneal epithelium. As a non-limiting example of the foregoing, the preparation may include one or more of the following: zinc metalloproteinases, copper metalloproteinases, papain, bromelain, actinidin, ficin (ficain), N-acetylcysteine, ambroxol, carbocysteine ​​or erdosteine. In certain embodiments, one or more preparations may also include one or more anesthetics (e.g., pilocarpine, proparacaine, tetracaine or oxybuprocaine).

[0905] In some embodiments, the chemical entities described herein can be administered in combination with one or more enhancing agents that are configured to: (i) remove one or more therapeutic agents from the corneal epithelium without diluting the one or more therapeutic agents delivered to the stroma; (ii) close the tight junctions of the epithelium to control corneal hydration; (iii) promote oxidation of the one or more therapeutic agents delivered to the stroma; or (iv) further deliver the one or more therapeutic agents from the epithelium to the stroma. As non-limiting examples of the foregoing, the enhancing agent may include one or more of the following: a divalent metal salt, one or more pro-oxidants, or one or more glycosaminoglycans.

[0906] In some embodiments, the chemical entities described herein can be administered in combination with one or more post-treatment formulations in response to the application of one or more enhancing formulations, and the one or more post-treatment formulations can include at least one of the following: one or more divalent metal salts, one or more viscosity agents, one or more glycosaminoglycans, or one or more antibiotics.

[0907] In some embodiments, the chemical entity can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS), such as d-α-tocopheryl polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms, such as Tweens, poloxamers or other similar polymer delivery matrices, serum proteins, such as human serum albumin, buffer substances, such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and lanolin. Cyclodextrins such as α-, β-, and γ-cyclodextrins, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives can also be used to enhance the delivery of the compounds described herein. Dosage forms or compositions comprising the chemical entities described herein in the range of 0.005%-100% can be prepared, with the remainder being made up by non-toxic excipients. The contemplated compositions may comprise 0.001%-100% of the chemical entities provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, and in yet another embodiment 20-80%. The actual methods for preparing such dosage forms are known or will be understood by those skilled in the art; for example, see Remington: The Science and Practice of Pharmacy, 22nd edition (Pharmaceutical Press, London, England, 2012).

[0908] Routes of administration and composition components

[0909] The composition can be prepared as a liquid solution or suspension; a solid form suitable for adding a liquid to prepare a solution or suspension before administration can also be prepared; and the preparation can also be emulsified. Based on the present disclosure, the preparation of such preparations is known to those skilled in the art.

[0910] The composition may be administered topically (eg, intraocularly in the form of topical instillations).

[0911] Pharmaceutical forms suitable for intraocular use include sterile aqueous solutions (e.g., buffers such as citrate buffer; for example, ophthalmic solutions such as 20% dextran ophthalmic solution) or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol solutions; and sterile powders for the extemporaneous preparation of sterile solutions or dispersions. In general, the form must be sterile and fluid to the extent that it can be easily syred. It should also be stable under the conditions of manufacture and storage and must be able to resist the contaminating effects of microorganisms such as bacteria and fungi during storage.

[0912] The carrier can also be a solvent or dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof, and vegetable oils. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size, and by using a surfactant. The effects of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, isotonic agents are preferably included, such as sugars or sodium chloride. The absorption of the composition can be prolonged by using agents that delay absorption, such as aluminum monostearate and gelatin, in the composition.

[0913] Sterile solutions are prepared by incorporating the desired amount of the active compound and, if necessary, the other ingredients listed above into a suitable solvent followed by filtration sterilization. Typically, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium and the other required ingredients listed above. When preparing sterile powders as needed for the preparation of sterile solutions, vacuum drying and freeze-drying techniques are preferred methods of preparation to obtain a powder of the active ingredient and any other required ingredients from a previously sterile-filtered solution.

[0914] In certain embodiments, the excipient is sterile and generally free of undesirable substances. The composition can be sterilized by conventional, well-known sterilization techniques. For various oral dosage form excipients, such as tablets and capsules, sterility is not required. USP / NF standards are generally sufficient.

[0915] Ophthalmic compositions may include, but are not limited to, any one or more of the following: dextran, viscogens (e.g., carboxymethylcellulose, glycerol, polyvinylpyrrolidone, polyethylene glycol); stabilizers (e.g., Pluronic (triblock copolymer), cyclodextrin); preservatives (e.g., benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol and zinc chloride; Alcon Laboratories Inc.), Purite (stabilized chlorine oxide complex; Allergan, Inc.).

[0916] Compositions can include ointments and creams. Ointments are semisolid preparations, typically based on petrolatum or other petroleum derivatives. Creams containing the selected active agent are typically viscous liquids or semisolid emulsions, typically oil-in-water or water-in-oil. The cream base is typically washable and comprises an oil phase, an emulsifier, and an aqueous phase. The oil phase, sometimes also referred to as the "inner" phase, typically consists of petrolatum and a fatty alcohol (such as cetyl alcohol or stearyl alcohol); although not necessarily, the aqueous phase typically exceeds the volume of the oil phase and typically contains a wetting agent. The emulsifier in a cream formulation is typically a nonionic, anionic, cationic, or amphoteric surfactant. Like other carriers or vehicles, the ointment base should be inert, stable, non-irritating, and non-sensitive.

[0917] In certain embodiments, the compounds and compositions disclosed herein can be applied to the cornea using an applicator. Non-limiting examples of applicators can include an eyedropper or a syringe.

[0918] In certain embodiments, the compounds and compositions described herein can be administered in a formulation that allows the compound of the composition to pass through the corneal epithelium to the underlying area in the corneal stroma. In other embodiments, the corneal epithelium can be removed or otherwise cut to allow the compound or composition provided herein to be applied more directly to the underlying tissue.

[0919] Thus, in some embodiments, the compounds and compositions described herein are applied directly to the cornea (e.g., without removing or otherwise cutting the corneal epithelium). In other embodiments, the corneal epithelium is removed or otherwise cut prior to applying the compounds and compositions described herein.

[0920] dose

[0921] The dosage can vary depending on the patient's needs, the severity of the disease being treated, and the specific compound being used. The appropriate dosage for a particular situation can be determined by a person skilled in the art of medicine. In some cases, the total dosage can be administered in batches or by providing continuous delivery throughout the entire process.

[0922] In some embodiments, the composition is a solution (e.g., a buffer, such as a citrate buffer; such as an ophthalmic solution, such as a 20% dextran ophthalmic solution) comprising 0.01-100 mg / mL of a chemical entity described herein (e.g., 0.02-50 mg / mL, 0.04-25 mg / mL, 0.08-12.5 mg / mL, 0.16-6.25 mg / mL, 0.2-5 mg / mL). In certain embodiments of the foregoing, the unit dose is 0.001-1 mL (e.g., 0.002-0.5 mL, 0.010-0.25 mL, e.g., 0.020-0.1 mL).

[0923] In some embodiments, the composition is a solution (e.g., a buffer, such as a citrate buffer; such as an ophthalmic solution, such as a 20% dextran ophthalmic solution) comprising 0.001%-20% of a chemical entity described herein (e.g., 0.002%-10%, 0.004%-5%, 0.008%-2.5%). In certain embodiments of the foregoing, the unit dose is 0.001-1 mL (e.g., 0.002-0.5 mL, 0.010-0.25 mL, e.g., 0.020-0.2 mL).

[0924] Dosage regimen

[0925] The above dosage can be administered regularly within a specific duration. In some embodiments, a unit dose can be administered every 1-1200 seconds (e.g., every 2-300 seconds, every 2-150 seconds, every 5-150 seconds, every 5-100 seconds, every 5-10 seconds, every 10-150 seconds, every 50-150 seconds). In some of the aforementioned embodiments, dosage is administered within a time period of 1-1200 minutes (e.g., 1-600 minutes, 5-120 minutes, 10-120 minutes).

[0926] Treatment

[0927] Overview

[0928] The present disclosure features methods for treating a subject (e.g., a human) having a disease, disorder, or condition in which an abnormal shape of the cornea (e.g., corneal thinning, e.g., bilateral corneal thinning, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or corneal steepening (e.g., bulge)) contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. In certain embodiments, the methods described herein may include or further include treating one or more conditions associated with, concurrent with, or sequelae to any one or more of the conditions described herein.

[0929] In some embodiments, the method further comprises identifying the object.

[0930] In certain embodiments, the chemical entities described herein provide refractive correction to the cornea (e.g., by imparting mechanical rigidity). In certain embodiments, the chemical entities described herein strengthen and stabilize the corneal structure. In certain embodiments, the chemical entities described herein can be used for vision correction.

[0931] method

[0932] In some embodiments, the method comprises administering a compound disclosed herein or a pharmaceutical composition thereof to the cornea of ​​a subject in need thereof; and applying electromagnetic radiation (eg, light) to the cornea, thereby generating crosslinks in the cornea.

[0933] In certain of the foregoing embodiments, the method comprises administering a compound disclosed herein, or a pharmaceutical composition thereof, to the corneal stroma of a subject in need thereof.

[0934] In certain embodiments, a compound disclosed herein or pharmaceutical composition thereof is administered to the cornea without requiring removal of corneal epithelial cells.

[0935] In certain embodiments, the method further comprises increasing or decreasing O2 concentration on the cornea during irradiation.

[0936] In certain embodiments, the method further comprises administering one or more delivery agents to the cornea, wherein the one or more delivery agents are as described elsewhere herein.

[0937] In certain embodiments, the method further comprises administering to a subject in need thereof (e.g., to the cornea of ​​a subject in need thereof) one or more preparations that increase the permeability of the corneal epithelium, wherein the one or more preparations are as described elsewhere herein.

[0938] In certain embodiments, the method further comprises administering one or more enhancing formulations to the corneal epithelium, wherein the one or more enhancing formulations are configured as one or more of the following:

[0939] (i) removing one or more therapeutic agents from the corneal epithelium without diluting one or more therapeutic agents delivered to the stroma;

[0940] (ii) closing the tight junctions of the epithelium to control corneal hydration;

[0941] (iii) promoting oxidation of one or more therapeutic agents delivered to the matrix; or

[0942] (iv) further delivering one or more therapeutic agents from the epithelium to the stroma,

[0943] wherein the one or more enhancing agents are as described elsewhere herein.

[0944] In certain embodiments, the method further comprises administering one or more post-treatment formulations to a subject in need thereof in response to applying one or more boosting formulations, wherein the one or more boosting formulations are as described elsewhere herein.

[0945] electromagnetic radiation

[0946] In some embodiments, the electromagnetic radiation applied to the cornea of ​​a subject in need thereof is light radiation. In certain embodiments, the light radiation has a suitable wavelength, energy, and duration to cause a reaction (e.g., photoinduced electron transfer and / or fragmentation) of a compound described herein to allow crosslinking.

[0947] In some embodiments, the wavelength of light can be selected so that it corresponds to or encompasses absorption by a compound described herein and reaches an area of ​​tissue that has been contacted with a compound described herein, eg, penetrates to an area where a compound described herein is present.

[0948] In some embodiments, the energy of the applied electromagnetic radiation is less than 2000 J / cm 2 In some of the aforementioned embodiments, the applied electromagnetic energy is in the range of 1 to 500 J / cm 2 The total energy dose absorbed in the cornea can be described as the effective dose, which is the energy absorbed by the area of ​​the corneal epithelium. For example, the effective dose for an area of ​​the corneal surface can be, for example, at 5 J / cm 2 and 20 J / cm 2 or 30J / cm 2 between (e.g., 5.4 J / cm 2 ).

[0949] In some embodiments, the electromagnetic radiation is at a power of about 1-100 mW / cm 2 In some embodiments, the electromagnetic radiation is applied at a radiation intensity of about 1-5 mW / cm 2 (For example, 3mW / cm 2 ) of the radiosity applied.

[0950] In some embodiments, the electromagnetic radiation has a wavelength in the visible, infrared or ultraviolet spectrum. In some embodiments, the electromagnetic radiation comprises radiation of a wavelength from about 300 nm to about 800 nm (e.g., from 300 nm to 700 nm). In certain embodiments, the electromagnetic radiation comprises ultraviolet A (UVA) light (e.g., with a wavelength between 350 and 380 nm, e.g., 360-370 nm, e.g., 365 nm). In certain embodiments, the electromagnetic radiation comprises visible wavelengths (e.g., with a wavelength between 400 nm and 550 nm, e.g., about 452 nm). In some embodiments, the electromagnetic radiation is laser radiation. In certain embodiments, the laser radiation is applied with an average power of 1-100 mW.

[0951] In some embodiments, the duration of irradiation is between 30 seconds and 1 hour. In certain embodiments, the duration of irradiation is between 1 minute and 1 hour (e.g., 30 minutes).

[0952] In some embodiments, the cornea can be treated more extensively with a compound or composition described herein; and radiation can be selectively directed to the treated corneal area according to a specific pattern.

[0953] In certain embodiments, one or more mirrors or lenses can be used to direct and focus electromagnetic radiation into a specific pattern on the cornea (e.g., at a specific focal plane within the cornea, e.g., at a specific depth in the underlying region where cross-linking activity is desired).

[0954] In some embodiments, a specific electromagnetic radiation pattern can be modulated to achieve a desired degree of cross-linking in a selected area of ​​the cornea. For example, the electromagnetic radiation can be delivered according to any combination of wavelength, bandwidth, intensity, power, location, penetration depth, and / or treatment duration (duration of the exposure period, duration of the dark period, and the ratio of the exposure period to the dark period).

[0955] In some embodiments, electromagnetic radiation is delivered using a system comprising a digital micromirror device (DMD) to modulate the application of electromagnetic radiation in space and time. In certain of the aforementioned embodiments, light is projected in a precise spatial pattern generated by microscopic mirrors arranged in a matrix on a semiconductor chip. Each mirror represents one or more pixels in the projected light pattern. Topography-guided crosslinking can be performed using the DMD. Control of the DMD based on topography allows for several different spatial and temporal irradiance and dose profiles. These spatial and temporal dose profiles can be generated using continuous wave irradiation, but can also be modulated using pulsed irradiation by pulsing the irradiation source at varying frequencies and duty cycles, as described above. Alternatively, the DMD can be modulated at different frequencies and duty cycles on a pixel-by-pixel basis to achieve maximum flexibility using continuous wave irradiation. Alternatively, a combination of pulsed irradiation and modulated DMD frequency and duty cycle can be combined. This allows for a specific amount of spatially determined corneal crosslinking. This spatially determined crosslinking can be combined with dosimetry, interferometry, optical coherence tomography (OCT), corneal topography, and the like for pre-treatment planning and / or real-time monitoring and modulation of corneal crosslinking during treatment. Furthermore, preclinical patient information can be combined with finite element biomechanical computer modeling to create patient-specific pretreatment plans.

[0956] In some embodiments, electromagnetic radiation is delivered using multiphoton excitation microscopy. Specifically, instead of delivering a single photon of a specific wavelength to the cornea, multiple photons of longer wavelengths (i.e., lower energy) are delivered, which combine to initiate crosslinking. Advantageously, longer wavelengths scatter less within the cornea than shorter wavelengths, allowing longer wavelengths of light to penetrate the cornea more efficiently than shorter wavelengths. Since the photosensitizer absorbs much less light of longer wavelengths, the shielding effect of incident radiation deeper within the cornea is also reduced compared to conventional short-wavelength irradiation. This allows enhanced control of depth-specific crosslinking. For example, in some embodiments, two photons can be used, each of which carries about half the energy necessary to excite a molecule of a compound or composition disclosed herein to produce a photochemical kinetic reaction further described below. When a compound disclosed herein absorbs two photons simultaneously, it absorbs enough energy to release active free radicals in corneal tissue. Embodiments can also utilize lower energy photons such that a molecule of the compounds disclosed herein must absorb, for example, three, four, or five photons simultaneously to release active free radicals. The probability of nearly simultaneous absorption of multiple photons is low, so a high flux of excitation photons may be required, and a high flux can be delivered by a femtosecond laser.

[0957] In some embodiments, the electromagnetic radiation is applied continuously (continuous wave (CW)) or as pulsed radiation. In certain embodiments, this choice has an impact on the amount, rate, and degree of cross-linking. In certain embodiments, when the electromagnetic radiation light is applied as pulsed radiation, the duration of the exposure period, the duration of the dark period, and the ratio of the exposure period to the dark period duration have an impact on the resulting corneal hardening. For the same amount or dose of delivered energy, pulsed radiation can be used to produce more or less corneal tissue hardening compared to continuous wave irradiation. Light pulses of appropriate length and frequency can be used to achieve more ideal chemical amplification. For pulsed light treatment, the on / off duty cycle can be between about 1000 / 1 and about 1 / 1000; the irradiance can be about 0.1 mW / cm 2 to about 1000mW / cm 2 The pulse rate may be between about 0.01 Hz and about 1000 Hz or between about 1000 Hz and about 100,000 Hz for an average irradiance.

[0958] In some embodiments, pulsed radiation can be delivered by using a DMD, electronically turning on and off the light source 110 and / or using a mechanical or photoelectric (e.g., Pockels cells) shutter or mechanical chopper or rotating aperture. Due to the pixel-specific modulation capability of the DMD and the subsequent stiffness imparted based on the modulation frequency, duty cycle, irradiance and dose delivered to the cornea, a complex biomechanical stiffness pattern of the cornea can be imparted to allow various degrees of refractive correction. For example, these refractive corrections may involve a combination of myopia, hyperopia, astigmatism, irregular astigmatism, presbyopia and complex corneal refractive surface corrections because of ophthalmic diseases such as keratoconus, transparent edge disease, ectasia after laser vision correction surgery and other corneal biomechanical conditions change / degeneration, etc. A specific advantage of the DMD system and method is that it allows randomized asynchronous pulsed topographic patterning, creating non-periodic and uniformly occurring illumination, eliminating the possibility of triggering photosensitive epileptic seizures or flicker vertigo at pulse frequencies between 2 Hz and 84 Hz.

[0959] Examples of systems and methods for delivering electromagnetic radiation are described, for example, in U.S. Patent Application Publication No. 2011 / 0237999, filed on March 18, 2011, entitled “Systems and Methods for Applying and Monitoring Eye Therapy”; U.S. Patent Application Publication No. 2012 / 0215155, filed on April 3, 2012, entitled “Systems and Methods for Applying and Monitoring Eye Therapy”; and U.S. Patent Application Publication No. 2013 / 0245536, filed on March 15, 2013, entitled “Systems and Methods for Corneal Cross-Linking with Pulsed Light,” the contents of which are incorporated herein by reference in their entirety.

[0960] oxygen

[0961] In some embodiments, the concentration of O2 is actively increased or decreased (e.g., increased) during irradiation to control the crosslinking rate. Oxygen can be administered in different ways during the crosslinking process. In some embodiments, a pharmaceutical composition comprising a compound as described herein can be supersaturated with O2. Thus, when the compound as described herein is applied to the eye, a higher concentration of O2 is delivered directly to the cornea along with riboflavin, and affects reactions involving O2 when riboflavin is exposed to electromagnetic radiation. According to another approach, a steady state of O2 can be maintained on the corneal surface (at a selected concentration, e.g., >21%) to expose the cornea to a selected amount of O2 and cause O2 to enter the cornea. Exemplary systems and methods for applying oxygen during the cross-linking process are described, for example, in U.S. Patent No. 8,574,277, filed on October 21, 2010, entitled “Eye Therapy,” and U.S. Patent Application Publication No. 2013 / 0060187, filed on October 31, 2012, entitled “Systems and Methods for Corneal Cross-Linking with Pulsed Light,” the contents of which are incorporated herein by reference in their entirety.

[0962] Thus, in some embodiments, the method can further comprise applying a selected concentration of oxygen to the eye, wherein the selected concentration is greater than the concentration of oxygen in the atmosphere.

[0963] Indications

[0964] In some embodiments, the condition, disease, or disorder is an ophthalmic disease.

[0965] In some embodiments, the ophthalmic disease comprises decreased corneal stiffness.

[0966] Expansive disease

[0967] In some embodiments, the condition, disease, or disorder is a corneal ectatic disorder. Non-limiting examples of ectatic disorders include keratoconus (e.g., keratoconus with a papillary cone, an ellipsoidal cone, or a spherical cone; e.g., progressive keratoconus), corneal sphericity, pellucid marginal degeneration, corneal ectasia (e.g., postoperative ectasia, such as post-LASIK ectasia), and Terrien marginal degeneration.

[0968] In certain embodiments, the condition, disease, or disorder is corneal ectasia following refractive surgery (e.g., postoperative corneal ectasia). Non-limiting examples of refractive surgery include radial keratotomy (RK), photorefractive keratectomy (PRK), or laser in situ keratomileusis (LASIK).

[0969] In some embodiments, the condition, disease, or disorder is bacterial keratitis.

[0970] Vision condition

[0971] In some embodiments, the disease, disorder, or condition is myopia, hyperopia, astigmatism, irregular astigmatism, presbyopia.

[0972] In some embodiments, the ophthalmic disorder is a cataract (eg, nuclear, cortical, posterior polar, secondary, traumatic, or radiation cataract) or a lens disorder.

[0973] Combination therapy

[0974] The present disclosure encompasses monotherapy regimens as well as combination therapy regimens.

[0975] In some embodiments, the methods described herein can further comprise administering one or more additional therapies (eg, one or more additional therapeutic agents and / or one or more treatment regimens) in combination with the compounds described herein.

[0976] In some embodiments, the compounds described herein can be administered in combination with one or more other therapeutic agents. Representative additional therapeutic agents include, but are not limited to, therapeutic agents for the following conditions: inflammation, cataracts, lens disorders, or ectatic disorders, including, but not limited to, keratoconus (e.g., keratoconus with a papillary cone, ellipsoidal cone, or spherical cone), corneal sphericity, pellucid marginal degeneration, corneal ectasia (e.g., postoperative ectasia, such as post-LASIK ectasia), and Terrien marginal degeneration.

[0977] In some embodiments, the one or more additional therapeutic agents include those useful as, for example, cross-linking agents, including those described in U.S. Patent Application Publication No. 2014 / 0343480, filed May 19, 2014, which is incorporated herein by reference in its entirety. Non-limiting examples include:

[0978] Riboflavin (e.g., riboflavin or riboflavin phosphate);

[0979] 2,3-Butanedione;

[0980] Folic acid;

[0981] Quinoxalines (for example, Olaquidox);

[0982] Quinolines (for example, chloroquine, hydroxychloroquine, and quinine);

[0983] Dibucaine;

[0984] Methotrexate;

[0985] Menadione; and

[0986] Verteporfin

[0987] and their derivatives.

[0988] Other non-limiting examples of cross-linking agents may include photosensitizers such as Rose Bengal, methylene blue, and N-hydroxypyridine-2-(1H)-thione. Other non-limiting examples of cross-linking agents may also include photosensitizers such as photofrin.RTM, synthetic diporphyrins and dichlorins, phthalocyanines with or without metal substituents, chloroaluminum phthalocyanines with or without various substituents, O-substituted tetraphenylporphyrins, 3,1-meso-tetrakis(o-propionylaminophenyl)porphyrin, verdins, purpurins, tin and zinc derivatives of octaethylpurpurin, etiopurpurin, hydroporphyrins, bacteriochlorins of the tetrakis(hydroxyphenyl)porphyrin series (e.g., protoporphyrins I to protoporphyrin IX, coproporphyrins, uroporphyrins, mesoporphyrins, hematoporphyrins and sapphyrins), chlorins, chlorine 6, mono-1-aspartyl derivatives of chlorine 6, di-1-aspartyl derivatives of chlorine 6, tin ( IV) Chloro-6, m-tetrahydrophenylchlorin, benzoporphyrin derivatives, benzoporphyrin monoacid derivatives, tetracyanoethylene adducts of benzoporphyrin, dimethyl acetylene dicarboxylate adducts of benzoporphyrin, Diels-Adler adducts, monoacid ring "a" derivatives of benzoporphyrin, sulfonated aluminum PC, sulfonated AlPc, disulfonated and tetrasulfonated derivatives, sulfonated aluminum naphthalocyanines, naphthalocyanines with or without metal substituents and with or without different substituents, chlorophyll, bacteriochlorophyll A, anthraquinones, anthrapyrazoles, aminoanthraquinones, phenoloxazine dyes, thiazines, methylene blue, phenothiazine derivatives, chalcogenapyrylium dyes, cationic selenium and telluropyrylium derivatives selena and tellurapyrylium derivatives, ring-substituted cationic PC, pheophorbide derivatives, natural porphyrins, hematoporphyrin, ALA-induced protoporphyrin IX, endogenous metabolic precursors, 5-aminolevulinic acid, benzonaphthoporphyrazines, cationic imminium salts, tetracyclines, lutetium texaphyrin, texaphyrin, tin-etio-purpurin, porphycenes, benzophenothiazinium, xanthenes, rose bengal bengal), eosin, erythrosine, cyanine, merocyanine 540, selenium-substituted cyanines, flavin, riboflavin, proflavin, quinones, anthraquinones, benzoquinones, naphthaldiimides, naphthalimides, Victoria blue, toluidine blue, dianthraquinones (e.g., hypericin), fullerenes, rhodamine, and their photosensitive derivatives.

[0989] In some embodiments, the one or more additional agents include a metal (including elemental and ionic forms) (e.g., a metal salt, such as a divalent metal salt). Non-limiting examples include:

[0990] Iron (e.g., iron (II), such as FeSO4) (in certain embodiments, the iron additive can be dissolved in a citrate buffer);

[0991] ·copper;

[0992] ·manganese;

[0993] ·chromium;

[0994] ·vanadium;

[0995] ·aluminum;

[0996] ·cobalt;

[0997] ·mercury;

[0998] ·cadmium;

[0999] Nickel; and

[1000] ·arsenic;

[1001] Optionally in combination with hydrogen peroxide.

[1002] In some embodiments, the one or more additional therapeutic agents include, for example, those useful as anesthetics. Non-limiting examples include: pilocarpine, proparacaine, tetracaine, or oxybuprocaine.

[1003] In some embodiments, the one or more additional therapeutic agents include, for example, those useful as analgesics. Non-limiting examples include: menthol, benzyl alcohol, or phenylethyl alcohol.

[1004] In some embodiments, the one or more additional therapeutic agents include, for example, those that can be used to increase the permeability of the corneal epithelium. Non-limiting examples include: zinc metalloproteinases, copper metalloproteinases, papain, bromelain, actinidin, ficin, N-acetylcysteine, ambroxol, carbocysteine, or erdosteine.

[1005] In some embodiments, the one or more additional therapeutic agents include, for example, those useful as therapeutic agents for cataracts and / or lens disorders.

[1006] In some embodiments, the one or more additional therapeutic agents include, for example, those useful as antibiotics.

[1007] In some embodiments, the one or more additional therapeutic agents include, for example, those useful in gene therapy.

[1008] In some embodiments, the one or more additional treatment regimens include treatment regimens for inflammation, cataracts, lens disorders, or ectatic disorders, including but not limited to keratoconus (e.g., keratoconus with a papillary cone, ellipsoidal cone, or spherical cone), corneal globus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, such as post-LASIK ectasia), and Terrien marginal degeneration.

[1009] In some embodiments, the one or more additional treatment regimens include treatment regimens for myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.

[1010] In some embodiments, the one or more additional treatment options include ophthalmic surgery. Non-limiting examples include:

[1011] Corneal transplant surgery;

[1012] Cataract surgery;

[1013] Laser surgery;

[1014] Corneal transplantation (eg, penetrating keratoplasty or lamellar keratoplasty);

[1015] Refractive surgery (e.g., photorefractive keratectomy (RK), photorefractive keratectomy (PRK), or laser in situ keratomileusis (LASIK));

[1016] Corneal reshaping; and

[1017] Treatment of corneal lacerations.

[1018] Additional non-limiting examples of the one or more additional treatment regimens include contact lens therapy, amniotic membrane therapy, LASIK therapy, and administration of antibiotics.

[1019] Preparation and biological experiments of compounds

[1020] As will be appreciated by those skilled in the art, methods for synthesizing compounds of the formulae described herein will be readily apparent to those of ordinary skill in the art. Synthetic chemical transformations and protecting group methods (protection and deprotection) useful in synthesizing compounds described herein are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Press (1989); T. W. Greene and R. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

[1021] In some embodiments, intermediates useful in preparing compounds described herein can be prepared using the chemistry described in any one or more of the following schemes and non-limiting examples.

[1022] abbreviation

[1023]

[1024]

[1025]

[1026] Compound preparation

[1027] The compound of the present invention can be obtained according to the following process.

[1028] General process

[1029] General process 1

[1030] Step 1

[1031]

[1032] Commercially available compound (i) such as riboflavin or roseflavin can be converted to compound (ii) by treatment with a base such as NaOH or KOH in a suitable solvent such as water or ethanol at a temperature ranging from room temperature to the boiling point of the solvent, and then neutralized with an acid (e.g., acetic acid, citric acid or hydrochloric acid) to pH 6 at a temperature ranging from 0°C to room temperature.

[1033] wherein X is as defined elsewhere herein.

[1034] Step 2

[1035]

[1036] Compound (ii) can be converted to compound (iii) by treating with A and a coupling agent (such as thionyl chloride, CDI or EDCI) in a suitable solvent (such as methanol, ethanol, THF or dioxane) at a temperature ranging from room temperature to the boiling point of the solvent.

[1037] Where X and R 6Y as defined elsewhere herein, and A is an alcohol, such as methanol, allyl alcohol, or ethylene glycol.

[1038] General process 2

[1039] Step 1

[1040]

[1041] Compound (ii) can be converted to compound (iv) by treatment with B and, if necessary, a base (such as TEA or DIPEA) in a suitable solvent (such as DCM, THF or dioxane) at a temperature ranging from room temperature to the boiling point of the solvent.

[1042] wherein X is as defined elsewhere herein, B is a hydroxy protecting group reagent such as acetic anhydride, MOM-Cl or MEM-Cl, and P is a hydroxy protecting group such as acetyl, MOM or MEM.

[1043] Step 2

[1044]

[1045] Compound (iv) can be converted to compound (vi) by treatment with an amine (v) such as methylamine, dimethylamine or N,N-dimethylethane-1,2-diamine, C and, if necessary, a base (e.g., TEA or DIPEA) in a suitable solvent (e.g., DMF, DCM, THF or dioxane) at a temperature ranging from room temperature to the boiling point of the solvent.

[1046] Among them, X, R 4Y 、R 5Yand P are as defined elsewhere herein, and C is a coupling agent, such as EDCI, CDI or PyBOP.

[1047] Step 3

[1048]

[1049] Compound (vi) can be converted to compound (vii) by treatment with D in a suitable solvent (eg MeOH, DCM, THF or dioxane) at a temperature ranging from 0°C to the boiling point of the solvent.

[1050] Among them, X, R 4Y and R 5Y As defined elsewhere herein, D is a reagent capable of removing the protecting group P, such as sodium methoxide, HCl (gas) in dioxane, HBr or NH4OH.

[1051] General process 3

[1052] Step 1

[1053]

[1054] Compound (viii) obtained using General Procedure 1 can be converted to compound (ix) by treatment with E and, if necessary, a base (such as TEA or DIPEA) in a suitable solvent (such as MeOH, DCM, THF or dioxane) at a temperature ranging from -70°C to room temperature.

[1055] Where X and R 7Z As defined elsewhere herein, E is an anhydride, such as acetic anhydride, propionic anhydride, or isopropionic anhydride, or an activated ester or acid, such as pentafluorophenol acetate or acetic acid activated with CDI.

[1056] Step 2

[1057]

[1058] Compound (ix) can be converted to compound (x) by treatment with F and, if necessary, a base (such as TEA, pyrrolidine or DIPEA) in a suitable solvent (such as MeCN, DCM, THF or dioxane) at a temperature ranging from 0°C to room temperature.

[1059] Where X and R 7Z as defined elsewhere herein, and F is a reagent capable of selectively removing an allyl ester protecting group, such as Pd(PPh3)4 or Pd(OAc)2.

[1060] General process 4

[1061] Step 1

[1062]

[1063] Compound (xi) obtained using General Procedure 1 can be converted to compound (xii) by treating with G and, if necessary, a base (e.g., TEA, N,N-dimethylaminopyridine or DIPEA) in a suitable solvent (e.g., pyridine, DCM, THF or dioxane) at a temperature ranging from 0°C to the boiling point of the solvent.

[1064] wherein X is as defined elsewhere herein, G is a protecting group reagent capable of reacting selectively at the primary hydroxyl group, such as trityl chloride or 2-chlorotrityl chloride, and P 1 is a primary hydroxyl protecting group such as trityl or 2-chlorotrityl.

[1065] Step 2

[1066]

[1067] Compound (xii) can be converted to compound (xiii) by treatment with B according to General Procedure 2, Step 1.

[1068] Among them, X, P and P 1 As defined elsewhere herein.

[1069] Step 3

[1070]

[1071] Compound (xiii) can be converted to compound (xix) by treatment with H in a suitable solvent (e.g., water, MeOH, THF, or dioxane) at a temperature ranging from 0°C to the boiling point of the solvent.

[1072] Among them, X, P and P 1 As defined elsewhere herein, and H is a reagent capable of hydrolyzing the methyl ester, such as NaOH, LiOH, or NH4OH.

[1073] Step 4

[1074]

[1075] Compound (xix) can be converted to compound (xx) by treatment with C according to General Procedure 2, step 2.

[1076] Among them, X, R 4Y 、R 5Y ,P,P 1 and C are as defined elsewhere herein.

[1077] Step 5

[1078]

[1079] Compound (xx) can be converted to compound (xxi) by treatment with D according to General Procedure 2, step 3.

[1080] Among them, X, R 4Y 、R 5Y ,P,P 1 and D are as defined elsewhere herein.

[1081] General process 5

[1082] Step 1

[1083]

[1084] Compound (xx) can be converted to compound (xxii) by treatment with J in a suitable solvent (eg, diethyl ether, MeOH, THF or dioxane) at a temperature ranging from 0°C to room temperature.

[1085] Among them, X, R 4Y 、R 5Y , P and P 1 As defined elsewhere herein, J is a reagent capable of selectively removing a trityl or 2-chlorotrityl protecting group, such as pentafluoroethanol, silica gel supported ceric ammonium nitrate formic acid, or acetic acid.

[1086] Step 2

[1087]

[1088] Compound (xxii) can be converted to compound (xxiii) by treating with K and, if necessary, a base (e.g., TEA, N,N-dimethylaminopyridine or DIPEA) in a suitable solvent (e.g., DMF, DCM, MeOH, THF or dioxane) at a temperature ranging from 0°C to room temperature.

[1089] Among them, X, R 4Y 、R 5Y and P are as defined elsewhere herein, K is a reagent capable of converting a hydroxyl group into a leaving group, such as Ms-Cl, TsCl, or methyltriphenoxyphosphonium iodide. LG is a leaving group, such as mesylate, tosylate, or iodine.

[1090] Step 3

[1091]

[1092] Compound (xxiii) can be converted to compound (xxv) by treating with an amine (xxiv) such as methylamine, dimethylamine, morpholine or N,N-dimethylethane-1,2-diamine and, if necessary, a base (e.g., TEA, N,N-dimethylaminopyridine or DIPEA) in a suitable solvent (e.g., DMF, DCM, MeOH, THF or dioxane) at a temperature ranging from 0°C to the boiling point of the solvent.

[1093] Among them, X, R 4Y 、R 5Y 、R 4Z 、R 5Z , LG and P are as defined elsewhere herein.

[1094] Step 4

[1095]

[1096] Compound (xxv) can be converted to compound (xxvi) by treatment with D according to General Procedure 2, step 3.

[1097] Among them, X, R 4Y 、R 5Y 、R 4Z 、R 5Z , P and D are as defined elsewhere herein.

[1098] Reactions that are sensitive to moisture or air are carried out under nitrogen or argon using anhydrous solvents and reagents. The progress of the reactions is determined by analytical thin layer chromatography (TLC) or liquid chromatography-mass spectrometry (LC-MS), typically performed using Sanpont pre-coated TLC plates, silica gel GF-254, 0.25 mm layer thickness.

[1099] Typically, the analytical LC-MS system used consists of an Agilent 6120 platform with electrospray ionization in positive ion detection mode and an Agilent 1260 Series HPLC with an autosampler. The column is typically a 3.0 × 50 mm, 2.7 μm Agilent poroshell C18. The flow rate is 0.6 mL / min, and the injection volume is 5 μL. The UV detection range is 190–400 nm. The mobile phase consists of solvent A (water + 0.1% TFA) and solvent B (acetonitrile + 0.05% TFA), with a gradient of 90% solvent A to 95% solvent B over 1.7 minutes, held for 1.8 minutes, then back to 90% solvent A over 0.1 minutes and held for 1.4 minutes.

[1100] Preparative HPLC purifications were typically performed on a Waters 2555-2767 system with a 2489 UV detector. The column was a Welch C-18, 21.2 x 150 mm, 5 μm. The mobile phase consisted of a mixture of acetonitrile (5-95%) in water containing 0.05% TFA. The flow rate was maintained at 20 mL / min, the injection volume was 1800 μL, and the UV detector used two channels at 254 nm and 280 nm. The mobile phase gradient was optimized for each compound.

[1101] Reactions using microwave irradiation are typically performed using an Initiator manufactured by Biotage. Solutions are concentrated on a rotary evaporator under reduced pressure. Flash chromatography is typically performed using a Biotage flash chromatograph (Dyax) on silica gel (40-63 mM, pore size Unless otherwise stated, the spectra were obtained in CDCl3 solution in a 400 MHz spectrometer. 1 H NMR spectra. Chemical shifts are reported in parts per million (ppm). Tetramethylsilane (TMS) was used as the internal standard for CD3Cl solutions, and the residual CH3OH peak or TMS was used as the internal standard for CD3OD solutions. Coupling constants (J) are expressed in Hertz (Hz). Chiral analytical chromatography was performed on a Chiralpak AS, Chiralpak AD, Chiralcel OD, Chiralcel IA, or Chiralcel OJ column (250 x 4.6 mm) (Daicel Chemical Industries, Ltd.), using the specified percentage of ethanol / hexane (% Et / Hex) or isopropanol / heptane (% IPA / Hep) as the isocratic solvent system. Chiral preparative chromatography was performed on a Chiralpak AS, Chiralpak AD, Chiralcel OD, Chiralcel IA, or Chiralcel OJ column (20 x 250 mm) (Daicel Chemical Industries, Ltd.), and the desired isocratic solvent system was identified on the chiral analytical chromatography or by supercritical fluid chromatography (SFC) conditions.

[1102] Synthesis Example

[1103] Synthesis of Compound 3 (Example 1) and Compound 4 (Example 5)

[1104] Example 1 and Example 5 were synthesized according to the following scheme:

[1105]

[1106] Compound 2

[1107] 1200 mL of 1 M NaOH aqueous solution was added to riboflavin (1) (50 g, 133 mmol), and the mixture was stirred at 90°C for 2 hours. The mixture was cooled to 20°C, and glacial acetic acid was added to adjust the pH to 6. The mixture was partially evaporated to a volume of 800 mL and placed in a refrigerator at 5°C overnight for crystallization. The particles thus formed were filtered, washed with water, and dried to obtain 41 g of compound (2).

[1108] 1 H-NMR(DMSO-d6,δ,ppm):2.25(s,3H),2.31(s,3H),3.42-3.48(m,1H),3.55-3.66(m,2H),4.53(dd,1H,J1=3.9Hz, J2=9.8Hz),4.62(br.s,1H),4.72(br.d,1H,J=6.0Hz),5.02(br.s,1H),5.14(br.s,1H),7.41(s,1H),7.46(s,1H).

[1109] LCMS, m / z: 353.4 (M+H) + .

[1110] Compound 3 (Example 1)

[1111] To a suspension of compound (2) (1.5 g, 4.3 mmoles) in 100 mL of MeOH was added pure SOCl (0.51 g, 4.3 mmoles) dropwise at ambient temperature. The reaction mixture was stirred overnight under reflux and evaporated to dryness. The residue was passed through a silica gel pad and eluted with 20% MeOH in chloroform to give 1.0 g of compound (3) (Example 1).

[1112] 1 H-NMR(DMSO-d6,δ,ppm):2.30(s,3H),2.38(s,3H),3.41-3.49(m,1H),3.55-3.65(m,3H),4.07-4.14(m,1H),4.18(br.d,1H,J=14.0Hz),4.47(d d,1H,J1=J2=5.8Hz), 4.59(dd,1H,J1=3.6Hz,J2=14.0Hz), 4.72(d,1H,J=5.8Hz), 4.82(d,1H,J=2.7Hz), 4.97(d,1H,J=4.3Hz), 7.61(br.s,2H).

[1113] 13C-NMR (DMSO-d6, δ, ppm): 18.63, 20.33, 44.50, 52.61, 63.51, 68.60, 72.76, 73. 83,116.26,129.66,129.96,132.34,132.68,142.20,147.65,152.41,164.54.

[1114] LCMS, m / z: 367.0 (M+H) + ,389.5(M+Na) + .

[1115] Compound 4 (Example 5)

[1116] Compound (2) (2.5 g, 7.1 mmol) was suspended in 20 mL of pyridine and acetic anhydride (7.2 g, 71 mmol) was added. The mixture was stirred at 70°C overnight and evaporated to dryness. The residue was passed through a silica gel pad and eluted with 25% MeOH in chloroform to give 0.77 g of compound (4) (Example 5).

[1117] 1 H-NMR(DMSO-d6,δ,ppm):1.70(3,3H),2.00(s,3H),2.11(s,3H),2.13(s,3H),2.31(s,3H),2.40(s,3H),4.19(dd,1H,J1=5.4Hz,J2 =12.2Hz), 4.32 (br.d, 1H, J = 12.2Hz), 4.42 (br.d, 1H, J = 14.0Hz), 4.60-4.68 (m, 1H), 5.30-5.42 (m, 3H), 7.40 (s, 1H), 7.52 (s, 1H).

[1118] 13 C-NMR(DMSO-d6,δ,ppm):18.67,20.10,20.19,20.51,20.57,20.73,41.78,61.56,68.99,69.15,70.17,11 5.00,129.60,130.30,130.72,132.48,140.35,152.58,152.70,166.26,169.33,169.56,169.62,170.16.

[1119] LCMS, m / z: 521.4 (M+H) + ,543.5(M+Na) + .

[1120] Synthesis of Compound 7 (Example 6)

[1121] Example 6 was synthesized according to the following scheme:

[1122]

[1123] Hydrolysis of roseflavin (5) (CAS# 51093-55-1) with NaOH followed by re-acidification of the resulting carboxylate moiety with acetic acid affords compound (6). Compound (6) is subjected to esterification conditions with methanol (e.g., with thionyl chloride) to provide compound (7) (Example 6).

[1124] Synthesis of Compound 10 (Example 2), Compound 12 (Example 3) and Compound 14 (Example 4)

[1125] Examples 2-4 were synthesized according to the following scheme:

[1126]

[1127] Compound 8

[1128] To a suspension of compound (2) (31.5 g, 89.4 mmol) in allyl alcohol (allOH) (200 mL) was added pure SOCl (10.6 g, 89.4 mmol) dropwise at ambient temperature. The reaction mixture was stirred at 80-90° C. for 4 hours and evaporated to dryness. The residue was purified by column chromatography on silica gel using 20-100% EtOAc / hexane → 10% i-PrOH / EtOAc as wash-out to give 16.0 g of compound (8).

[1129] 1 H-NMR(DMSO-d6,δ,ppm):2.30(s,3H),2.39(s,3H),3.42-3.49(m,1H),3.58-3.66(m, 3H),4.10-4.14(m,1H),4.20(br.d,1H,J=12.3Hz),4.60(dd,1H,J1=3.5Hz,J2=13.6H z),4.72(br.s,1H),4.82(br.s,1H),4.85(d,2H,J=5.3Hz),4.97(br.s,1H),5.30(d, 1H, J=10.7Hz), 5.50 (d, 1H, J=17.2Hz), 5.98-6.08 (m, 1H), 7.60 (s, 1H), 7.62 (s, 1H).

[1130] LCMS, m / z: 393.5 (M+H) + .

[1131] Compound 9

[1132] To a suspension of compound (8) (14.1 g, 35.9 mmol) in DCM (500 mL) was added DIPEA (23.2 g, 179.5 mmol). The mixture was cooled to -70°C and isobutyric anhydride (5.7 g, 35.9 mmol) was added in one portion. The mixture was stirred at -70°C for 5 hours and then at ambient temperature for 48 hours. The reaction mixture was quenched with 5% aqueous citric acid, the organic layer was separated, and the aqueous layer was extracted with DCM. The combined organic extracts were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel eluting with 30→70% EtOAc / hexane to give 3.6 g of compound (9).

[1133] 1 H-NMR(DMSO-d6,δ,ppm):1.10(dd,6H,J1=1.8Hz,J2=7.0Hz),2.31(s,3H),2.39(s,3H),2.52-2.59(m,1H),3 .59-3.64(m,1H),3.80-3.87(m,1H),4.02(dd,1H,J1=7.1Hz,J2=11.3Hz),4.07-4.14(m,1H),4.20-4.26(m,2 H),4.55(dd,1H,J1=3.8Hz,J2=13.5Hz),4.83-4.88(m,3H),5.16(dd,1H,J1=5.4Hz,J2=16.4Hz),5.30(dd,1 H, J1=1.3Hz, J2=10.5Hz), 5.49 (dd, 1H, J1=1.3Hz, J2=17.2Hz), 5.97-6.06 (m, 1H), 7.57 (s, 1H), 7.62 (s, 1H).

[1134] LCMS,m / z:445.0(M-H2O),463.5(M+H) + ,485.3(M+Na) + .

[1135] Compound 10 (Example 2)

[1136] Compound (9) (3.6 g, 7.7 mmol) was dissolved in MeCN (50 mL). The solution was purged with nitrogen and Pd(PPh3)4 (0.89 g, 0.77 mmol) was added, followed by pyrrolidine (0.66 g, 9.2 mmol). After 16 hours at room temperature, the MeCN was evaporated, EtOAc was added, and the formed particles were filtered out and washed with EtOAc. The particles were dissolved in water and 10% HCl was added to adjust the pH to 2. The formed particles were filtered out, washed with water and dried to give 1.56 g of compound (10) (Example 2).

[1137] 1 H-NMR(DMSO-d6,δ,ppm):1.10(dd,6H,J1=1.7Hz,J2=7.1Hz),2.32(s,3H),2.40(s,3H ),2.52-2.59(m,1H),3.60-3.62(m,1H),3.81-3.88(m,1H),4.02(dd,6H,J1=7.0Hz,J 2=10.9Hz),4.10-4.12(m,1H),4.20-4.30(m,2H),4.58(dd,6H,J1=10.2Hz,J2=13.7H z),4.82-4.89(m,1H),5.12-5.23(m,2H),7.60(s,1H),7.65(s,1H),13.98(br.s,1H).

[1138] 13 C-NMR(DMSO-d6,δ,ppm):18.67,18.91(2×),20.38,33.31,44.84,66.28,68.44,69.74,7 3.78,116.26,129.79,130.41,132.07,132.98,142.11,147.51,153.54,165.03,176.39.

[1139] LCMS, m / z: 423.5 (M+H) + ,445.3(M+Na) + .

[1140] Compound 11

[1141] To a suspension of compound (8) (8.9 g, 22.7 mmol) in DCM (400 mL) was added DIPEA (14.7 g, 113.5 mmol). The mixture was cooled to -70°C and propionic anhydride (3.0 g, 22.7 mmol) was added in one portion. The mixture was stirred at -70°C for 5 hours and then at ambient temperature for 48 hours. The reaction mixture was quenched with 5% aqueous citric acid solution, the organic layer was separated, and the aqueous layer was extracted with DCM. The combined organic extracts were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel eluting with 30→70% EtOAc / hexane to give 2.6 g of compound (11).

[1142] 1 H-NMR (DMSO-d6, δ, ppm): 1.02 (t, 3H, J = 7.4Hz), 2.30-2.42 (m, 8H), 3.58-3.62 (m, 1H), 3.80-3 .87(m,1H),4.00-4.05(m,1H),4.09-4.12(m,1H),4.20-4.24(m,2H),4.55(dd,1H,J1=3.3Hz,J 2=10.4Hz),4.85-4.90(m,3H),5.18(dd,1H,J1=5.9Hz,J2=16.3Hz),5.30(dd,1H,J1=1.3Hz,J 2=10.5Hz),5.49(dd,1H,J1=1.3Hz,J2=17.2Hz),5.97-6.05(m,1H),7.57(s,1H),7.63(s,1H).

[1143] LCMS,m / z:431.3(M-H2O),449.4(M+H) + ,471.0(M+Na) + .

[1144] Compound 12 (Example 3)

[1145] Compound (11) (2.6 g, 5.8 mmol) was dissolved in MeCN (50 mL). The solution was purged with nitrogen and Pd(PPh3)4 (0.68 g, 0.58 mmol) was added, followed by pyrrolidine (0.62 g, 8.7 mmol). After 16 hours at room temperature, MeCN was evaporated, EtOAc was added, and the formed particles were filtered out and washed with EtOAc. The particles were dissolved in water, 10% HCl was added to adjust the pH to 2, the formed particles were filtered out, washed with water and dried to obtain 0.84 g of compound (12) (Example 3).

[1146] 1H-NMR (DMSO-d6, δ, ppm): 1.03 (t, 3H, J = 7.4Hz), 2.30-2.43 (m, 8H), 3.60-3.6 3(m,1H),3.82-3.89(m,1H),4.03(dd,6H,J1=7.0Hz,J2=10.9Hz),4.10-4.13( m,1H),4.21-4.30(m,2H),4.57(dd,6H,J1=10.2Hz,J2=13.7Hz),4.82(br.d, 1H,J=4.6Hz),5.12-5.21(m,2H),7.60(s,1H),7.65(s,1H),13.95(br.s,1H).

[1147] 13 C-NMR(DMSO-d6,δ,ppm):9.07,18.67,20.38,26.91,44.83,66.25,68.45,69.70,73.7 9,116.25,129.79,130.41,132.07,132.99,142.11,147.53,153.53,165.04,173.88.

[1148] LCMS, m / z: 409.5 (M+H) + ,431.5(M+Na) + .

[1149] Compound 13

[1150] To a suspension of compound (8) (16.1 g, 41.0 mmol) in DCM (600 mL) was added DIPEA (26.5 g, 205.0 mmol). The mixture was cooled to -70°C and acetic anhydride (4.2 g, 41.0 mmol) was added in one portion. The mixture was stirred at -70°C for 5 hours and then at ambient temperature for 24 hours. The reaction mixture was quenched with 5% aqueous citric acid solution, the organic layer was separated, and the aqueous layer was extracted with DCM. The combined organic extracts were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel eluting with 30→100% EtOAc / hexane to give 2.5 g of compound (13).

[1151] 1H-NMR(DMSO-d6,δ,ppm):2.01(s,3H),2.31(s,3H),2.40(s,3H),3.58-3.62(m,1H),3.81-3.8 8(m,1H),4.00-4.05(m,1H),4.09-4.12(m,1H),4.20-4.24(m,2H),4.55(dd,1H,J1=3.3Hz,J2 =10.4Hz),4.85-4.90(m,3H),5.18(dd,1H,J1=5.9Hz,J2=16.3Hz),5.30(dd,1H,J1=1.3Hz,J2 =10.5Hz), 5.49 (dd, 1H, J1 = 1.3Hz, J2 = 17.2Hz), 5.97-6.05 (m, 1H), 7.57 (s, 1H), 7.62 (s, 1H).

[1152] LCMS, m / z: 417.5 (M-H2O) + ,435.0(M+H) + .

[1153] Compound 14 (Example 4)

[1154] Compound (13) (2.5 g, 5.8 mmol) was dissolved in MeCN (50 mL). The solution was purged with nitrogen and Pd(PPh 3 ) 4 (0.68 g, 0.58 mmol) was added, followed by pyrrolidine (0.62 g, 8.7 mmol). After 16 hours at room temperature, MeCN was evaporated, EtOAc was added, the particles formed were filtered out and washed with EtOAc. The residue was dissolved in water, 10% HCl was added to adjust the pH to 2, the particles formed were filtered out, washed with water and dried to give 1.56 g of compound (14) (Example 4).

[1155] 1 H-NMR(DMSO-d6,δ,ppm):2.02(s,3H),2.32(s,3H),2.39(s,3H),3.60-3.6 3(m,1H),3.82-3.85(m,1H),4.03(dd,6H,J1=7.0Hz,J2=10.9Hz),4.08-4.1 2(m,1H),4.20-4.28(m,2H),4.57(dd,6H,J1=10.2Hz,J2=13.7Hz),4.80-4 .90(m,1H),5.10-5.29(m,2H),7.59(s,1H),7.64(s,1H),13.96(br.s,1H).

[1156] 13C-NMR(DMSO-d6,δ,ppm):18.67,20.38,20.91,44.83,66.35,68.44,69.65,73.78, 116.24,129.79,130.40,132.07,132.99,142.13,147.50,153.53,165.03,170.60.

[1157] LCMS, m / z: 395.3 (M+H) + ,417.5(M+Na) + .

[1158] Synthesis of Compound 15 (Example 8), Compound 16 (Example 9) and Compound 17 (Example 13)

[1159] Examples 8, 9 and 13 were synthesized according to the following scheme:

[1160]

[1161] Compound 15 (Example 8)

[1162] To a DCM solution of compound (4) (1.7 g, 3.3 mmol) was added Et3N (1 mL), N,N-dimethylethane-1,2-diamine (1.2 g, 4.3 mmol) and TBTU (1.68 g, 5.3 mmol). The mixture was stirred at ambient temperature for 15 hours and quenched with saturated NaHCO3 aqueous solution. The organic layer was separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel eluting with 10-20% EtOAc / DCM to obtain a mixture of di-, tri- and tetraacetates of compound (12). The mixture was dissolved in MeOH, Dowex-OH resin and NH3 aqueous solution were added, and the mixture was stirred at ambient temperature for 15 hours. The resin was filtered off and the filtrate was evaporated to obtain 0.12 g of compound (15) (Example 8).

[1163] 1H-NMR(DMSO-d6,δ,ppm):2.30(s,6H),2.32(s,3H),2.40(s,3H),2.56(dd, 1H, J1=J2=5.8Hz),3.40-3.48(m,3H),3.60-3.65(m,3H),4.10-4.15(m,1H) ,4.24(br.d,1H,J=13.5Hz),4.45-4.48(m,1H),4.58-4.68(m,2H),4.82(b r.s,1H),4.97(br.s,1H),7.61(s,1H),7.66(s,1H),9.19(t,1H,J=4.7Hz).

[1164] 13 C-NMR(DMSO-d6,δ,ppm):18.69,20.34,37.06,45.23,57.92,63.52,68.73,72.78, 73.81,116.13,129.95,130.53,132.10,132.67,141.90,147.25,154.20,162.81.

[1165] LCMS,m / z:378.2(M-NMe2),423.5(M+H) + ,445.3(M+Na) + .

[1166] Compound 16 (Example 9)

[1167] To a solution of compound (2) (1.0 g, 2.8 mmol) in 1.76 g (28 mmol) of ethylene glycol was added thionyl chloride (0.68 g, 5.6 mmol) dropwise. The mixture was stirred under reflux for 2 hours and cooled to room temperature. The excess solvent was evaporated in vacuo and the oily residue was washed with Et2O and DCM. The residue was crystallized from THF-MeCN and the resulting particles were washed with MeCN and Et2O and dried to give 0.70 g of compound (16) (Example 9).

[1168] 1H-NMR(DMSO-d6,δ,ppm):2.31(s,3H),2.39(s,3H),3.40-3.48(m,1H),3.58-3.65(m,3 H),3.66-3.71(m,2H),4.10-4.15(m,1H),4.20(br.d,1H,J=12.9Hz),4.30-4.34(m,2H) ,4.45-4.50(m,1H),4.60(dd,1H,J1=2.8Hz,J2=10.4Hz),4.74(d,1H,J=6.4Hz),4.84(b r.s,1H),4.92(dd,1H,J1=J2=5.3Hz),4.98(d,1H,J=3.1Hz),7.61(s,1H),7.62(s,1H).

[1169] 13 C-NMR(DMSO-d6,δ,ppm):18.65,20.34,44.53,58.81,63.51,67.30,68.59,72.75, 73.84,116.31,129.63,129.96,132.32,132.70,142.11,147.91,152.43,164.24.

[1170] LCMS, m / z: 379.5 (M-H2O) + ,397.3(M+H) + ,419.5(M+Na) + .

[1171] Compound 17 (Example 13)

[1172] To a solution of compound (2) (1.0 g, 2.8 mmol) in 5 mL of DMF was added ammonium chloride (0.64 g, 11.8 mmol), followed by EDCI (0.65 g, 3.4 mmol) and HOBt (0.5 g, 3.6 mmol). The mixture was stirred at ambient temperature for 15 hours, diluted with water and extracted with EtOAc. The combined organic extracts were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel eluting with 10% EtOAc / DCM to give 0.62 g of compound (17) (Example 13).

[1173] 1H-NMR(DMSO-d6,δ,ppm):2.32(s,3H),2.38(s,3H),3.16(br.s,1H),3.40-3.48(m,1H),3.57-3.67(m,3H),4.10-4.18(m,1H),4.21(br.d,1H,J =13.4Hz),4.45-4.51(m,1H),4.56-4.70(m,2H),4.82(br.s,1H),5.00(br.s,1H),7.60(s,1H),7.62(s,1H),7.79(br.s,1H),8.35(br.s,1H).

[1174] 13 C-NMR(DMSO-d6,δ,ppm):18.69,20.32,44.52,63.50,68.85,72.76,73.83, 116.10,129.79,130.38,132.10,132.53,141.60,148.83,153.81,164.93.

[1175] LCMS, m / z: 352.6 (M+H) + ,374.5(M+Na) + .

[1176] Synthesis of Compound 24 (Example 10)

[1177] Example 10 was synthesized according to the following scheme:

[1178]

[1179] Compound 18

[1180] Compound (3) (5.2 g, 14.2 mmol) was dissolved in pyridine (50 mL) and trityl chloride (6.3 g, 22.7 mmol) was added. The mixture was stirred at 50°C for 15 hours. Pyridine was evaporated, and the residue was diluted with 5% aqueous citric acid solution and extracted with EtOAc. The combined organic extracts were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel, eluting with EtOAc-hexane, 1:2→2:1, to give 4.1 g of compound (18).

[1181] 1H-NMR(DMSO-d6,δ,ppm):2.30(s,6H),2.32(s,3H),3.06(dd,1H,J1=2.4Hz,J2=6.8Hz),3.18( dd,1H,J1=2.8Hz,J2=9.0Hz),3.56-3.62(m,1H),4.07-4.13(m,1H),4.20(br.d,1H,J=13.9Hz) ,4.58(dd,1H,J1=3.9Hz,J2=9.9Hz),4.75(d,1H,J=6.1Hz),4.94(d,1H,J=5.3Hz),5.20(d,1H, J=5.8Hz),7.22-7.28(m,3H),7.29-7.35(m,6H),7.42-7.47(m,6H),7.52(s,1H),7.62(s,1H).

[1182] LCMS, m / z: 631.5 (M+Na) + .

[1183] Compound 19

[1184] Compound (18) (6.6g, 10.8 mmoles) is dissolved among the 100mL DMF, add DIPEA (16.8g, 129.6 mmoles), then add MOM-Cl (5.2g, 64.8 mmoles).Mixture is stirred 72 hours at 70 ℃.Mixture is cooled to room temperature, diluted with 5% citric acid aqueous solution, and extracted with EtOAc.The organic extract liquid merged is used Na SO Drying, and evaporated.Resistates obtains 5.2g compound (19) by column chromatography on silica gel purification, eluting with 5-30% EtOAc-hexane.

[1185] 1 H-NMR(DMSO-d6,δ,ppm):2.28(s,6H),2.30(s,3H),2.70(s,3H),3.24(s,3H),3.11-3.17(m ,1H),3.23(s,3H),3.29-3.31(m,1H),3.33(s,3H),3.89(s,3H),3.95-4.04(m,2H),4.15(d ,1H,J=6.9Hz),4.21-4.35(m,3H),4.56(d,1H,J=6.4Hz),4.66(d,1H,J=6.6Hz),4.72-4.83 (m,3H),7.22-7.28(m,3H),7.29-7.34(m,6H),7.37-7.42(m,6H),7.47(s,1H),7.66(s,1H).

[1186] LCMS, m / z: 741.8 (M+H) + ,763.7(M+Na) + .

[1187] Compound 20

[1188] Compound (19) (4.8 g, 6.5 mmol) was dissolved in 50 mL of Et2O and formic acid (50 mL) was added in 10 mL portions at 5°C. The mixture was stirred at 5°C for 1 hour and poured into a saturated aqueous Na2CO3 solution at 5°C in portions. The mixture was extracted with EtOAc and the combined organic extracts were dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel eluting with 5-30% EtOAc-hexane to give 2.6 g of compound (20).

[1189] 1 H-NMR(DMSO-d6,δ,ppm):2.32(s,6H),2.39(s,3H),2.64(s,3H),3.36(s,3H),3.38(s,3H),3.59-3.62(m,2H),3.80-3.82(m,1H),3.89( s,3H),4.00-4.02(m,1H),4.20(d,1H,J=6.9Hz),4.22-4.34(m,2H),4.41(d,1H,J=6.4Hz),4.72-4.85(m,6H),7.50(s,1H),7.64(s,1H).

[1190] LCMS, m / z: 499.5 (M+H) + ,521.3(M+Na) + .

[1191] Compound 21

[1192] To a solution of compound (20) (1.4 g, 2.8 mmol) in 50 mL of DCM was added Et3N (0.58 g, 5.6 mmol), followed by the dropwise addition of MsCl (0.39 g, 3.4 mmol) in 10 mL of DCM at 5-10°C. The mixture was stirred at ambient temperature for 1 hour and quenched with saturated aqueous NaHCO3. The mixture was extracted with EtOAc, and the combined organic extracts were dried over Na2SO4 and evaporated to give 1.6 g of compound (21), which was used in the next step without further purification.

[1193] 1H-NMR(DMSO-d6,δ,ppm):2.33(s,6H),2.41(s,3H),2.71(s,3H),3.06-3.12(m,1H),3.23(s,3H),3.37(s,3H),3.38(s,3H),3.89(s,3H),3. 98-4.00(m,1H),4.08-4.12(m,1H),4.20-4.35(m,4H),4.41-4.52(m, 2H),4.70-4.82(m,4H),4.85-4.89(m,1H),7.50(s,1H),7.65(s,1H).

[1194] LCMS, m / z: 577.3 (M+H) + ,599.3(M+Na) + .

[1195] Compound 22

[1196] To a solution of compound (21) (2.4 g, 4.1 mmol) in 80 mL of DMF was added sodium azide (1.9 g, 28.7 mmol) and the mixture was stirred at 70° C. for 15 hours. Water was added, the mixture was extracted with EtOAc, and the combined organic extracts were dried over Na 2 SO 4 and evaporated to give 2.1 g of compound (22), which was used in the next step without further purification.

[1197] 1 H-NMR(DMSO-d6,δ,ppm):2.32(s,6H),2.40(s,3H),2.70(s,3H),3.36(s,3H) ,3.39(s,3H),3.46-3.52(m,1H),3.72-3.77(m,1H),3.89(s,3H),3.95-4.00 (m,2H),4.20-4.34(m,3H),4.42(d,1H,J=7.2Hz),4.68-4.72(m,1H),4.76(s ,2H),4.81(d,1H,J=6.2Hz),4.88(d,1H,J=6.1Hz),7.49(s,1H),7.65(s,1H).

[1198] LCMS, m / z: 524.7 (M+H) + ,546.2(M+Na) + .

[1199] Compound 24 (Example 10)

[1200] To a solution of compound (22) (0.31 g, 0.59 mmol) in 20 mL of THF was added triphenylphosphine (0.31 g, 1.18 mmol) and the mixture was stirred at 60°C for 4 hours. 10% HCl (5 mL) was added and the mixture was stirred at 60°C for 2 hours. The mixture was diluted with water and extracted with chloroform, and the combined organic extracts were discarded. The aqueous layer was evaporated to dryness, and the solid residue was washed with chloroform and Et2O to give 0.13 g of compound (24) (Example 10).

[1201] 1 H-NMR(DMSO-d6,δ,ppm):2.31(s,3H),2.40(s,3H),2.80-2.84(m,1H),2.98-3.02(m, 1H),3.32-3.40(m,2H),3.60-3.65(m,1H),3.89(s,3H),3.90-3.92(m,1H),3.95-4.0 2(m,1H),4.28(br.d,1H,J=13.4Hz),4.48(dd,1H,J1=3.8Hz,J2=9.7Hz),5.10(d,1H, J=6.5Hz),5.48(d,1H,J=5.8Hz),7.61(s,1H),7.62(s,1H),7.88(br.s,3H,NH2.HCl).

[1202] 13 C-NMR(DMSO-d6,δ,ppm):18.63,20.33,41.74,45.32,52.64,68.29,68.71,74. 62,116.30,129.65,129.96,132.45,132.77,142.32,146.51,152.34,164.49.

[1203] LCMS, m / z: 348.6 (M-H2O) + ,366.1(M+H) + ,388.3(M+Na) + .

[1204] Synthesis of Compound 27 (Example 11) and Compound 26 (Example 12)

[1205] Examples 11-12 were synthesized according to the following scheme:

[1206]

[1207] The azide moiety on compound (22) was subjected to Staudinger reduction with triphenylphosphine and water to afford compound (23). Compound (23) was subjected to reductive amination with formaldehyde and STAB to afford compound (25), followed by removal of the MOM group to afford compound (26) (Example 12). The ester group of compound (26) (Example 12) was hydrolyzed with aqueous HCl and heating to afford compound (27) (Example 11).

[1208] Synthesis of Compound 31 (Example 14)

[1209] Example 14 was synthesized according to the following scheme:

[1210]

[1211] Compound 28

[1212] To a solution of compound (4) (3.0 g, 5.7 mmol) in DMF (15 mL) was added EDC-HCl (1.3 g, 6.8 mmol) and HOBt (1.5 g, 11.4 mmol) at ambient temperature, followed by NH4Cl (1.3 g, 24.0 mmol). The reaction mixture was stirred at ambient temperature for 12 hours, ice-cold water was added and the mixture was extracted with EtOAc. The combined organic layers were dried over Na2SO4 and evaporated to dryness. The residue was passed through a silica gel pad and eluted with 4% MeOH / DCM to give 0.95 g of compound (28).

[1213] 1 H-NMR (DMSO-d6, δ, ppm): 1.70 (s, 3H), 2.00 (s, 3H), 2.11 (s, 3H), 2.13 (s, 3H), 2.33 (s, 3H), 2.42 (s, 3H), 4.18 (dd, 1H, J1=5.4Hz, J2=12. 0Hz),4.33-4.37(m,1H),4.46-4.50(m,1H),4.64-4.70(m,1H),5.31-5.40(m,3H),7.47(s,1H),7.64(s,1H),7.80(s,1H),8.22(s,1H).

[1214] LCMS, m / z: 520 (M+H) + ,542.5(M+Na) + .

[1215] Compound 29

[1216] To a solution of compound (28) (0.95 g, 1.9 mmol) in THF (25 mL) was added DMFDMA (0.24 g, 2.0 mmol) at ambient temperature, and the reaction mixture was heated to reflux for 3 hours. The reaction mixture was evaporated to dryness to give the desired compound (29). The crude product (1.05 g) was used in the next step without further purification.

[1217] LCMS, m / z: 575.3 (M+H) + ,597.3(M+Na) + .

[1218] Compound 30

[1219] To a solution of compound (29) (1.05 g, 1.8 mmol) in 70% AcOH (10 mL) was added hydrazine hydrate (0.22 g, 4.3 mmol) at ambient temperature and the reaction mixture was heated to reflux for 2 hours. The reaction mixture was evaporated to dryness and co-evaporated with toluene. The residue was dissolved in EtOAc, washed with water, dried over Na2SO4 and evaporated to dryness. The residue was passed through a silica gel pad and eluted with 5% MeOH / DCM to give 0.18 g of compound (30).

[1220] 1 H-NMR(DMSO-d6,δ,ppm):1.67(s,3H),1.99(s,3H),2.11(s,3H),2.13(s,3 H),2.35(s,3H),2.44(s,3H),4.15-4.19(m,1H),4.34-4.37(m,1H),4.56- 4.61(m,1H),4.72-4.78(m,1H),5.32-5.35(m,1H),5.40-5.48(m,2H),7.4 6-7.54(m,1H),7.62-7.72(m,1H),8.15-8.59(m,1H),14.32-14.47(m,1H).

[1221] LCMS, m / z: 544.5.0 (M+H) + ,566.7(M+Na) + .

[1222] Compound 31 (Example 14)

[1223] To a solution of compound (30) (0.18 g, 0.33 mmol) in MeOH (3.5 mL) was added aqueous NH 3 solution (3.5 mL) at ambient temperature. The reaction mixture was stirred at ambient temperature for 12 hours. The reaction mixture was evaporated to 1 / 2 volume, and the formed particles were filtered off and dried to obtain 0.099 g of compound (31) (Example 14).

[1224] 1 H-NMR(DMSO-d6,δ,ppm):2.34(s,3H),2.40(s,3H),3.43-3.48(m,1H),3.59-3.66(m,3H),4.15-4.21(m,1H),4.29-4.32(m,1H),4.46 -4.49(m,1H),4.64-4.73(m,2H),4.81-4.82(m,1H),4.98-4.99(m,1H),7.62(s,1H),7.68(s,1H),8.23(br.s,1H),14.36(br.s,1H).

[1225] 13 C-NMR(DMSO-d6,δ,ppm):18.70,20.34,44.68,63.50,68.65,72.73,73.83,116.08,12 9.82,131.09,131.71,132.63,141.53,142.20(br),150.16(br),151.42(br),153.79.

[1226] LCMS, m / z: 376.5 (M+H) + ,398.4(M+Na) + .

[1227] Synthesis of Compound 37 (Example 15)

[1228] Example 15 was synthesized according to the following scheme:

[1229]

[1230] Compound 32

[1231] Compound (3) (10.1 g, 27.5 mmol) was dissolved in DMF (100 ml), MOM chloride (16.75 ml, 220 mmol) and DIPEA (38 ml, 220 mmol) were added and the reaction mixture was stirred at 60°C overnight. The reaction mixture was concentrated in vacuo, diluted with water and extracted with EtOAc. The combined organic extracts were dried with Na2SO4 and evaporated to give 12.1 g of compound (32). Compound (32) was used in the next step without further purification.

[1232] 1 H-NMR(DMSO-d6,δ,ppm):2.39(s,3H),2.67(s,3H),3.27(s,3H),3.31(s,3H),3.37(s,3H),3.38(s,2H),3.62-3.73(m,2H),3.89(s,3H),3.9 6-4.06(m,2H),4.21-4.25(m,2H),4.3(br.d,1H,J=13.2Hz),4.41(d,1H,J=7.4Hz),4.6(s,2H),4.74-4.80(m,6H),7.49(s,1H),7.64(s,1H).

[1233] LCMS, m / z: 543.5 (M+H) + ,565.5(M+Na) + .

[1234] Compound 33

[1235] Compound (32) (12.1 g, 22.3 mmol) was dissolved in MeOH (150 ml) and a solution of NaOH (2.2 g, 55.75 mmol) in water (15 ml) was added. The reaction mixture was stirred at room temperature overnight. The MeOH was evaporated and the residue was diluted with water, acidified to pH 2 with 10% H2SO4 and extracted with EtOAc. The combined organic extracts were dried over Na2SO4 and evaporated to dryness to give 10.8 g of compound (33).

[1236] 1H-NMR(DMSO-d6,δ,ppm):2.33(s,3H),2.4(s,3H),2.69(s,3H),3.28(s,3H),3.37(s,3H),3.38(s,3H),3.65(dd,1H,J1=10.5Hz,J2=4.5Hz),3. 72(dd,1H,J1=11Hz,J2=4Hz),3.96-4.04(m,2H),4.21-4.43(m,4H),4.6(s,2H),4.74-4.80(m,5H),7.5(s,1H),7.65(s,1H),.13.95(br.s,1H)

[1237] LCMS, m / z: 529.5 (M+H) + ,551.3(M+Na) + .

[1238] Compound 34

[1239] Compound (33) (5 g, 9.5 mmol) was dissolved in THF (100 ml) and triethylamine (1.1 g, 11.4 mmol) was added. The reaction mixture was cooled to 0°C and ethyl chloroformate (1.08 g, 10 mmol) was added dropwise. Stirring was continued at -5°C for 30 minutes, then aqueous ammonia (150 mL) was added and the mixture was stirred at room temperature overnight. The precipitate formed was filtered off, washed with water and air-dried to obtain 4.4 g of compound (34).

[1240] 1 H-NMR(DMSO-d6,δ,ppm):2.33(s,3H),2.39(s,3H),2.69(s,3H),3.28(s,3 H),3.37(s,3H),3.38(s,3H),3.64(dd,1H,J1=10.5Hz,J2=4.5Hz),3.73(dd ,1H,J1=11.0Hz,J2=4.0Hz),3.89-4.08(m,2H),4.11-4.47(m,4H),4.61(s, 2H),4.69-4.87(m,5H),7.48(s,1H),7.64(s,1H),7.79(s,1H),8.27(s,1H)

[1241] LCMS, m / z: 528.3 (M+H) + ,550.5(M+Na) + .

[1242] Compound 35

[1243] Compound (34) (2.1 g, 4 mmoles) was dissolved in THF (50 mL). Pyridine (0.6 g, 8.0 mmoles) was added under an inert atmosphere, followed by the dropwise addition of trifluoroacetic anhydride (1.0 g, 4.8 mmoles). The reaction mixture was stirred at room temperature for 24 hours under an inert atmosphere. An additional amount of pyridine (0.6 g, 8.0 mmoles) and trifluoroacetic anhydride (1 g, 4.8 mmoles) were added and stirring continued for 4 hours. The reaction mixture was poured into water, extracted with EtOAc, dried over Na2SO4, concentrated and purified on silica gel by column chromatography, eluting with 25-30% EtOAc / DCM to obtain 1.5 g of compound (35).

[1244] 1 H-NMR(DMSO-d6,δ,ppm):2.34(s,3H),2.43(s,3H),2.71(s,3H),3.28(s,3H),3.37(s,3H),3.38(s,3H),3.63(dd,1H,J1=11.5Hz,J2=5.3 Hz),3.73(dd,1H,J1=11.4,Hz,J2=4Hz),3.93-4.06(m,2H),4.16-4.41(m,4H),4.61(s,2H),4.74-4.84(m,5H),7.55(s,1H),7.71(s,1H)

[1245] LCMS, m / z: 511.0 (M+H) + ,532.0(M+Na) + .

[1246] Compound 36

[1247] A mixture of compound (35) (1.5 g, 2.9 mmol), triethylammonium chloride (1.6 g, 11.6 mmol) and sodium azide (0.76 g, 11.6 mmol) in DMF (30 ml) was stirred at 120° C. for 5 hours. The reaction mixture was concentrated under vacuum, diluted with water and extracted with EtOAc. The combined organic extracts were dried over Na2SO4 and evaporated to give 1.5 g of compound (36).

[1248] 1H-NMR(DMSO-d6,δ,ppm):2.35(s,3H),2.42(s,3H),2.66(s,3H),3.28(s,3H),3.37(s,3H),3.38(s,3H),3.66(dd,1H,J1=10.5Hz,J2=5.3Hz ),3.73(dd,1H,J1=11.4Hz,Hz,J2=4.0Hz),3.93-4.11(m,2H),4.14-4.49(m,4H),4.61(s,2H),4.71-4.99(m,6H),7.53(s,1H),7.72(s,1H)

[1249] LCMS, m / z: 553.5 (M+H) + ,575.3(M+Na) + .

[1250] Compound 37 (Example 15)

[1251] Compound (36) (1.3 g, 2.3 mmol) was dissolved in MeOH (50 ml) and concentrated HCl (10 mL) was added. The reaction mixture was heated at 60°C for 40 minutes. The resulting precipitate was filtered and washed with water to obtain 0.45 g of compound (37) (Example 15).

[1252] 1 H-NMR(DMSO-d6,δ,ppm):2.35(s,3H),2.41(s,3H),3.22-3.38(m,4H),3.42-3.50(m,1H),3.60-3.66(m,3H),4.18(m,1H),4 .36(br.d,1H,J=13.5Hz),4.40-4.56(m,1H),4.62-4.83(m,3H),5.00(br.s,1H),7.66(s,1H),7.75(s,1H),16.8(br.s,1H).

[1253] 13 C-NMR (DMSO-d6, δ, ppm): 18.68, 20.45, 44.88, 63.47, 68.44, 68.49, 72.71, 73. 75,116.26,130.06,131.15,132.24,133.08,139.99,142.73,150.96,153.47.

[1254] LCMS, m / z: 377.6 (M+H) + ,399.0(M+Na) + .

[1255] Synthesis of Compound 40 (Example 16)

[1256] Example 16 was synthesized according to the following scheme:

[1257]

[1258] Compound 38

[1259] To a solution of compound (4) (2 g, 3.8 mmol) in DMF (40 mL) were added methylamine hydrochloride (0.52 g, 7.6 mmol), EDCI (2.2 g, 11.4 mmol) and HOBt (1.17 g, 7.6 mmol). The mixture was stirred at room temperature for 18 hours, diluted with water and extracted with EtOAc. The combined organic extracts were dried over Na2SO4 and evaporated to give 0.9 g of compound (38).

[1260] 1 H-NMR(DMSO-d6,δ,ppm):1.69(s,3H),2.0(s,3H),2.11(s,3H),2.12(s,3H),2.33(s,3H),2.42(2,3H),2.8(s,3H),4.11-4.23(m, 1H),4.3-4.39(m,1H),4.43-4.54(m,1H),4.61-4.74(m,1H),5.26-5.44(m,3H),7.48(s,1H),7.64(s,1H),8.77(d,1H,J=3.4Hz).

[1261] LCMS, m / z: 534.3.0 (M+H) + ,556.3(M+Na) + .

[1262] Compound 39

[1263] Under nitrogen, PCl5 (0.28 g, 1.32 mmol) was added to a stirred solution of compound (38) (0.65 g, 1.2 mmol) in DCM. The stirred reaction mixture was cooled to -5°C and TMSN3 (0.56 g, 4.8 mmol) was added dropwise, then warmed to ambient temperature and maintained for 16 hours. The mixture was then cooled to 0°C and saturated NaHCO3 was added dropwise. The two layers were separated; the organic layer was washed with water, dried over Na2SO4 and evaporated to give 0.26 g of compound (39).

[1264] 1H-NMR(DMSO-d6,δ,ppm):1.69(s,3H),2.0(s,3H),1.99(s,3H),2.09(s,3H),2.13(s,3H),2.36(2,3H),2.47(s,3H),4 .12-4.21(m,3H),4.3-4.39(m,1H),4.51-4.6(m,1H),4.69-4.78(m,1H),5.29-5.47(m,3H),7.59(s,1H),7.75(s,1H).

[1265] LCMS, m / z: 559.2.0 (M+H) + ,581.3(M+Na) + .

[1266] Compound 40 (Example 16)

[1267] Compound (39) (0.26 g, 0.4 mmol) was dissolved in MeOH (10 mL). Aqueous ammonia (5 mL) was added and the mixture was stirred at ambient temperature overnight. The formed precipitate was filtered and washed with water to give 0.12 g of compound (40) (Example 16).

[1268] 1 H-NMR(DMSO-d6,δ,ppm):2.35(s,3H),2.43(s,3H),3.32(s,3H),3.39-3.51(m,1H),3.55-3.67(m,3H),4.09-4.21(m,4H),4.22-4.31(d,1 H, J=3.7Гц),4.43-4.51(m,1H),4.62-4.74(m,1H),4.76-4.89(m,2H) ,4.99(d,1H,J=4.0Гц),5.29-5.47(m,3H),7.68(s,1H),7.72(s,1H).

[1269] 13 C-NMR (DMSO-d6, δ, ppm): 18.65, 20.47, 35.32, 44.85, 63.53, 68.52, 72.79, 73. 72,116.26,130.04,131.04,132.54,132.97,141.58,142.99,151.20,153.40.

[1270] LCMS, m / z: 391.4 (M+H) + ,413.6(M+Na) + .

[1271] Synthesis of Compound 43 (Example 17)

[1272] Example 17 was synthesized according to the following scheme:

[1273]

[1274] Compound 41

[1275] Under nitrogen atmosphere, a solution of compound (4) (2.0 g, 3.8 mmol), EDC-HCl (1.5 g, 7.6 mmol) and 1-hydroxybenzo-triazole (1.04 g, 7.6 mmol) in anhydrous DCM (40 mL) was stirred for 30 minutes at ambient temperature. N-hydroxyacetamidine (0.57 g, 7.6 mmol) was added and the reaction mixture was stirred for 12 hours at ambient temperature. The reaction mixture was quenched with water and extracted with DCM. The combined organic layer was washed with 10% sodium bicarbonate, water and brine, dried over Na2SO4, filtered and concentrated. The residue was passed through a silica gel pad and eluted with 2% MeOH / DCM to obtain 1.00 g of compound (41).

[1276] 1 H-NMR(DMSO-d6,δ,ppm):1.70(s,3H),1.78(s,3H),2.00(s,3H),2.10(s,3H),2.13(s,3H),2.33(s,3H),2.44(s,3H),4.15-4.19(m,1H),4. 32-4.36(m,1H),4.48-4.52(m,1H),4.62-4.71(m,1H),5.29-5.33(m, 1H),5.35-5.41(m,2H),6.41-6.69(m,2H),7.49(s,1H),7.66(s,1H).

[1277] LCMS, m / z: 577.5 (M+H) + ,599.2(M+Na) + .

[1278] Compound 42

[1279] To a solution of compound (41) (1.00 g, 1.7 mmol) in THF (30 mL) was added TBAF (0.077 g, 1.7 mmol) at ambient temperature. The reaction mixture was stirred at ambient temperature for 12 hours. The reaction mixture was dissolved in EtOAc, washed with water, 5% citric acid, water and brine, dried over Na2SO4, filtered and concentrated. The residue was passed through a silica gel pad and eluted with 30% EtOAc / CCl4 to give 0.26 g of compound (42).

[1280] 1 H-NMR(CDCl3,δ,ppm):1.82(s,3H),2.08(s,3H),2.18(s,3H),2.20(s,3H),2.39(s,3H),2.50(s,3H),2.57(s,3H),4.2 1-4.25(m,1H),4.40-4.44(m,1H),4.56-4.72(m,2H),5.39-5.46(m,2H),5.61-5.63(m,1H),7.34(s,1H),7.82(s,1H).

[1281] LCMS, m / z: 559.3 (M+H) + ,581.3(M+Na) + .

[1282] Compound 43 (Example 17)

[1283] To a solution of compound (42) (0.26 g, 0.46 mmol) in MeOH (5 mL) was added aqueous NH 3 solution (5 mL) at ambient temperature. The reaction mixture was stirred at ambient temperature for 12 hours. The reaction mixture was evaporated to 1 / 2 volume, and the formed particles were filtered off and dried to obtain 0.11 g of compound (43) (Example 17).

[1284] 1 H-NMR(DMSO-d6,δ,ppm):2.33(s,3H),2.41(s,3H),2.48(s,3H),3.41-3.48(m,1H),3.56-3.66(m,3H),4.13-4.16(m,1H),4.25-4 .29(m,1H),4.45-4.47(m,1H),4.64-4.65(m,1H),4.73-4.74(m,1H),4.82(br.s,1H),4.98(br.s,1H),7.65(s,1H),7.71(s,1H).

[1285] 13 C-NMR(DMSO-d6,δ,ppm):11.34,18.62,20.53,44.80,63.50,68.58,72.73,73. 81,116.25,130.24,130.75,133.05,139.61,143.85,152.56,167.56,171.70.

[1286] LCMS, m / z: 391.4 (M+H) + ,413.6(M+Na)+ .

[1287] Synthesis of Compound 44 (Example 7)

[1288] Example 7 was synthesized according to the following scheme:

[1289]

[1290] Compound (33) was converted to compound (44) by coupling with 2-dimethylaminoethanol (CAS# 108-01-0) and acid-mediated removal of the MOM protecting group (Example 7).

[1291] Synthesis of Compound 50 (Example 18), Compound 52 (Example 19), and Compound 54 (Example 20)

[1292] Examples 18-20 were synthesized according to the following schemes.

[1293]

[1294] Compound 45

[1295] At 0 ℃, lithium hydroxide (6.47 g, 269.96 mmol) in water (120 mL) was added dropwise to a stirred solution of compound (19) (40.0 g, 53.99 mmol) in MeOH (120 mL) and THF (120 mL). The resulting mixture was stirred at 0 ℃ for 3 hours. The mixture was neutralized to pH 7 with 1M HCl and diluted with water (0.8 L). The resulting mixture was extracted with EtOAc (3 × 200 mL). The combined organic layer was washed with water (3x100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain compound (45), which can be directly used in the next step without further purification.

[1296] LCMS:(ES,m / z):[M+Na] + =749.5

[1297] Compound 46

[1298] To a stirred solution of compound (45) (30.0 g, 41.27 mmol), (2-aminoethyl)dimethylamine (7.28 g, 82.55 mmol) and DIPEA (16.0 g, 0.124 mol) in DMF (400 mL) at 0°C was added PyBOP (42.99 g, 82.55 mmol) in portions. The resulting mixture was stirred at 25°C for 3 hours and then diluted with water (1.2 L). The resulting mixture was extracted with EtOAc (3×300 mL). The combined organic layers were washed with water (3×200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give compound (46), which was used directly in the next step without further purification.

[1299] LCMS:(ES,m / z):[M+H] + =797.5

[1300] Compound 47

[1301] Formic acid (120 mL) was added dropwise to a THF (120 mL) solution of compound (46) (25.0 g, 31.37 mmol) stirred at 0°C. The resulting mixture was stirred at 25°C for 3 hours and adjusted to pH 10 with a saturated Na2CO3 aqueous solution. The mixture was subsequently diluted with water (0.8 L) and extracted with EtOAc (3x300 mL). The combined organic layers were washed with water (3x200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile aqueous solution (0.1% formic acid), 25% to 35% gradient over 20 minutes; detector, UV 254 nm to obtain compound (47) (8 g) as a yellow oil.

[1302] LCMS:(ES,m / z):[M+H] + =555.4

[1303] Compound 48

[1304] Under argon atmosphere, MsCl (6.20 g, 54.09 mmol) was added dropwise to a solution of compound (47) (6.00 g, 10.82 mmol) and DIPEA (13.98 mg, 108.18 mmol) in DCM stirred at 0°C. The resulting mixture was stirred at 25°C for 2 hours and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient from 25% to 40% over 20 minutes; detector, UV 254 nm, to obtain compound (48) (5.2 g) as a yellow oil.

[1305] LCMS:(ES,m / z):[M+H] + =633.3

[1306] Compound 49

[1307] In a 40 mL sealed tube, compound (48) (400 mg) and 7M NH3 (g) were mixed in MeOH (20 mL) at 25°C. The mixture was stirred at 60°C for 18 hours and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient from 25% to 40% over 20 minutes; detector, UV 254 nm to give compound (49) (300 mg) as a yellow oil.

[1308] LCMS:(ES,m / z):[M+H] + =554.4

[1309] Compound 50 (Example 18)

[1310] 4M HCl in 1,4-dioxane (10 mL) was added dropwise to a solution of compound (49) (300 mg, 0.54 mmol) in THF (1 mL) stirred at 0°C. The resulting mixture was stirred at 0°C for 3 hours under a nitrogen atmosphere. The mixture was then concentrated under reduced pressure and purified by preparative HPLC using the following conditions: column: X Bridge Shield RP18 OBD column, 5 μm, 19x150 mm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 25 mL / min; gradient: 4% B to 18% B in 8 minutes; 220 nm; Rt: 7.8 min) to give compound (50) (Example 18) (55 mg) as a yellow solid.

[1311] LCMS:(ES,m / z):[M+H] + =422.2

[1312] 1H NMR (300MHz, methanol-d4) δ7.82(s,1H),7.66(s,1H),4.64(d,J=24.3Hz,2H),4.19(s,1H),4.03(d,J=10.2Hz,1H),3.76(t,J=6.0Hz,1H),3.65 (t, J=6.5Hz, 2H), 3.16 (dd, J=12.9, 3.7Hz, 1H), 3.04 (dd, J=12.9, 7.5Hz, 1H), 2.65 (t, J=6.5Hz, 2H), 2.46 (d, J=25.9Hz, 3H), 2.36 (s, 9H).

[1313] Compound 51

[1314] To a solution of compound (48) (300 mg, 0.47 mmol) stirred at 25°C was added 2M dimethylamine in MeOH (5 mL). The resulting mixture was stirred at 75°C for 18 hours and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient from 25% to 40% over 20 minutes; detector, UV 254 nm, to afford compound (51) (200 mg) as a yellow oil.

[1315] LCMS:(ES,m / z):[M+H] + =582.4

[1316] Compound 52 (Example 19)

[1317] 4M HCl in 1,4-dioxane (10 mL) was added dropwise to a 0°C solution of compound (51) (200 mg) in THF (10 mL) and stirred at 0°C for 3 hours. The mixture was then neutralized to pH 7 with saturated aqueous NaHCO3. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by preparative HPLC using the following conditions: column: XBridge Shield RP18 OBD column, 5 μm, 19×150 mm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 25 mL / min; gradient: from 20% B to 50% B in 12 minutes; 220 nm; Rt: 11.8 min to obtain compound (52) (Example 19) (60 mg) as a yellow solid.

[1318] LCMS:(ES,m / z):[M+H] + =450.2

[1319] 1H NMR (300MHz, DMSO-d6) δ9.15(s,1H),7.63(d,J=22.7Hz,2H),4.91(s,2H),4.72(s,1H),4.55(t,J=12.2Hz,1H),4.31(d ,J=13.8Hz,1H),4.05(s,1H),3.77(s,1H),3.58(s,3H),2.41(d,J=6.6Hz,7H),2.33(s,3H),2.26(s,6H),2.20(s,6H).

[1320] Compound 53

[1321] To a solution of compound (48) (400 mg, 0.60 mmol) in THF (10 ml) was added 2-aminoethan-1-ol (10 mL) at 25° C. The resulting mixture was stirred at 60° C. for 18 hours, concentrated under reduced pressure, and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water, 20% to 50% gradient over 25 minutes; detector, UV 254 nm, to obtain compound (53) (350 mg) as a yellow solid.

[1322] LCMS:(ES,m / z):[M+H] + =598.4

[1323] Compound 54 (Example 20)

[1324] To a solution of compound (53) (300 mg, 0.50 mmol) in THF (10.00 mL) stirred at 0° C. was added 4 M HCl in 1,4-dioxane (10.00 mL) dropwise. The resulting mixture was stirred at 25° C. for 3 hours and neutralized to pH 7 with saturated aqueous NaHCO 3 . After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by preparative HPLC using the following conditions: column: Welch Xtimate C18 21.2 x 250 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile; flow rate: 25 mL / min; gradient: from 13% B to 16% B in 9 minutes; 254 nm; Rt: 6.33 min to obtain compound (54) (Example 20) (130 mg) as a yellow solid.

[1325] LCMS:(ES,m / z):[M+H] + =466.3

[1326] 1H NMR (300MHz, methanol-d4) δ7.80(s,1H),7.66(s,1H),4.70(d,J=9.0Hz,1H),4.59(dd,J=14.0,2.9Hz,1H),4.25–4.11(m,2H),3.92–3.80(m ,5H),3.45(t,J=5.8Hz,2H),3.30(s,1H),3.27(d,J=4.5Hz,1H),3.21(td,J=4.8,2.0Hz,2H),3.03(s,6H),2.52(s,3H),2.43(s,3H).

[1327] Synthesis of Compound 56 (Example 21)

[1328] Example 21 was synthesized according to the following scheme.

[1329]

[1330] Compound 55

[1331] KMnO4 (854.79 mg, 5.41 mmol) in acetone (10 mL) was added dropwise to a solution of compound (47) (600 mg, 1.08 mmol) in acetone (10 mL) at 0°C. The resulting mixture was stirred at 25°C for 3 hours, then filtered and washed with water (3 x 5 mL). The filtrate was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, aqueous ACN (0.1% aqueous NH3), 10% to 50% gradient over 20 minutes; detector, UV 254 nm, to afford compound (55) (200 mg) as a yellow solid.

[1332] LCMS:(ES,m / z):[M+H] + =569.4

[1333] Compound 56 (Example 21)

[1334] Under an argon atmosphere, 4M HCl in 1,4-dioxane (5.00 mL) was added dropwise to a solution of compound (55) (200 mg) in H2O (10.00 mL) stirred at 0°C. The resulting mixture was stirred at 25°C for 6 hours and then neutralized to pH 7 with saturated aqueous NaHCO3. The resulting mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC using the following conditions: column: SunFire Prep C18 OBD column 19×150 mm, 5 μm; mobile phase A: water (0.1% formic acid), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 15% B to 15% B in 6 minutes; 254 / 220 nm; Rt: 4.50 min to obtain compound (56) (Example 21) (31.9 mg) as a yellow solid.

[1335] LCMS:(ES,m / z):[M+H] + =437.2

[1336] 1 H NMR (300 MHz, methanol-d4) δ 8.07 (d, J = 10.8 Hz, 1H), 7.75 (d, J = 28.8 Hz, 2H), 4.81–4.75 (m, 1H), 4.62–4.46 (m, 2H), 4.28 (d, J = 9.2 Hz, 1H), 3.88–3.75 (m, 3H), 3.74–3.57 (m, 5H), 3.12 (s, 1H), 2.98 (s, 2H), 2.46 (d, J = 26.2 Hz, 6H).

[1337] Synthesis of Compound 59 (Example 22)

[1338] Example 22 was synthesized according to the following scheme.

[1339]

[1340] Compound 57

[1341] Compound (48) (350 mg, 0.55 mmol) and NaI (331.66 mg, 2.21 mmol) were mixed in acetone (20 mL) in a sealed tube. The resulting mixture was stirred at 70°C for 18 hours. After cooling to 0°C, the mixture was concentrated under reduced pressure. The residue was then purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN aqueous solution (0.1% formic acid), 25% to 45% gradient over 20 minutes; detector, UV 254 nm to obtain compound (57) (280 mg) as a yellow oil.

[1342] LCMS:(ES,m / z):[M+H] + =665.2

[1343] Compound 58

[1344] A mixture of compound (57) (280 mg, 0.42 mmol), TEA (85.02 mg, 0.84 mmol) and Pd / C (60 mg) in MeOH (20 mL) was stirred at 25° C. under a hydrogen atmosphere for 18 hours. The mixture was filtered and the residual solid was washed with MeOH (3×5 mL). The combined filtrates were concentrated under reduced pressure to give compound (58) (200 mg) as a yellow oil.

[1345] LCMS:(ES,m / z):[M+H] + =539.3

[1346] Compound 59 (Example 22)

[1347] Under nitrogen atmosphere, 4M HCl in 1,4-dioxane (5 mL) was added dropwise to a solution of compound (58) (300 mg, 0.56 mmol) in MeOH (10 mL) stirred at 0°C. The resulting mixture was stirred at 25°C for 3 hours, then cooled to 0°C and neutralized to pH 7 with saturated aqueous NaHCO3. The mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: Column: XBridge C18 OBD Prep Column, 5 μm, 19 mm × 250 mm; mobile phase A: water (10 mmol, NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 19% B to 27% B in 11 minutes; 254 nm; Rt: 9.32 minutes to obtain Compound (59) (Example 22) (16.1 mg) as a yellow solid.

[1348] LCMS:(ES,m / z):[M+H] + =407.3

[1349] 1 H NMR (300MHz, methanol-d4) δ7.82(s,1H),7.69(s,1H),4.61(s,1H),4.18(t,J=6.4Hz,1H),3.96(t,J=6.3Hz,1H) ,3.69–3.58(m,4H),2.65(t,J=6.6Hz,2H),2.50(s,3H),2.42(s,3H),2.36(s,6H),1.29(d,J=6.3Hz,3H).

[1350] Synthesis of Compound 61 (Example 23), Compound 63 (Example 24), and Compound 65 (Example 25)

[1351] Examples 23-25 ​​were synthesized according to the following schemes.

[1352]

[1353] Compound 60

[1354] To a stirred solution of compound (45) (300 mg, 0.41 mmol), 2-aminoethan-1-ol (240 mg, 3.93 mmol) and DIPEA (600 mg, 4.64 mmol) in DMF (10 ml) at 0°C was added PyBOP (400 mg, 0.77 mmol) in portions. The resulting mixture was stirred at 25°C for 3 hours and then diluted with water (100 mL). The mixture was extracted with EtOAc (3 x 50 mL), and the combined organic layers were washed with water (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient from 25% to 40% over 20 minutes; detector, UV 254 nm, to obtain compound (60) (250 mg) as a yellow solid.

[1355] LCMS:(ES,m / z):[M+H] + =770.4

[1356] Compound 61 (Example 23)

[1357] 4M HCl in 1,4-dioxane (10 mL) was added dropwise to a solution of compound (60) (360 mg, 0.45 mmol) in THF (10 mL) at 0°C and stirred at 25°C for 3 hours. The mixture was then neutralized to pH 7 with saturated aqueous NaHCO3 and concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions: column: XBridge Shield RP18OBD column, 5 μm, 19x150 mm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 25 mL / min; gradient: from 8% B to 25% B in 8 minutes; 220 nm; Rt: 7.9 min to obtain compound (61) (Example 23) (90 mg) as a yellow solid.

[1358] LCMS:(ES,m / z):[M+H] + =396.2

[1359] 1H NMR (300MHz, DMSO-d6) δ9.25(t,J=5.5Hz,1H),7.65(d,J=16.5Hz,2H),4.99(d,J=3.9Hz,1H),4.88–4.79(m,2H),4.65(d d,J=25.2,8.7Hz,2H),4.49(t,J=5.3Hz,1H),4.28–4.07(m,2H),3.67–3.49(m,6H),3.35(d,2H),2.37(d,J=19.4Hz,6H).

[1360] Compound 62

[1361] To a stirred solution of compound (45) (300 mg, 0.41 mmol), [2-(2-aminoethoxy)ethyl]dimethylamine (109.14 mg, 0.83 mmol) and DIPEA (192.42 mg, 1.48 mmol) in DMF (10 mL) at 0°C was added PyBOP (384.91 mg, 0.74 mmol) in portions. The resulting mixture was stirred at 25°C for 3 hours and then diluted with water (100 mL). The mixture was extracted with EtOAc (3 x 50 mL), and the combined organic layers were washed with water (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient 10% to 50% over 20 minutes; detector, UV 254 nm to afford compound (62) as a yellow solid (200 mg).

[1362] LCMS:(ES,m / z):[M+H] + =841.5

[1363] Compound 63 (Example 24)

[1364] Under nitrogen atmosphere, 4M HCl in 1,4-dioxane (10 mL) was added dropwise to a 0°C solution of compound (62) (200 mg, 0.24 mmol) in THF (10 mL). The resulting mixture was stirred at 25°C for 3 hours and neutralized to pH 7 with saturated aqueous NaHCO3. The mixture was concentrated under reduced pressure and purified by preparative HPLC using the following conditions: column: XBridge Shield RP18 OBD column, 5 μm, 19x150 mm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile; flow rate: 25 mL / min; gradient: from 12% B to 40% B in 8 minutes; 220 nm; Rt: 7.9 min to give compound (63) (Example 24) (70 mg) as a yellow solid.

[1365] LCMS:(ES,m / z):[M+H] + =467.2

[1366] 1 H NMR (300MHz, DMSO-d6) δ9.26(d,J=5.8Hz,1H),7.64(d,J=13.5Hz,2H),4.91(d,J=48.1Hz,2H ),4.75–4.36(m,3H),4.31–4.01(m,2H),3.73–3.49(m,9H),2.55–2.28(m,8H),2.14(s,6H).

[1367] Compound 64

[1368] To a stirred solution of compound (45) (300 mg, 0.41 mmol), 2-(2-aminoethoxy)ethan-1-ol (130.19 mg, 1.24 mmol) and DIPEA (214.56 mg, 1.65 mmol) in DMF (10 mL) at 0°C was added PyBOP (429.59 mg, 0.83 mmol) in portions. The resulting mixture was stirred at 25°C for 3 hours and then diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient 25% to 50% over 20 minutes; detector, UV 254 nm to afford compound (64) as a yellow solid (200 mg).

[1369] LCMS:(ES,m / z):[M+H] + =814.4

[1370] Compound 65 (Example 25)

[1371] Under an argon atmosphere, 4M HCl in 1,4-dioxane (10 mL) was added dropwise to a 0°C solution of compound (64) (200 mg, 0.18 mmol) in THF (10 mL). The resulting mixture was stirred at 25°C for 3 hours and then neutralized to pH 7 with saturated aqueous NaHCO3. The resulting mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (0.1% formic acid), gradient from 20% to 35% over 20 minutes; detector, UV 254 nm, to obtain compound (65) (Example 25) (50 mg) as a yellow solid.

[1372] LCMS:(ES,m / z):[M+H] + =440

[1373] 1 H NMR (300MHz, DMSO-d6) δ9.19(t,J=5.5Hz,1H),7.64(d,J=14.0Hz,2H),4.99(d,J=4.5Hz,1H),4.83(d,J=3.5 Hz,1H),4.71–4.56(m,3H),4.48(t,J=5.4Hz,1H),4.29–4.07(m,2H),3.68–3.40(m,12H),2.43–2.29(m,6H).

[1374] Synthesis of Compound 67 (Example 27) and Compound 69 (Example 26)

[1375] Examples 26 and 27 were prepared according to the following scheme:

[1376]

[1377] The OMs portion of compound (21) was replaced with ethylene glycol to obtain compound (66), or replaced with 2-dimethylaminoethanol-1-ol to obtain compound (68). The MOM protecting group on compound (66) was removed under acidic conditions to obtain compound (67) (Example 27), and the MOM protecting group on compound (68) was removed to obtain compound (69) (Example 26).

[1378] Synthesis of Compound 71 (Example 28) and Compound 73 (Example 29)

[1379] Example 28 and Example 29 were synthesized according to the following scheme.

[1380]

[1381] Compound 70

[1382] To a stirred solution of 1-methylpiperazine (82.69 mg, 0.83 mmol) and compound (45) (300 mg, 0.41 mmol) in DMF (5.00 mL) at 0°C was added DIPEA (160.04 mg, 1.24 mmol) and PyBOP (279.23 mg, 0.54 mmol). The resulting mixture was stirred at 20°C for 2 hours. The mixture was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% NH4HCO3 aqueous solution; B: acetonitrile; detector, UV 254 nm; 40% B to afford compound (70) (500 mg) as a yellow oil.

[1383] ESI-MS m / z=809.8[M+H] + ;831.6[M+Na] +

[1384] Compound 71 (Example 28)

[1385] 4M HCl in 1,4-dioxane (1.5 mL) was added dropwise to a 0°C solution of compound (70) (300 mg, 0.37 mmol). The resulting mixture was stirred at 20°C for 2 hours and then concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: Column: XBridge Prep Phenyl OBD column 5 μm, 19x250 mm; Mobile phase A: water (0.05% NH4OH), Mobile phase B: acetonitrile; Flow rate: 25 mL / min; Gradient: 3% B to 3% B in 2 minutes; 254 / 220 nm; Rt: 8.50 min to afford compound (71) (Example 28) (90 mg) as a light yellow solid.

[1386] LCMS:ESI-MS m / z=435.5[M+H] +

[1387] 1H-NMR (400MHz, methanol-d4): δ7.72–7.65(d,2H), 4.95–4.83(dd,J=14.1,9.7Hz,1H), 4.45(dd,J=14.1,2.8Hz,1H), 4.28(ddd,J=9.7,4.6,2. 8Hz,1H),3.91–3.80(m,5H),3.80–3.74(m,1H),3.45(dd,J=5.9,4.2Hz,2H),2.60(t,J=5.3Hz,2H),2.48(s,5H),2.38(d,J=16.8Hz,6H).

[1388] Compound 72

[1389] To a stirred solution of morpholine (71.92 mg, 0.83 mmol) and compound (45) (300 mg, 0.41 mmol) in DMF (3.00 mL) at 0°C was added DIPEA (160.04 mg, 1.24 mmol) and PyBOP (279.23 mg, 0.54 mmol). The resulting mixture was stirred at 20°C for 2 hours and then purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.5% NH4HCO3 aqueous solution, B: acetonitrile, UV 254 nm, 40% B to afford compound (72) (300 mg) as a light yellow solid.

[1390] ESI-MS m / z=818.4[M+Na] +

[1391] Compound 73 (Example 29)

[1392] 4M HCl in dioxane (3.00 mL) was added to a solution of compound (72) (300 mg, 0.38 mmol) and stirred at 20° C. for 6 hours. The mixture was neutralized to pH 7 with saturated aqueous NaHCO 3 at 0° C. The resulting mixture was concentrated under reduced pressure and purified by preparative HPLC using the following conditions (column: Welch Xtimate C18 21.2×250 mm, 5 μm; mobile phase A: 10 mmol NH 4 HCO 3 water, mobile phase B: acetonitrile; flow rate: 25 mL / min; gradient: from 21% B to 26% B in 9 minutes; detector 254 nm; Rt: 6.44 min) to give compound (73) (Example 29) (30.7 mg) as a yellow solid.

[1393] LCMS:ESI-MS m / z=422.2[M+H] +

[1394] 1 H-NMR (300 MHz, methanol-d4): δ7.73–7.61 (d, 2H), 4.81–4.70 (m, 1H), 4.46 (dd, J = 14.0, 2.8 Hz, 1H), 4.28 (dt, J = 9.8, 3.2 Hz, 1H), 3.89–3.73 (m, 7H), 3.73–3.63 (m, 3H), 3.48–3.39 (m, 2H), 2.49 (s, 3H), 2.40 (s, 3H).

[1395] Synthesis of Compound 75 (Example 30) and Compound 78 (Example 32)

[1396] Example 30 and Example 32 were synthesized according to the following scheme.

[1397]

[1398] Compound 74

[1399] To a solution of compound (4) (1 g, 1.92 mmol) in DMF (8 mL) stirred at room temperature was added CDI (800.63 mg, 4.94 mmol). The resulting mixture was stirred at 30°C for 16 hours and ethyl (N-hydroxycarbamoyl)formate (800 mg, 6.06 mmol) was added. After maintaining at 80°C for another 5 hours, the mixture was cooled to room temperature. The mixture was then purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% formic acid in water, B: ACN, gradient from 10% to 100% over 30 minutes; detector, UV 254 nm, 70% B, to afford compound (74) (350 mg) as a yellow semisolid.

[1400] ESI-MS m / z=617.5[M+H] +

[1401] Compound 75 (Example 30)

[1402] To a stirred solution of compound (74) (350 mg, 0.57 mmol) in MeOH (20 mL) at 0°C was added LiBH4 (61.83 mg, 2.84 mmol) in portions. The resulting mixture was stirred at 20°C for 16 hours. Aqueous NH3 solution (5 mL) was added dropwise to the mixture at 20°C and stirring was continued for another 2 hours at 40°C. The resulting mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC using the following conditions (column: XBridge Prep OBD C18 column 19x250 mm, 5 μm; mobile phase A: water (10 mmol NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 17% B to 21% B in 12 minutes; 254 / 220 nm; Rt: 8.13 min) to give compound (75) (Example 30) (66.6 mg) as a light yellow solid.

[1403] LCMS ESI-MS m / z=407.15[M+H] +

[1404] 1 H NMR (300MHz, DMSO-d6) δ7.74(s,1H),7.67(s,1H),5.83(t,J=6.3Hz,1H),4.99(d,J=4.4Hz,1H),4.84(s,1H),4.76(d,J=6.0Hz, 1H), 4.69 (d, J = 6.3Hz, 2H), 4.48 (t, J = 5.5Hz, 1H), 4.29 (d, J = 14.0Hz, 1H), 4.16 (s, 1H), 3.62 (s, 3H), 2.43 (s, 3H), 2.35 (s, 3H).

[1405] Compound 76

[1406] To a stirred solution of compound (74) (700 mg, 1.16 mmol) in MeOH (10 mL) at 0°C was added LiBH4 (75.92 mg, 3.49 mmol) in portions. The resulting mixture was stirred at 0°C for 0.5 h. The mixture was quenched at 0°C by the addition of water (1 mL) and purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% TFA in water, gradient from 0% to 100% in 30 minutes; detector, UV 254 nm, 60% B to afford compound (76) (300 mg) as a yellow oil.

[1407] LCMS:ESI-MS m / z=575.3[M+H] +

[1408] Compound 77

[1409] To a stirred solution of compound (76) (300 mg, 0.52 mmol) in DCM (10 mL) at 0°C was added DIPEA (202.45 mg, 1.57 mmol) and methanesulfonyl chloride (65.79 mg, 0.57 mmol) dropwise. The resulting mixture was stirred at 0°C for 2 hours and quenched with water. The organic layer was separated, washed with water (2 x 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give compound (77) (400 mg) as a yellow oil.

[1410] LCMS:ESI-MS m / z=653.4[M+H] + 675.5[M+Na] +

[1411] Compound 78 (Example 32)

[1412] At 30 ℃, compound (77) (400mg) is stirred in 2M dimethylamine / THF (30mL) for 3 hours, then concentrated under reduced pressure. Ammonia (10mL) is added dropwise to the residue and the resulting mixture is stirred at 40 ℃ for another 16 hours. The crude product is purified by preparative HPLC using the following conditions (column: XBridge Prep OBD C18 column 19x250mm, 5μm; mobile phase A: water (0.05% ammonia), mobile phase B: ACN; flow rate: 25mL / min; gradient: from 19% B to 25% B in 15 minutes; 220 / 254nm; Rt: 11.72min) to give compound (78) (Example 32) (25.5mg) as a yellow solid.

[1413] LCMS:ESI-MS m / z=434.2[M+H] +

[1414] 1 H NMR (300 MHz, methanol-d4): δ 7.79 (s, 1H), 7.74 (s, 1H), 4.80 (s, 1H), 4.53 (dd, J = 14.0, 2.8 Hz, 1H), 4.33 (dq, J = 9.7, 3.1 Hz, 1H), 3.90–3.79 (m, 5H), 3.75–3.68 (m, 1H), 2.52 (s, 3H), 2.43 (d, J = 1.6 Hz, 8H).

[1415] Synthesis of Compound 79 (Example 31)

[1416] Example 31 was synthesized according to the following scheme.

[1417]

[1418] Compound 78 (Example 32)

[1419] A solution of compound 77 (200 mg, 0.31 mmol) in MeOH (10 ml) was treated portionwise with sodium methoxide (200 mg, 3.70 mmol) at 0°C. The mixture was stirred at 0°C for 3 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% TFA in water, B: ACN; gradient from 10% to 70% over 20 minutes; detector, UV 254 nm, to afford compound (79) (Example 31) (67 mg) as a yellow solid.

[1420] LCMS:ESI-MS m / z=421.20[M+H] +

[1421] 1 H-NMR (300 MHz, methanol-d4) δ7.75 (d, J = 16.5 Hz, 2H), 4.82 (s, 1H), 4.73 (s, 2H), 4.51 (dd, J = 14.0, 2.7 Hz, 1H), 4.32 (ddd, J = 9.8, 4.4, 2.7 Hz, 1H), 3.91–3.76 (m, 3H), 3.71 (dd, J = 12.1, 6.2 Hz, 1H), 3.52 (s, 3H), 2.51 (s, 3H), 2.41 (s, 3H).

[1422] Synthesis of Compound 83 (Example 33)

[1423] Example 33 was synthesized according to the following scheme.

[1424]

[1425] Compound 80

[1426] To a solution of compound (70) (2.0 g, 2.47 mmol) in THF (10 mL) stirred at 0°C was added formic acid (10 mL) dropwise. The resulting mixture was stirred at 25°C for 18 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN:water (0.1% FA), 10% to 50% ACN gradient over 20 minutes; detector, UV 254 nm, to afford compound (80) (0.7 g) as a yellow oil.

[1427] LCMS:(ES,m / z):[M+H] + =567.4

[1428] Compound 81

[1429] To a stirred solution of compound (80) (0.70 g, 1.24 mmol) and DIPEA (803.01 mg, 6.178 mmol) in DCM (30 mL) at 0°C was added dropwise a DCM solution (30 mL) of MsCl (281.58 mg, 2.47 mmol) under an argon atmosphere. The resulting mixture was stirred at 25°C for 1 hour under an argon atmosphere and then diluted with water (50 mL). The resulting mixture was extracted with DCM (3x20 mL), and the combined organic layers were washed with water (3x10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by preparative thin layer chromatography, eluting with (DCM / MeOH 10:1) to obtain compound (81) (500 mg) as a yellow solid.

[1430] LCMS:(ES,m / z):[M+H] + =645.3

[1431] Compound 82

[1432] Compound (81) (500 mg, 0.78 mmol) and 7M NH3(g) in MeOH (10 mL) were placed in a sealed tube and the mixture was stirred at 70°C for 16 hours. Subsequently, the mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN: water (0.1% FA), 10% to 50% ACN gradient in 10 minutes; detector, UV 254 nm to give compound (82) (350 mg) as a yellow oil.

[1433] LCMS:(ES,m / z):[M+H] + =566.4

[1434] Compound 83 (Example 33)

[1435] To a mixture of compound (82) (200 mg, 0.35 mmol) in MeOH (5 mL) stirred at 0°C was added HCl (6 M in dioxane) (5 mL) dropwise. The resulting mixture was stirred at 25°C for 3 hours and then neutralized to pH 7 with saturated aqueous NaHCO3. The resulting mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column: Gemini-NX C18 AXAI 21.2*150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 7% B to 15% B in 10 minutes; 254 / 220 nm; Rt: 7.09 min to give compound (83) (Example 33) (50 mg) as a yellow solid.

[1436] LCMS:(ES,m / z):[M+H] + =434.2

[1437] 1 H NMR (300MHz, methanol-d4) δ7.66(s,2H),4.65(d,J=8.9Hz,1H),4.55(dd,J=14.0,3.1Hz,1H),4.20–4.04(m,3 H),3.77(t,J=6.0Hz,2H),3.38–3.34(m,4H),3.27–3.06(m,4H),2.96(s,3H),2.50(s,3H),2.41(s,3H).

[1438] Synthesis of Compound 84 (Example 34)

[1439] Example 34 was synthesized according to the following scheme.

[1440]

[1441] Compound 84 (Example 34)

[1442] A solution of compound (74) (300 mg) in 7M NH3 / MeOH (20 mL) was stirred at 20°C for 16 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% NH4HCO3 in water; mobile phase B: ACN, 0% to 50% gradient over 30 minutes; detector, UV 254 nm to afford compound (84) (Example 34) (85.9 mg) as a yellow solid.

[1443] LCMS:ESI-MS m / z=420.10[M+H] +

[1444] 1 H-NMR: (300MHz, DMSO-d6): δ8.48(s,1H),8.22(s,1H),7.75(s,1H),7.69(s,1H),5.01(d,J=4.0Hz,1H),4.85(s,1H),4.77(d,J=5.9Hz,1H) ,4.74–4.61(m,1H),4.48(d,J=5.5Hz,1H),4.30(d,J=14.1Hz,1H),4.17(s,1H),3.62(s,3H),3.50–3.40(m,1H),2.44(s,3H),2.36(s,3H).

[1445] Synthesis of Compound 92 (Example 35)

[1446] Example 35 was synthesized according to the following scheme.

[1447]

[1448] Compound 85

[1449] To a stirred 25°C solution of compound (45) (10 g, 13.76 mmol) in DMF (50 mL) was added CDI (6.69 g, 41.28 mmol) in portions, followed by ethyl (N-hydroxycarbamoyl)formate (6.54 g, 49.5 mmol) in portions. The mixture was irradiated with microwave radiation at 50°C for 18 hours and then at 80°C for 5 hours. The resulting mixture was diluted with water (200 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with water (3×20 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN:water (0.1% FA), gradient from 60% to 85% over 20 minutes; detector, UV 254 nm to afford compound (85) (4 g) as a yellow solid.

[1450] LCMS:(ES,m / z):[M+Na] + =845.5

[1451] Compound 86

[1452] To a 0°C stirred solution of compound (85) (4.0 g, 4.86 mmol) in MeOH (50 mL) was added LiBH4 (1.06 g, 48.66 mmol) in portions. The resulting mixture was stirred at 0°C for 2 hours and then quenched with a saturated NH4Cl aqueous solution (10 mL). The mixture was diluted with water (200 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with water (3 200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure after filtration. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (1: 1) to give compound (86) (3.5 g) as a yellow oil.

[1453] LCMS:(ES,m / z):[M+Na] + =803.5

[1454] Compound 87

[1455] To a stirred solution of compound (86) (2.0 g, 2.56 mmol) and DIPEA (3310.21 mg, 25.61 mmol) in DCM (20 mL) at 0°C was added dropwise MsCl (1466.96 mg, 12.81 mmol) in DCM (1 mL). The resulting mixture was stirred at 25°C for 1 hour and then concentrated in vacuo. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN:water (0.1% FA), 10% to 70% gradient over 20 minutes; detector, UV 254 nm, to afford compound (87) (2 g) as a yellow oil.

[1456] LCMS:(ES,m / z):[M+Na] + =881.5

[1457] Compound 88

[1458] A solution of compound (87) (2.0 g, 2 mmol) and dimethylamine (2 M in MeOH) (5 mL) in THF (5 mL) was stirred at 80° C. for 16 hours and then concentrated in vacuo. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN: water (0.1% FA), 10% to 50% gradient over 20 minutes; detector, UV 254 nm to give compound (88) (1.6 g) as a yellow oil.

[1459] LCMS:(ES,m / z):[M+H] + =808.6

[1460] Compound 89

[1461] To a solution of compound (88) (1.60 g, 1.98 mmol) in THF (20 mL) stirred at 0°C was added formic acid (20 mL, 0.44 mmol) dropwise. The resulting mixture was stirred at 25°C for 16 hours and then concentrated in vacuo. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN:water (0.1% FA), 10% to 50% gradient over 10 minutes; detector, UV 254 nm, to afford compound (89) (700 mg) as a yellow oil.

[1462] LCMS:(ES,m / z):[M+H] + =566.4

[1463] Compound 90

[1464] To a stirred solution of compound (89) (700 mg, 1.24 mmol) and DIPEA (1599.48 mg, 12.38 mmol) in DCM at 0°C was added MsCl (708.83 mg, 6.19 mmol) in DCM (1 mL) dropwise. The resulting mixture was stirred at 25°C for 1 hour and then concentrated in vacuo. The residue was purified by preparative thin layer chromatography (DCM / MeOH 10:1) to afford compound (90) (500 mg) as a yellow oil.

[1465] LCMS:(ES,m / z):[M+H] + =644.5

[1466] Compound 91

[1467] Compound (90) (550 mg, 0.85 mmol) and NH3(g) / MeOH (12 mL, 422.77 mmol) were stirred in a sealed tube at 70°C for 16 hours. The resulting mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN: water (0.1% FA), 10% to 50% gradient over 20 minutes; detector, UV 254 nm to obtain compound (91) (260 mg) as a yellow oil.

[1468] LCMS:(ES,m / z):[M+H] + =565.5

[1469] Compound 92 (Example 35)

[1470] To a solution of compound (91) (240 mg, 0.43 mmol) in MeOH (4 mL, 98.8 mmol) stirred at 0°C was added 4M HCl (g) in 1,4-dioxane (4 mL, 131.65 mmol) dropwise. The resulting mixture was stirred at 25°C for 3 hours and then concentrated in vacuo. The residue was purified by reverse phase flash chromatography using the following conditions: Column: SunFire Prep C18 OBD column, 19×150 mm, 5 μm; Mobile phase A: water (0.05% TFA), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 8% B to 15% B over 12 minutes; 254 / 220 nm to afford compound (92) (Example 35) (40 mg) as a yellow solid.

[1471] LCMS:(ES,m / z):[M+H] + =433.2

[1472] 1 H NMR (400MHz, methanol-d4) δ7.82(s,1H),7.72(s,1H),4.73(s,3H),4.64(dd,J=14.1,2.9Hz,1H),4.22(ddd,J=9.2,6.2,2.8Hz,1H),4.10(ddd,J=8 .2,5.8,3.6Hz,1H),3.81(t,J=6.0Hz,1H),3.24(dd,J=12.9,3.7Hz,1H),3.17–3.11(m,1H),3.07(s,6H),2.54(s,3H),2.45(d,J=0.9Hz,3H).

[1473] Synthesis of Compound 97 (Example 36)

[1474] Example 36 was synthesized according to the following scheme.

[1475]

[1476] Compound 93

[1477] To a 0°C stirred solution of compound (86) (1.00 g, 1.28 mmol) and imidazole (261.54 mg, 3.84 mmol) in DCM (40 mL) was added triisopropylsilyl chloride (370.35 mg, 1.92 mmol). The resulting mixture was stirred at 30°C for 16 hours, then diluted with water (200 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (3 x 50 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (1:1) to give compound (93) (1.1 g) as a yellow oil.

[1478] LCMS:(ES,m / z):[M+Na] + =959.8

[1479] Compound 94

[1480] To a solution of compound (93) (1.1 g, 1.17 mmol) in THF (20 mL, 0.28 mmol) stirred at 0°C was added formic acid (20 mL, 0.44 mmol) dropwise. The resulting mixture was stirred at 25°C for 16 hours. The resulting mixture was concentrated in vacuo, and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH: water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm, to afford compound (94) (220 mg) as a yellow oil.

[1481] LCMS:(ES,m / z):[M+Na] + =717.6

[1482] Compound 95

[1483] To a stirred solution of compound (94) (220 mg, 0.32 mmol) and DIPEA (409.18 mg, 3.17 mmol) in DCM (5 mL) at 0°C was added dropwise MsCl (181.33 mg, 1.58 mmol) in DCM. The resulting mixture was stirred at 25°C for 1 hour and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give compound (95) (230 mg) as a yellow solid.

[1484] LCMS:(ES,m / z):[M+Na] + =881.5

[1485] Compound 96

[1486] Compound (95) (230 mg, 0.3 mmol) and 7M NH3(g) / MeOH (10 mL, 0.59 mmol) were stirred in a sealed tube at 70°C for 18 hours. The resulting mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH: water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm to give compound (96) (170 mg) as a yellow oil.

[1487] LCMS:(ES,m / z):[M+H] + =694.6

[1488] Compound 97 (Example 36)

[1489] To a solution of compound (96) (170 mg, 0.25 mmol) in THF (4 mL, 0.055 mmol) stirred at 0°C was added 4M HCl (g) in 1,4-dioxane (4 mL, 0.11 mmol) dropwise. The resulting mixture was stirred at 25°C for 4 hours and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions: Column: Gemini-NX C18 AXAI packed column, 21.2 x 150 mm, 5 μm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 7% B to 28% B in 12 minutes; 254 / 220 nm to afford compound (97) (Example 36) (60 mg) as a yellow solid.

[1490] LCMS:(ES,m / z):[M+H] + =406.3

[1491] 1 H NMR (300MHz, methanol-d4) δ8.55(s,1H),7.75(d,J=34.8Hz,2H),4.83(s,2H),4.65(s,2H),4.15( d,J=32.7Hz,2H),3.79(s,1H),3.21(s,1H),3.12(d,J=9.5Hz,1H),2.48(d,J=27.7Hz,6H).

[1492] Synthesis of Compound 99 (Example 37)

[1493] Example 37 was synthesized according to the following scheme.

[1494]

[1495] Compound 98

[1496] A mixture of compound (4) (2 g, 3.84 mmol) in SOCl2 (10 mL) was stirred at 50°C for 5 hours and then concentrated under reduced pressure. The residue was diluted with DCM (10 mL) and a solution of ethyl (hydrazinecarbonyl)formate (0.51 g, 3.86 mmol) and DIPEA (1.49 g, 11.53 mmol) in DCM (10 mL) was added dropwise while stirring at 0°C. After 30 minutes, the mixture was diluted with DCM (50 mL) and washed with water (3×50 mL). The combined organic layers were concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.5% NH4HCO3, mobile phase B: ACN, gradient from 0% to 50% over 3 minutes; detector, UV 254 nm, to obtain the intermediate as a yellow solid. The intermediate was then stirred in POCl3 (10 mL) at 70°C overnight and then concentrated in vacuo. The residue was diluted with DCM (50 mL) and washed with water (3 x 50 mL). The combined organic layers were concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% TFA, mobile phase B: ACN, 0% to 70% gradient in 30 minutes; detector, UV 254 nm to give compound (98) as a yellow solid.

[1497] Compound 99 (Example 37)

[1498] To a solution of compound (98) (200 mg, 0.32 mmol) in MeOH (5 mL) stirred at 0°C was added dropwise LiOH. . A solution of H2O (27.22 mg, 0.65 mmol) in water (2 mL) was added. The resulting mixture was stirred at 0°C for 1 hour and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% TFA in water, mobile phase B: ACN, gradient from 0% to 50% over 50 minutes; detector, UV 254 nm, to afford compound (99) (Example 37) (41.8 mg) as a yellow solid.

[1499] LCMS: ESI-MS m / z = 377.25 [M+H] +

[1500] 1H-NMR: (300MHz, DMSO-d6): δ9.47(s,1H),7.73–7.68(d,2H),5.02–5.00(m,1H),4.86-4.84(m,1H),4.66-4.63(m,1H),4.63-4.51 (m,1H),4.48-4.29(m,1H),4.25-4.16(m,1H),4.22-4.01(m,1H),3.73-3.61(s,3H),3.51-3.43(s,1H),2.42(s,3H),2.34(s,3H).

[1501] Synthesis of Compound 104 (Example 38) and Compound 105 (Example 39)

[1502] Example 38 and Example 39 were synthesized according to the following scheme.

[1503]

[1504] Compound 100

[1505] To a 0°C stirred solution of compound (4) (3 g, 5.76 mmol), DIPEA (3.72 g, 28.82 mmol), and tert-butyl N-(2-aminoethyl)-N-methylcarbamate (1.21 g, 6.94 mmol) in DMF (50 mL) was added PyBOP (6 g, 11.53 mmol) in portions. The resulting mixture was stirred at 25°C for 1 hour, then diluted with water (200 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (3 x 100 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with (EtOAc / PE=1:1) to give compound (100) (2.8 g) as a yellow solid.

[1506] LCMS:(ES,m / z):[M+H] + =677.2

[1507] Compound 101

[1508] To a solution of compound (100) (2.8 g, 4.14 mmol) in DCM (30 mL) stirred at 0°C was added TFA (15 mL) dropwise. The resulting mixture was stirred at 25°C for 2 hours and then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using EtOAc / PE = 1:1 as eluent to afford compound (101) (2 g) as a yellow solid.

[1509] LCMS:(ES,m / z):[M+H]+ =577.2

[1510] Compound 102

[1511] To a solution of compound (101) (2 g, 3.47 mmol) in DCE (30 mL) stirred at 0°C was added POCl3 (1.06 g, 6.91 mmol) dropwise. The resulting mixture was stirred at 70°C for 4 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH:water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm, to obtain compound (102) (1.2 g) as a yellow solid.

[1512] LCMS:(ES,m / z):[M+H] + =382.3

[1513] Compound 103

[1514] To a solution of compound (102) (600 mg, 1.07 mmol) in acetone (30 mL) stirred at 0°C was added KMnO4 (509.25 mg, 3.22 mmol) in acetone (5 mL) dropwise. The resulting mixture was stirred at 25°C for 16 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH:water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm to afford compound (103) (200 mg) as a yellow solid.

[1515] LCMS:(ES,m / z):[M+H] + =557.1

[1516] Compound 104 (Example 38)

[1517] To a solution of compound (103) (300 mg, 0.54 mmol) in MeOH (5 mL) stirred at 0°C was added 4 M HCl (g) in MeOH (21.41 mL, 704.64 mmol). The resulting mixture was stirred at 25°C for 4 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH:water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm to afford compound (104) (Example 38) (30 mg) as a yellow solid.

[1518] LCMS:(ES,m / z):[M+H] + =389.2

[1519] 1 H NMR: (400MHz, methanol-d4) δ7.79(d,J=18.3Hz,2H),7.73–7.69(m,1H),7.59–7.55(m,1H),4.88–4.84(m,1H),4.55(dd,J=1 4.0, 2.7Hz, 1H), 4.35 (d, J = 10.0Hz, 1H), 4.30 (s, 3H), 3.87–3.80 (m, 3H), 3.74–3.68 (m, 1H), 2.53 (s, 3H), 2.44 (s, 3H).

[1520] Compound 105 (Example 39)

[1521] Compound (102) (400 mg, 0.72 mmol) in 7M NH3(g) / MeOH (8 mL) was stirred at room temperature and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions (column: XBridge Shield RP18 OBD column, 5 μm, 19×150 mm; mobile phase A: water (0.05% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 31% B to 54% B in 10 minutes; 254 nm) to give compound (105) (Example 39) (60 mg) as a yellow solid.

[1522] LCMS: (ES, m / z): [M+H] = 391.2

[1523] 1 H NMR: (400 MHz, methanol-d4) δ = 8.55 (s, 1H), 7.79 (s, 2H), 4.88-4.82 (m, 1H), 4.53-4.49 (m, 1H), 4.32-4.21 (m, 1H), 4.20-4.06 (m, 4H), 3.89-3.79 (m, 3H), 3.73-3.68 (m, 1H), 3.57 (s, 2H), 2.54 (s, 3H), 2.41 (s, 3H).

[1524] Synthesis of Compound 110 (Example 40)

[1525] Example 40 was synthesized according to the following scheme.

[1526]

[1527] Compound 106

[1528] To a stirred mixture of compound (4) (10 g, 19.21 mmol) and N,O-dimethylhydroxylamine hydrochloride (3.52 g, 57.63 mmol) in DMF (150 mL) at 0°C was added DIPEA (24.83 g, 192.12 mmol) and PyBOP (20 g, 38.43 mmol) in portions. The resulting mixture was stirred at room temperature for 1 hour, then quenched with 1M HCl (200 mL) and extracted with EtOAc (3×150 mL). The combined organic layers were washed with saturated aqueous NaCl (3×200 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:3) to give compound (106) (8.5 g) as a yellow solid.

[1529] LCMS:(ES,m / z):[M+H] + =564.4

[1530] Compound 107

[1531] To a mixture of compound (106) (8 g, 14.2 mmol) in THF (200 mL) stirred at -10°C was added methylmagnesium bromide (56.78 mL, 56.78 mmol) dropwise under an argon atmosphere. The mixture was quenched with NH4Cl (200 mL) at 0°C and then extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with saturated aqueous NaCl (3 x 150 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give compound (107) (1.6 g) as a yellow oil.

[1532] LCMS:(ES,m / z):[M+H] + =519.4

[1533] Compound 108

[1534] To a stirred solution of compound (107) (2 g, 3.86 mmol) in EtOAc (200 mL) at 0°C was added CuBr2 (1033.81 mg, 4.63 mmol) in portions. The resulting mixture was stirred at room temperature for 3 hours. Subsequently, the mixture was diluted with 1M HCl (2 x 100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (3 x 100 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN: water, 10% to 100% gradient over 30 minutes; detector, UV 254 nm to obtain compound (108) (800 mg) as a yellow oil.

[1535] LCMS:(ES,m / z):[M+H] + =597.1

[1536] Compound 109

[1537] To a solution of compound (108) (200 mg, 0.34 mmol) in ACN stirred at room temperature was added N-carbamoimidoacetamide (67.7 mg, 0.67 mmol) in portions. The resulting mixture was stirred at 50°C for 16 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN:water (0.1% FA), gradient from 10% to 50% over 10 minutes; detector, UV 254 nm, to afford compound (109) (120 mg) as a yellow oil.

[1538] LCMS:(ES,m / z):[M+H] + =558.1

[1539] Compound 110 (Example 40)

[1540] To a stirred solution of compound (109) (200 mg) in MeOH was added 7M NH3 (g) in MeOH (3 mL) dropwise at 25°C. The resulting mixture was stirred at 25°C for 3 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN: water, 10% to 50% gradient over 20 minutes; detector, UV 254 nm to afford compound (110) (Example 40) (70 mg) as a yellow solid.

[1541] LCMS: (ES, m / z): [M+H]+=390.2

[1542] 1H NMR: (400 MHz, methanol-d4) δ 8.48 (s, 1H), 7.91 (s, 1H), 7.64 (d, J = 4.1 Hz, 2H), 4.88-4.90 (m, 1H), 4.46 (dd, J = 14.1, 2.7 Hz, 1H), 4.31 (ddd, J = 9.6, 4.7, 2.5 Hz, 1H), 3.88–3.78 (m, 3H), 3.74–3.68 (m, 1H), 2.46 (s, 3H), 2.39 (s, 3H).

[1543] Synthesis of Compound 113 (Example 41)

[1544] Example 41 was synthesized according to the following scheme.

[1545]

[1546] Compound 111

[1547] A solution of compound (4) (2056 mg, 3.95 mmoles) in SOCl2 (15.00 mL) was stirred at 50 ° C for 5 hours and then concentrated under reduced pressure. The residue was dissolved in DCM (20 mL) and added dropwise to a 0 ° C stirred solution of DIPEA (1531.12 mg, 11.85 mmoles) and (2-aminoethyl) dimethylamine (1044.35 mg, 11.85 mmoles) in THF (20 mL). The resulting mixture was stirred at 20 ° C for 1 hour, then diluted with DCM (50 mL) and washed with water (2 x 50 mL). After filtration, the organic layer was dried with anhydrous Na2SO4 and the filtrate was concentrated under reduced pressure to obtain compound (111), which can be used in the next step without further purification.

[1548] ESI-MS m / z=591.4[M+H] +

[1549] Compound 112

[1550] To a stirred solution of compound (111) (500 mg, 0.85 mmol) in DCE (10 mL) at 0°C was added PCl5 (705.08 mg, 3.39 mmol) in portions. The mixture was cooled to -5°C and trimethylsilyl azide (487.66 mg, 4.23 mmol) was added dropwise. The resulting mixture was then stirred at 80°C for another 16 hours, then diluted with DCM (20 mL) and quenched with saturated aqueous NH4CO3 solution (30 mL) at room temperature. The mixture was washed with water (2×50 mL) and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% aqueous NH4HCO3, mobile phase B: ACN; gradient from 0% to 100% over 30 minutes; detector, UV 254 nm to obtain compound (112) (200 mg) as a yellow solid.

[1551] ESI-MS m / z=616.4[M+H] +

[1552] Compound 113 (Example 41)

[1553] To a solution of compound (112) (200 mg, 0.33 mmol) in MeOH (10 mL) stirred at room temperature was added 7M NH 3 .H 2 O (8 mL). The resulting mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions (column: XBridge Shield RP18 OBD column, 5 μm, 19×150 mm; mobile phase A: water (10 mmol NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 5% B to 38% B in 8 minutes; 254 / 220 nm) to give compound (113) (Example 41) (60 mg) as a yellow solid.

[1554] LCMS:ESI-MS m / z=448.2[M+H] +

[1555] 1H-NMR: (400MHz, DMSO-d6): δ7.70(d,J=8.5Hz,2H),5.01(d,J=4.0Hz,1H),4 .90–4.84(m,1H),4.76(d,J=6.2Hz,1H),4.73–4.60(m,3H),4.50(t,J=5.4Hz ,1H),4.28(dd,J=13.8,2.5Hz,1H),4.17(s,1H),3.62(d,J=4.6Hz,3H),3.49 –3.42(m,1H),2.62(t,J=6.1Hz,2H),2.43(s,3H),2.35(s,3H),1.94(s,6H).

[1556] Synthesis of Compound 116 (Example 42)

[1557] Example 42 was synthesized according to the following scheme.

[1558]

[1559] Compound 114

[1560] Compound (4) (4 g, 7.69 mmol) was stirred in SOCl2 (30 mL) at 50 ° C for 5 hours, then cooled to room temperature and concentrated under reduced pressure. The residue (3.5 g) was diluted with DCM (20 mL) and stirred at room temperature, while NH3 (g) / 1,4-dioxane (0.4 M) (200 mL) was added dropwise over 20 minutes. The resulting mixture was stirred at 0 ° C for another hour, then diluted with water (200 mL) and extracted with EtOAc (3×200 mL). The combined organic layer was washed with water (2x 300 mL), dried over anhydrous Na2SO4, and the filtrate was concentrated under reduced pressure after filtration. The residue was dissolved in POCl3 (40 mL) and stirred at 80 ° C for 16 hours. The mixture was concentrated under reduced pressure, diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (3 x 100 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (1:1) as eluent to give Compound (114) (2.2 g) as a yellow solid.

[1561] ESI-MS m / z=502.3[M+H] +

[1562] Compound 115

[1563] A mixture of AgNO3 (328.23 mg, 1.93 mmol) and NaN3 (440.75 mg, 6.78 mmol) in DMF (15 mL) was stirred at room temperature for 10 minutes. A DMF solution of compound (114) (1.70 g, 3.39 mmol) was then added dropwise at room temperature, and the resulting mixture was stirred at 110°C for another 16 hours. The mixture was acidified to pH 5 with 1M HCl and extracted with EtOAc (3×50 mL). The combined organic layers were washed with water (2×100 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.1% FA in water, B: ACN, gradient from 10% to 50% over 30 minutes; detector, UV 254 nm, 35%, to obtain compound (115) (1 g) as a yellow solid.

[1564] ESI-MS m / z=545.3[M+H] +

[1565] Compound 116 (Example 42)

[1566] To a stirred solution of compound (115) (500 mg, 0.81 mmol) and K2CO3 (448.24 mg, 3.24 mmol) in DMF (10 mL) at 0°C was added 1-bromo-3-methylbutane (300 mg, 1.99 mmol) in portions. The resulting mixture was stirred at 20°C for 16 hours and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions (column: XBridgeShield RP18 OBD column, 5 μm, 19×150 mm; mobile phase A: water (10 mmol NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 5% B to 38% B in 8 minutes; 254 / 220 nm) to give compound (116) (Example 42) (48.9 mg) as a light yellow solid.

[1567] LCMS:ESI-MS m / z=448.2[M+H] +

[1568] 1H-NMR: (400MHz, DMSO-d6): δ7.69(s,1H),7.64(s,1H),4.99(d,J=4.3Hz,1H),4.89( t,J=6.2Hz,2H),4.84(d,J=3.9Hz,1H),4.75(d,J=6.2Hz,1H),4.66(dd,J=13.8,10.0 Hz,1H),4.48(t,J=5.5Hz,1H),4.27(dd,J=13.8,2.6Hz,1H),4.16(s,1H),3.62(s,3 H), 3.49–3.42 (m, 1H), 2.89 (t, J = 6.2Hz, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 2.19 (s, 6H).

[1569] Synthesis of Compound 117 (Example 43)

[1570] Example 43 was synthesized according to the following scheme.

[1571]

[1572] Compound 117 (Example 43)

[1573] To a stirred mixture of compound (115) (500 mg, 0.92 mmol) and K2CO3 (380.72 mg, 2.76 mmol) in ACN (15 mL) at 50°C was added methyl iodide (391.00 mg, 2.76 mmol). The resulting mixture was stirred at 50°C for 2 hours. After cooling to room temperature, ammonium hydroxide (10 mL) was added dropwise to the mixture and stirring was continued for another 16 hours at room temperature. After concentration under reduced pressure, the residue was purified by preparative HPLC using the following conditions (column: Welch XB-C18, 21.2x250 mm, 5 μm; mobile phase A: water (10 mmol NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 20% B, 254 / 220 nm) to give compound (117) (Example 43) (55.1 mg) as a light yellow solid.

[1574] ESI-MS m / z=391.15[M+H] +

[1575] 1H-NMR: (400 MHz, DMSO-d6): δ7.66 (d, J = 13.7 Hz, 2H), 4.98 (d, J = 4.5 Hz, 1H), 4.83 (d, J = 4.4 Hz, 1H), 4.74–4.65 (m, 2H), 4.49 (s, 4H), 4.27 (d, J = 13.7 Hz, 1H), 4.16 (s, 1H), 3.62 (d, J = 5.0 Hz, 3H), 3.50–3.40 (m, 1H), 2.41 (s, 3H), 2.34 (s, 3H). Synthesis of Compound 121 (Example 44)

[1576] Example 44 was synthesized according to the following scheme.

[1577]

[1578] Compound 118

[1579] A mixture of compound (4) (3 g, 5.76 mmol) in SOCl2 (20 mL) was stirred at 50°C for 5 hours and then concentrated in vacuo. The residue was diluted with DCM (10 mL), cooled to 0°C, and a solution of ethanolamine (1056.23 mg, 17.29 mmol) and DIPEA (2.23 g) in THF (10 mL) was added dropwise with stirring. The resulting mixture was stirred at room temperature for 30 minutes, then diluted with DCM (50 mL) and washed with water (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue of compound (118) was used in the next step without further purification.

[1580] Compound 119

[1581] A mixture of compound (118) (3.5 g, 6.21 mmol) and Ac2O (6.34 g, 62.10 mmol) in pyridine (15 mL) was stirred at room temperature for 16 hours. The resulting mixture was concentrated in vacuo, and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% FA in water, mobile phase B: ACN; 0% to 100% gradient over 30 minutes; detector, UV 254 nm to obtain compound (119) (3.1 g) as a yellow solid.

[1582] Compound 120

[1583] To a solution of compound (119) (1 g, 1.65 mmol) in DCE (20 mL) stirred at 0°C was added phosphorus pentachloride (1375.30 mg, 6.61 mmol) in portions. The resulting mixture was stirred at 0°C for 30 minutes. After cooling to -5°C, trimethylsilyl azide (951.22 mg, 8.26 mmol) was added dropwise to the mixture. The mixture was stirred at 50°C for another 16 hours, then diluted with DCM (100 mL) and quenched at 0°C by adding saturated ammonium bicarbonate (100 mL). The resulting mixture was washed with water (2×100 mL), and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% FA in water, mobile phase B: ACN; gradient from 0% to 100% B in 30 minutes; detector, UV 254 nm to afford compound (120) as a yellow solid (330 mg).

[1584] Compound 121 (Example 44)

[1585] A mixture of compound (120) (330 mg, 0.523 mmol) in 7M NH / MeOH (5 mL) was stirred at room temperature for 5 hours. After concentration under reduced pressure, the residue was purified by preparative HPLC using the following conditions (column: XBridge PrepOBD C18 column, 19x250 mm, 5 μm; mobile phase A: water (10 mmol NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: from 16% B to 24% B in 12 minutes; 254 / 220 nm) to give compound (121) (Example 44) (91.8 mg) as a yellow solid.

[1586] ESI-MS m / z=421.15[M+H] +

[1587] 1 H-NMR: (400MHz, DMSO-d6): δ7.70(d,J=10.6Hz,2H),5.01(d,J=3.9Hz,1H),4 .94(t,J=5.4Hz,1H),4.86(d,J=3.9Hz,1H),4.80(d,J=6.0Hz,1H),4.68–4.62 (m,3H),4.50(t,J=5.4Hz,1H),4.28(dd,J=13.6,2.6Hz,1H),4.17(s,1H),3.7 3(q,J=5.5Hz,2H),3.62(s,3H),3.49–3.41(m,1H),2.43(s,3H),2.36(s,3H).

[1588] Synthesis of Compound 129 (Example 45)

[1589] Example 45 was synthesized according to the following scheme.

[1590]

[1591] Compound 122

[1592] To a solution of compound (40) (8 g, 20.49 mmol) in pyridine (200 mL) stirred at 0°C was added Trt-Cl (17.14 g, 61.48 mmol) in portions. The resulting mixture was stirred at 70°C for 16 hours, then diluted with water (600 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with water (3 x 100 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give compound (122) (10 g) as a yellow solid.

[1593] LCMS:(ES,m / z):[M+Na] + =655.4

[1594] Compound 123

[1595] To compound (122) (3g, 4.74 mmoles) and DIPEA (18.39g, 142.29 mmoles) in DMF (300mL) 0 ℃ of stirred solutions was added dropwise MOM-Cl (30.28g, 455.43 mmoles) in DMF (50mL). The resulting mixture was stirred at 70 ℃ for 18 hours, then diluted with water (600mL) and extracted with EtOAc (3x 200mL). The combined organic layer was washed with water (3x 200mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure after filtration. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (2:1), to obtain compound (123) (2g) as a yellow solid.

[1596] LCMS:(ES,m / z):[M+Na] + =787.5

[1597] Compound 124

[1598] To a solution of compound (123) (2 g, 2.62 mmol) in THF (10 mL) stirred at 0°C was added formic acid (10 mL, 217.26 mmol) dropwise. The resulting mixture was stirred at 25°C for 4 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH:water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm, to afford compound (124) (750 mg) as a yellow oil.

[1599] LCMS:(ES,m / z):[M+H] + =523.5

[1600] Compound 125

[1601] To a stirred solution of compound (124) (2.30 g, 4.45 mmol) and DIPEA (5.76 g, 44.57 mmol) in DCM (100 mL) at 0°C was added dropwise Ms-Cl (2.55 g, 22.26 mmol) in DCM (10 mL). The resulting mixture was stirred at 25°C for 0.5 hours and then concentrated in vacuo. The residue was purified by silica gel column chromatography using PE / EtOAc (1:1) as eluent to afford compound (125) (2 g) as a yellow oil.

[1602] LCMS:(ES,m / z):[M+H] + =601.5

[1603] Compound 126

[1604] To a solution of compound (125) (300 mg, 0.5 mmol) in acetone (20 mL) stirred at 25°C was added NaI (374.34 mg, 2.5 mmol) in portions. The resulting mixture was stirred at 70°C for 18 hours and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (1:1) as eluent to afford compound (126) (290 mg) as a yellow solid.

[1605] LCMS:(ES,m / z):[M+H] + =633.3

[1606] Compound 127

[1607] To a mixture of compound (126) (290 mg, 0.46 mmol) in DMF (5 mL) stirred at 25°C was added NaN3 (59.62 mg, 0.92 mmol) in portions. The resulting mixture was stirred at 50°C for 18 hours, then diluted with water (50 mL) and the solid was filtered. The solid was washed with EtOAc (3×10 mL) and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give compound (127) (270 mg) as a yellow solid.

[1608] LCMS:(ES,m / z):[M+H] + =548.4

[1609] Compound 128

[1610] To a stirred solution of compound (127) (270 mg, 0.49 mmol) in water (1 mL) and THF (5 mL) at 25°C was added triphenylphosphine (718.49 mg, 2.74 mmol) in portions. The resulting mixture was stirred for 16 hours and then concentrated under reduced pressure. The residual compound (128) was used in the next step without further purification.

[1611] LCMS-PH-AVR-FTE0056-5:(ES,m / z):[M+H] + =522.4

[1612] Compound 129 (Example 45)

[1613] To a stirred solution of compound (128) (230 mg, 0.44 mmol) in THF (10 mL) was added 6 M HCl (5 mL) dropwise to maintain the temperature below 0° C. The resulting mixture was then stirred at 25° C. for 4 hours and then neutralized to pH 7 with saturated aqueous NaHCO 3 solution. The resulting mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH: water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm to afford compound (129) (Example 45) (70 mg) as a yellow solid.

[1614] LCMS:(ES,m / z):[M+H] + =390.3

[1615] 1H NMR: (400MHz, DMSO-d6) δ7.71(d,J=23.9Hz,2H),5.14–4.73(m,2H),4.61(dd,J=13.8,9.7Hz,2H),4.33(dd,J=13.9,2.7Hz,2H),4. 16(s,4H),3.62(dq,J=11.6,6.4,5.0Hz,3H),2.85(dd,J=12.8,3.7Hz,1H),2.69(dd,J=12.8,6.1Hz,1H),2.44(s,3H),2.36(s,3H).

[1616] Synthesis of Compound 132 (Example 46)

[1617] Example 46 was synthesized according to the following scheme.

[1618]

[1619] Compound 130

[1620] To a stirred solution of compound (4) (4 g, 7.69 mmol), glycine ethyl ester (1.19 g, 11.54 mmol) and DIPEA (2.98 g, 23.06 mmol) in DMF (50 mL) at 0°C was added HATU (5.84 g, 15.37 mmol) in portions. The resulting mixture was stirred at 0-20°C for 2 hours, then diluted with water (200 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with water (3×300 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give compound (130) (5 g) as a yellow solid.

[1621] Compound 131

[1622] To a solution of compound (130) (2.5 g, 4.23 mmol) in DCE (20 mL) stirred at 0°C were added silicon tetrachloride (2.15 g, 12.66 mmol) and trimethylsilyl azide (2.43 g, 21.09 mmol) dropwise. The resulting mixture was stirred at 70°C for 16 hours, then cooled to room temperature, diluted with DCM (100 mL) and washed with water (3 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% FA in water; mobile phase B: ACN; gradient from 0% to 70% over 30 minutes; detector, UV 254 nm, to afford compound (131) (1.6 g) as a yellow solid.

[1623] Compound 132 (Example 46)

[1624] To a solution of compound (131) (300 mg, 0.49 mmol) in MeOH (5 mL) stirred at 0°C was added dropwise an aqueous solution of lithium hydroxide (58.26 mg, 2.433 mmol). The resulting mixture was stirred at 0°C for 1 hour, then neutralized to pH 6 with 1 M HCl and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% TFA in water, mobile phase B: ACN, gradient from 0% to 30% over 30 minutes; detector, UV 254 nm to afford compound (132) (Example 46) (65 mg) as a yellow solid.

[1625] ESI-MS m / z=435.20[M+H] +

[1626] 1 H-NMR: (400MHz, MeOD-d4): δ7.76–7.71(d,2H),5.68(s,2H),4.83(dd,J=14.1,9.7Hz,1H),4.53(dd,J=14.1,2.8 Hz,1H),4.31(ddd,J=9.7,4.7,2.8Hz,1H),3.89–3.80(m,3H),3.75–3.66(m,1H),2.51(s,3H),2.47–2.39(m,3H).

[1627] Synthesis of Compound 135 (Example 47)

[1628] Example 47 was synthesized according to the following scheme.

[1629]

[1630] Compound 133

[1631] To a stirred solution of compound (4) (500 mg, 0.96 mmol), β-alanine ethyl ester (168.80 mg, 1.44 mmol) and DIPEA (620.78 mg, 4.80 mmol) in DMF (5 mL) at 0°C was added HATU (474.84 mg, 1.25 mmol) in portions. The resulting mixture was stirred at 0-20°C for 2 hours, then diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (2 x 50 mL), dried over anhydrous Na2SO4, and after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with (EtOAc) to give compound (133) (530 mg) as a yellow solid.

[1632] Compound 134

[1633] To a stirred mixture of compound (133) (585 mg, 0.94 mmol) in DCE (10 mL) at 0°C were added SiCl4 (481.21 mg, 2.83 mmol) and trimethylsilyl azide (543.87 mg, 4.72 mmol) in portions. The resulting mixture was stirred at 70°C for 16 hours, then diluted with DCM (20 mL), washed with water (3×20 mL), dried over anhydrous Na2SO4, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with (PE / EtOAc 2:3) to afford compound (134) (500 mg) as a yellow solid.

[1634] Compound 135 (Example 47)

[1635] To a solution of compound (134) (200 mg, 0.31 mmol) in DCE (10 mL) stirred at 0°C was added trimethyltin hydroxide (673.2 mg, 3.72 mmol) in portions. The resulting mixture was stirred at 80°C for 16 hours, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (5 mL), acidified to pH 6 with HCl (aq.), and purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% FA in water, mobile phase B: ACN, gradient from 0% to 30% over 20 minutes; detector, UV 254 nm, to afford compound (135) (Example 47) (56 mg) as a yellow solid.

[1636] ESI-MS m / z=449.15[M+H] +

[1637] 1H-NMR: (400 MHz, MeOD-d4): δ7.76 (d, J = 4.7 Hz, 2H), 4.95 (s, 2H), 4.81 (s, 1H), 4.53 (dd, J = 14.1, 2.8 Hz, 1H), 4.33 (ddd, J = 9.7, 4.6, 2.8 Hz, 1H), 3.89–3.77 (m, 3H), 3.70 (dd, J = 12.2, 6.4 Hz, 1H), 3.08 (t, J = 6.7 Hz, 2H), 2.52 (s, 3H), 2.42 (s, 3H). Synthesis of Compound 137 (Example 48)

[1638] Example 48 was synthesized according to the following scheme.

[1639]

[1640] Compound 136

[1641] To a mixture of compound (38) (900 mg, 1.69 mmol) in toluene (30 mL) stirred at 25 ° C, Lawesson's reagent (682.28 mg, 1.69 mmol) was added in batches. The resulting mixture was stirred at 120 ° C for 4 hours and then concentrated under reduced pressure. The residue was dissolved in THF (10 mL) and methyl iodide (2394.32 mg, 16.87 mmol) was added dropwise to the stirred mixture at 25 ° C. The mixture was stirred at 25 ° C for 18 hours and then concentrated under reduced pressure. N-formyl hydrazide (202.61 mg, 3.37 mmol) was added to the residue at 25 ° C. The resulting mixture was stirred at 70 ° C for 18 hours and then concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography and eluted with (PE / EtOAc 1: 1) to obtain compound (136) (300 mg) as a yellow solid.

[1642] LCMS:(ES,m / z):[M+H] + =558.3

[1643] Compound 137 (Example 48)

[1644] A mixture of compound (136) (300 mg, 0.54 mmol) and NH3(g) / MeOH (10 mL) was stirred at 25°C for 2 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH: water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm to afford compound (137) (Example 48) (100 mg) as a yellow solid.

[1645] LCMS:(ES,m / z):[M+H] + =390.2

[1646] 1 H NMR: (400MHz, DMSO-d6) δ8.63(s,1H),7.67(d,J=12.1Hz,2H),5.01(d,J=3.7Hz ,1H),4.88–4.84(m,1H),4.80(d,J=6.1Hz,1H),4.67(dd,J=13.8,10.0Hz,1H), 4.50(t,J=5.3Hz,1H),4.25(dd,J=13.8,2.6Hz,1H),4.16(td,J=6.8,3.4Hz,1H ),3.70(s,3H),3.65–3.57(m,3H),3.47–3.43(m,1H),2.42(s,3H),2.35(s,3H).

[1647] Synthesis of Compound 141 (Example 49)

[1648] Example 49 was synthesized according to the following scheme.

[1649]

[1650] Compound 138

[1651] To a 0°C solution of compound (4) (1 g, 1.92 mmol) and DIPEA (744.93 mg, 5.76 mmol) in DMF (10 mL) were added dropwise allylamine (164.54 mg, 2.88 mmol) and HATU (1095.78 mg, 2.88 mmol). The resulting mixture was stirred at 0-20°C for 2 hours, then diluted with water (50 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with water (2×100 mL), dried over anhydrous Na2SO4, and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to obtain compound (138) (1 g) as a yellow solid.

[1652] Compound 139

[1653] To a stirred mixture of compound (138) (800 mg, 1.43 mmol) in DCE (10 mL) at 0°C were added silicon tetrachloride (728.66 mg, 4.29 mmol) and trimethylsilyl azide (823.57 mg, 7.15 mmol). The resulting mixture was stirred at 70°C for 16 hours and then cooled to room temperature. DCM (50 mL) was added, and the mixture was washed with water (3×50 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with (PE / EtOAc 1:2) to give compound (139) (500 mg) as a yellow solid.

[1654] Compound 140

[1655] To a stirred mixture of compound (139) (200 mg, 0.34 mmol) in H2O / t-BuOH (10 mL) at 0°C were added K2CO3 (141.85 mg, 1.03 mmol), K2OsO4.2H2O (1.26 mg, 0.003 mmol), K3Fe(CN)6 (11.26 mg, 0.034 mmol) and AD-mix-β(dhqd)2phal (26.65 mg, 0.034 mmol) in portions. The resulting mixture was stirred at 0-20°C for 16 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% FA in water, mobile phase B: ACN; gradient from 10% to 50% over 20 minutes; detector, UV 254 nm to afford compound (140) (120 mg) as a yellow solid.

[1656] Compound 141 (Example 49)

[1657] To a solution of compound (140) (200 mg) in MeOH (4 mL) stirred at 0°C was added NH3.H2O (2 mL) dropwise. The resulting mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase A: 0.1% FA in water, mobile phase B: ACN; gradient from 0% to 30% over 20 minutes; detector, UV 254 nm to afford compound (141) (Example 49) (56 mg) as a yellow solid.

[1658] ESI-MS m / z=451.20[M+H] +

[1659] 1H-NMR: (400MHz, DMSO-d6): δ7.70(d,J=10.6Hz,2H),5.03(dd,J=8.9,4.7Hz,2 H),4.87(d,J=3.7Hz,1H),4.79(t,J=5.4Hz,2H),4.77–4.62(m,2H),4.49(dt,J =17.7,6.9Hz,2H),4.27(d,J=13.8Hz,1H),4.16(s,1H),3.79(s,1H),3.62(d,J =4.5Hz,3H),3.45(m,1H),3.32(m,1H),3.21(m,1H),2.43(s,3H),2.35(s,3H).

[1660] Synthesis of Compound 143 (Example 50)

[1661] Example 50 was synthesized according to the following scheme.

[1662]

[1663] Compound 142

[1664] To a stirred solution of compound (124) (200 mg, 0.38 mmol) and pyridine (151.37 mg, 1.91 mmol) in THF at 0°C was added POCl3 (176.06 mg, 1.148 mmol) dropwise. The resulting mixture was stirred at 20°C for 3 hours and then concentrated under reduced pressure. The residual compound (142) was used in the next step without further purification.

[1665] LCMS:(ES,m / z):[M+H] + =603.2

[1666] Compound 143 (Example 50)

[1667] To a solution of compound (142) (200 mg, 0.33 mmol) in THF (5 mL) stirred at 20°C was added 4M HCl (gas) in 1,4-dioxane (5.00 mL, 0.14 mmol) dropwise. The resulting mixture was stirred at 20°C for 2 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, ACN:water, 10% to 50% gradient over 30 minutes; detector, UV 254 nm to afford compound (143) (Example 50) (60 mg) as a yellow solid.

[1668] LCMS:(ES,m / z):[M+H] + =471.1

[1669] 1 H NMR: (400 MHz, methanol-d4) δ 7.77 (d, J = 13.2 Hz, 2H), 4.84–4.76 (m, 1H), 4.52 (dd, J = 14.1, 2.8 Hz, 1H), 4.38–4.24 (m, 5H), 4.13 (dt, J = 10.8, 6.5 Hz, 1H), 4.03–3.98 (m, 1H), 3.84 (dd, J = 7.4, 4.9 Hz, 1H), 2.53 (d, J = 6.2 Hz, 3H), 2.43 (s, 3H). Synthesis of Compound 145 (Example 51)

[1670] Example 51 was synthesized according to the following scheme.

[1671]

[1672] Compound 144

[1673] To a solution of compound (124) (300 mg, 0.57 mmol) in dioxane (5 mL) stirred at 25°C was added Meldrum's acid (165.48 mg, 1.15 mmol) in portions. The resulting mixture was stirred at 70°C for 18 hours and then concentrated in vacuo. The residue was purified by silica gel column chromatography using PE / EtOAc (1:1) as the eluent to afford compound (144) (300 mg) as a yellow solid.

[1674] LCMS:(ES,m / z):[M+H] + =609.3

[1675] Compound 145 (Example 51)

[1676] To a solution of compound (144) (200 mg, 0.33 mmol) in DCM (30 mL) stirred at 0°C was added TFA (3 mL) dropwise. The resulting mixture was stirred at 25°C for 3 hours and then concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeOH:water, 10% to 50% gradient over 10 minutes; detector, UV 254 nm to afford compound (145) (Example 51) (40 mg) as a yellow solid.

[1677] LCMS:(ES,m / z):[M+H] + =506.3

[1678] 1H NMR: (400 MHz, methanol-d4) δ 7.77 (s, 1H), 7.73 (s, 1H), 4.83–4.78 (m, 3H), 4.55–4.43 (m, 2H), 4.35–4.28 (m, 5H), 4.06 (tt, J = 7.0, 3.5 Hz, 1H), 3.82 (dd, J = 7.2, 5.1 Hz, 1H), 2.52 (s, 3H), 2.42 (s, 3H).

[1679] Synthesis of Compound 147 (Example 52)

[1680] Example 52 was synthesized according to the following scheme.

[1681]

[1682] Compound 146

[1683] To a stirred solution of compound (124) (300 mg, 0.57 mmol), DIPEA (370.99 mg, 2.87 mmol), and DMAP (14.03 mg, 0.12 mmol) in DCM (10 mL) at 0°C was added succinic anhydride (120.07 mg, 1.2 mmol) in portions. The resulting mixture was stirred at 25°C for 18 hours and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (1:1) as eluent to afford compound (146) (300 mg) as a yellow solid.

[1684] LCMS:(ES,m / z):[M+H] + =623.3

[1685] Compound 147 (Example 52)

[1686] To a mixture of compound (146) (200 mg, 0.32 mmol) in DCM stirred at 0°C was added TFA (2 mL) in DCM (1 mL) dropwise. The resulting mixture was stirred at 25°C for 3 hours and then concentrated in vacuo. The residue was purified by reverse phase flash chromatography using the following conditions: Column: XSelect CSH Prep C18 OBD column, 5 μm, 19×150 mm; Mobile phase A: water (0.05% FA), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 12% B to 26% B in 16 minutes; 254 nm to afford compound (147) (Example 52) (70 mg) as a yellow solid.

[1687] LCMS:(ES,m / z):[M+H] + =491.2

[1688] 1 H NMR: (400MHz, DMSO-d6) δ12.48–11.52(m,1H),7.74(s,1H),7.66(s,1H),5.27–5.17(m,2H),4.96(d,J=5.9Hz,1H),4.64(dd,J=13.8,9.9Hz,1H) ,4.34–4.23(m,2H),4.16(s,4H),4.03(dd,J=11.2,7.2Hz,1H),3.85(s, 1H), 3.63 (t, J = 5.9Hz, 1H), 2.57–2.53 (m, 4H), 2.44 (s, 3H), 2.36 (s, 3H).

[1689] Synthesis of Compound 150 (Example 53)

[1690] Example 53 was synthesized according to the following scheme.

[1691]

[1692] Compound 148

[1693] To a solution of compound (33) (1.9 g, 3.24 mmol) in DMF (17 mL) stirred at 20°C was added CDI (1.34 g, 8.28 mmol). The resulting mixture was stirred at 30°C for 16 hours, then ethyl (N-hydroxycarbamoyl)formate (1.35 g, 10.19 mmol) was added and the mixture was stirred at 80°C for another 5 hours. After concentration under reduced pressure, the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, A: 0.05% FA in water, B: ACN, gradient from 0% to 100% over 30 minutes; detector, UV 254 nm, to obtain compound (148) (1 g) as a yellow oil.

[1694] Compound 149

[1695] To a solution of compound (148) (200 mg, 0.32 mmol) in MeOH (2 mL) and THF (2 mL) stirred at 0° C. was added a solution of LiOH (38.34 mg, 1.60 mmol) in H O (2 mL). The resulting mixture was stirred at 25° C. for 1 hour, then neutralized to pH 7 with HCl (aqueous solution) and extracted with EtOAc (3 x 10 mL). The combined organic layer was washed with water (3 x 10 mL), dried over anhydrous Na SO , and the filtrate was concentrated under reduced pressure after filtration. The residual compound (149) was used in the next step without further purification.

[1696] LCMS:(ES,m / z):[M+H] + =597.4

[1697] Compound 150 (Example 53)

[1698] To a solution of compound (149) (170 mg, 0.29 mmol) in ACN (4 mL) stirred at 0°C was added 6 M HCl (4 mL) dropwise. The resulting mixture was stirred at 20°C for 3 hours and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions: Column: Gemini-NX C18 AXAI packed column, 21.2 x 150 mm, 5 μm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 10% B to 31% B in 11 minutes; 254 / 220 nm to afford compound (150) (Example 53) (80 mg) as a yellow solid.

[1699] LCMS:(ES,m / z):[M+H] + =421.1

[1700] 1 H NMR: (400 MHz, methanol-d4) δ 7.81 (s, 1H), 7.75 (s, 1H), 4.54 (d, J = 13.9 Hz, 1H), 4.36–4.29 (m, 1H), 3.88–3.79 (m, 3H), 3.68 (dq, J = 18.2, 6.0 Hz, 2H), 2.52 (s, 3H), 2.43 (s, 3H), 2.34 (d, J = 7.8 Hz, 1H).

[1701] Synthesis of Compound 153 (Example 54)

[1702] Example 54 was synthesized according to the following scheme.

[1703]

[1704] Compound 151

[1705] To a solution of ethyl carbamoylformate (8.80 g, 75.15 mmol) in toluene (tol) stirred at 20°C under an argon atmosphere was added chloro(chlorosulfanyl)methanone (9841.99 mg, 75.15 mmol). The resulting mixture was stirred at 120°C for 7 hours, then at 20°C for 16 hours, and then concentrated in vacuo. The residue was purified by silica gel column chromatography using PE / EtOAc (5:1) as the eluent to afford Compound (151) (7.3 g) as a yellow oil.

[1706] Compound 152

[1707] To a mixture of compound (114) (1 g, 1.99 mmol) in 1,2-dichlorobenzene stirred at 20°C under an argon atmosphere was added compound (151) (1047.83 mg, 5.98 mmol). The resulting mixture was stirred at 150°C under an argon atmosphere for 2 days. After cooling to 20°C, the mixture was concentrated under reduced pressure and the residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, aqueous ACN, gradient from 0% to 100% over 30 minutes; detector, UV 254 nm, to obtain compound (152) (70 mg) as a yellow solid.

[1708] Compound 153 (Example 54)

[1709] To a stirred solution of compound (152) (240 mg, 0.38 mmol) in MeOH (5 mL) and H2O (2 mL) at 0°C was added LiOH.H2O (79.60 mg, 1.9 mmol) in portions. The resulting mixture was stirred at 20°C for 16 hours and then concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions (column: XBridge Shield RP18 OBD; 5 μm, 19×150 mm; mobile phase A: water (0.05% FA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 10% B to 25% B in 8 minutes; 254 / 220 nm) to afford compound (153) (Example 54) (54.5 mg) as a yellow solid.

[1710] LCMS:ESI-MS m / z=437.05[M+H] +

[1711] 1 H-NMR: (300MHz, DMSO-d6): δ7.90(s,1H),7.75(s,1H),5.06(s,1H),4.99-4.70(m,3H), 4.53(m,2H),4.23(s,1H),3.66(d,J=8.8Hz,3H),3.47(m,2H),2.45(s,3H),2.39(s,3H).

[1712] Synthesis of Compound 158 (Example 55)

[1713] Example 55 was synthesized according to the following scheme.

[1714]

[1715] Compound 154

[1716] To a solution of compound (40) (12 g, 30.74 mmol) in pyridine (200 mL) stirred at 0° C., Trt-Cl (25.71 g, 92.23 mmol) was added portionwise. The resulting mixture was stirred at 70° C. for 16 hours and then concentrated under reduced pressure. The residue was diluted with water (0.6 L) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with water (3 x 100 mL), d...

Claims

1. A compound of formula (I): or a pharmaceutically acceptable salt thereof; in: X is a C1-C3 alkyl group; Y is selected from: (i)C(O)NR 4Y R 5Y , (ii) heteroaryl selected from tetrazolyl, oxadiazolyl, thiadiazolyl and imidazolyl, wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted, and one of the heteroaryl ring nitrogen atoms is optionally replaced by R d Replace, and (iii) Z is selected from: (i)NR 4Z R 5Z , (ii)OR 6Z , (iii)OC(O)R 7Z , (iv)OP(O)OR 8Z OR 9Z , (v) and (we) Each Z x is H; or each Z x Together with the carbon to which they are attached, they form C=O; Each R 1 , R 2 and R 3 YesR 6A ; R 4Y and R 5Y Each independently selected from: (i) H, and (ii)C 1-4 Alkyl, which is optionally substituted by 1-2 R a replace, R 4Z and R 5Z Each independently selected from: (i) H, and (ii)C 1-3 Alkyl, which is optionally replaced by 1 independently selected R a replace; Each time it appears, R 6A It is H; R 6Z Independently selected from: (i) H, (ii)C 1-3 Alkyl, optionally with 1-2 independently selected R a Replace, and (iii)–(C 1-2 Alkylene)-C(=O)NH-(C 1-3 Alkylene)-R 6Z’ ; R 6Z’ Selected from: C(=O)OH, N(C 1-4 alkyl)2, NH2 and NH(C 1-4 alkyl); Each time it appears, each R 7Z is independently optionally 1 or 2 independently selected R a Substituted C 1-6 alkyl; Each time it appears, R 8Z and R 9Z Each independently is H; Each time it appears, R a Independently selected from: –OH, –NR e R f and -C(=O)OH; Each time it appears, R c Independently selected from: (i)C 1-10 alkyl, (ii) R selected by 1 independently a Substituted C 1-10 alkyl, (iii)-NR e R f ,and (iv) -C(=O)OH; R d It is C 1-3 Alkyl, which is optionally substituted by 1-3 independently selected R g replace; Each time it appears, R e and R f Independently selected from H and C 1-6 alkyl; Each R g Selected from: –OH, –N(C 1-3 alkyl)2, -CONHS(O)2(C 1-4 alkyl) and –C(O)OH; and Provided that the compound is not: or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein The compound has formula (Ia): or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or 2, wherein Z is OR 6Z , where R 6Z selected from H and optionally 1-2 independently selected R a Substituted C 1-3 alkyl.

4. The compound according to claim 3, wherein R 6Z is optionally 1-2 independently selected R a Substituted C 1-3 alkyl.

5. The compound according to claim 3, wherein R 6Z It's H.

6. The compound according to claim 3, wherein X is CH3.

7. The compound according to claim 3, wherein Y is CONR 4Y R 5Y .

8. The compound according to claim 7, wherein Where R 4Y and R 5Y Each is independently H or optionally 1-2 independently selected R a Substituted C 1-4 alkyl.

9. The compound according to claim 8, wherein R 4Y It is H; R 5Y is selected by 1-2 independent R a Substituted C 1-4 alkyl.

10. The compound according to claim 9, wherein R 5Y yes 11. The compound according to claim 10, wherein R 5Y R a Selected from: –OH and –NR e R f .

12. The compound according to claim 11, wherein R 5Y R a It's NMe2.

13. The compound according to claim 11, wherein R 5Y Independently 14. The compound according to claim 3, wherein Y is tetrazolyl, wherein one or more ring carbon atoms are optionally replaced by 1-2 independently selected R c substituted, and one of the ring nitrogen atoms is optionally replaced by R d replace.

15. The compound according to claim 14, wherein Y is 16. The compound according to claim 14, wherein Y is selected from:

17. The compound according to claim 16, wherein Y is 18. The compound according to claim 16, wherein R a Selected from –OH and –NMe2.

19. The compound according to claim 3, wherein Each Z x It's H.

20. The compound according to claim 3, whereinEach Z x Together with the carbon to which they are attached they form C=O.

21. The compound of claim 1 or 2, wherein: Z is OR 6Z , where R 6Z It is H; X is CH3; Y is R a Selected from: –OH and –NR e R f ;and Each Z x Together with the carbon atom to which they are attached, they form C=O.

22. The compound of claim 21, wherein Y is 23. The compound of claim 1 or 2, wherein: Z is OR 6Z , where R 6Z It is H; X is CH3; Y is tetrazolyl, wherein one or more ring carbon atoms are optionally replaced by 1-2 independently selected R c and one of the ring nitrogen atoms is optionally replaced by R d Replacement; and Each Z x It's H.

24. The compound of claim 23, wherein Tetrazolyl is 25. The compound of claim 1, wherein The compound is selected from: or a pharmaceutically acceptable salt thereof.

26. The compound of claim 25, wherein The compound is or a pharmaceutically acceptable salt thereof.

27. The compound of claim 25, wherein The compound is or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition comprising the compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

29. Use of the compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating corneal ectasia.

30. The use of claim 29, further comprising applying electromagnetic radiation to the cornea, thereby producing crosslinks in the cornea.

31. The use according to claim 30, wherein: The one or more corneal ectatic conditions are selected from the group consisting of: keratoconus, keratosphere, pellucid marginal degeneration, postoperative ectasia, and Tring's marginal degeneration.

32. The use according to claim 31, wherein: The corneal ectatic disorder is keratoconus.

33. The use according to claim 32, wherein: Keratoconus is a progressive corneal cone.

34. The use according to claim 31, wherein: The corneal ectatic disorder is post-operative ectasia.

35. The use according to claim 34, wherein: The post-operative dilation is post-LASIK dilation.

36. The use according to claim 29, wherein: The use is for treating a vision condition selected from the group consisting of myopia, hyperopia, astigmatism, irregular astigmatism and presbyopia.

37. The use according to claim 29, wherein: Electromagnetic radiation includes ultraviolet light.

38. The use according to claim 37, wherein: The ultraviolet light is UV-A light.

39. The use according to claim 29, wherein: Electromagnetic radiation is laser radiation.

40. The use according to claim 29, wherein: The duration of radiation treatment ranges from 1 to 60 minutes.

41. The use according to claim 29, wherein: The wavelength of the radiation is 350-550nm.

42. The use according to claim 41, wherein: The wavelength of the radiation is 360-370nm.

43. The use according to claim 29, wherein: The irradiance of electromagnetic radiation is 0.1 to 100 mW / cm 2 .

44. The use of claim 29, further comprising applying an additional cross-linking agent to the cornea.

45. The use according to claim 44, wherein: The additional cross-linking agent is selected from the group consisting of riboflavin, 2,3-butanedione, folic acid, quinoxaline, quinoline, dibucaine, methotrexate, menadione and verteporfin.

46. ​​The use according to claim 29, further comprising one or more additives other than a cross-linking agent.

47. The use according to claim 46, wherein: The additive is selected from the group consisting of iron, copper, manganese, chromium, vanadium, aluminum, cobalt, mercury, cadmium, nickel, arsenic, 2,3-butanedione and folic acid.

48. The use of claim 29, further comprising an additional ophthalmic treatment for inflammation or lens disorders.

49. The use of claim 29, further comprising an additional ophthalmic treatment for cataracts.

50. The use of claim 29, further comprising applying a selected concentration of oxygen to the eye, wherein the selected concentration is greater than the concentration of oxygen in the atmosphere.